IDENTIFICATION AND EXPRESSION OF INSECT STEROID RECEPTOR DNA SEQUENCES

Abstract: The present invention involves the isolation of insect DNA sequences having characteristics of insect steroid receptors. Also described is the putative amino acid sequence for insect steroid receptors as deduced from the DNA sequence.

Description: Identification and Expression of Insect Steroid Receptor DNA Sequences This invention was made in part with U.S. government support under Grant DCB 8405370 from the National Science Foundation. The U.S. government may have certain rights in this invention. FIELD OF THE INVENTION This invention relates generally to the use of recombinant DNA methods as applied to the nucleic acid sequences and polypeptides characteristic of insect steroid receptor superfa ily members and, more particularly, to uses of such receptors and the DNA regulatory elements associated with genes whose expression they regulate for the production of proteins in cultured cells, and to uses of such hormone receptor proteins and genes in identifying new hormones that control insect development. BACKGROUND OF THE INVENTION The temporal sequence of gene expression determines the nature and sequence of steps in the development of the adult animal from the fertilized egg. The common fruit fly, Drosophila melanogaster. provides a favorable model system for studying this genetic control of development. Various aspects of Drosophila development are representative of general insect and, in many respects, vertebrate development. The steroid hormone 20-OH ecdysone, also known as β-ecdysone, controls timing of development in many insects. See, generally, Kool an (ed.) , Ecdysone: From Chemistry to Mode of Action, Thieme Medical Pub., N.Y. (1989) , which is hereby incorporated herein by reference. The generic term "ecdysone" is frequently used as an abbreviation for 20-OH ecdysone. Pulses, or rises and falls, of the ecdysone concentration over a short period of time in insect development are observed at various stages of Drosophila development. These stages include embryogenesis, three larval stages and two pupal stages. The last pupal stage ends with the formation of the adult fly. An ecdysone pulse at the end of the third, or last, larval stage pulse triggers the beginning of the metamorphosis of the larva to the adult fly. Certain tissues, called imaginal tissues, are induced to begin their formation of adult structures such as eyes, wings, and legs. During the larval stages of development, giant polytene chromosomes develop in non-imaginal larval tissues. These cable-like chromosomes consist of aggregates comprising up to about 2,000 chromosomal copies. These chromosome aggregates are extremely useful because they provide a means whereby the position of a given gene within a chromosome can be determined to a very high degree of resolution, several orders of magnitude higher than is typically possible for normal chromosomes. A "puff" in the polytene chromosomes is a localized expansion or swelling of these cable-like polytene chromosome aggregates that is associated with the transcription of a gene at the puff locus. A puff is, therefore, an indicator of the transcription of a gene located at a particular position in the chromosome. A genetic regulatory model was proposed to explain the temporal sequence of polytene puffs induced by the ecdysone pulse which triggers the larval-to-adult metamorphosis. See, Ashburner et al., "On the Temporal Control of Puffing Activity in Polytene Chromosomes," Cold Sprinα: Harbor Symp. Ouant. Biol. 38:655-662 (1974). This model proposed that ecdysone interacts reversibly with a receptor protein, the ecdysone receptor, to form an ecdysone-receptor complex. This complex would directly induce the transcription of a small set of "early" genes responsible for a half dozen immediately induced "early" puffs. These early genes are postulated to encode regulatory proteins that induce the transcription of a second set of "late" genes responsible for the formation of the "late" puffs. The model thus defines a genetic regulatory hierarchy of three ranks, the ecdysone-receptor gene in the first rank, the early genes in the second rank, and the late genes in the third. While this model was derived from the puffing pattern observed in a non-imaginal tissue, similar genetic regulatory hierarchies may also determine the metamorphic changes in development of imaginal tissues that are also targets of ecdysone, as well as the changes in tissue development induced by the pulses of ecdysone that occur at other developmental stages. Various structural data have been derived from receptors for vertebrate steroids and other lipophilic receptor proteins. A "superfamily" of such receptors has been defined on the basis of their structural similarities. See, Evans, "The Steroid and Thyroid Hormone Receptor Superfamily," Science 240:889-895 (1988) ; Green and Chambon, "Nuclear Receptors Enhance Our Understanding of Transcription Regulation," Trends in Genetics 4:309-314 (1988), both of which are hereby incorporated herein by reference. Where their functions have been defined, these receptors, complexed with their respective hormones, regulate the transcription of their primary target genes, as proposed for the ecdysone receptor in the above model. Cultivated agriculture has greatly increased efficiency of food production in the world. However, various insect pests exploit cultivated sources of food to their own advantage. These insect pests typically develop by a temporal sequence of events characteristic of their order. Many, including Drosophila. initially develop in a caterpillar or maggot-like larval form. Thereafter, they undergo a metamorphosis from which emerges an adult having characteristic anatomical features. Anatomic similarity is a reflection of developmental, physiological and biochemical similarities shared by these insects. In particular, the principles governing the role of insect ecdysteroid-hormone receptors in Drosophila development, as described above, likely are shared by many different types of insects. As one weapon against the destruction of cultivated crops by insects, organic molecules with pesticidal properties are used commonly in attempts to eliminate insect populations. However, the ecological side effects of these pesticides, due in part to their broad activity and lack of specificity, and also in part to the fact that some of these pesticides are not easily biodegradable, significantly affect populations of both insects and other species of animals. Some of these populations may be advantageous from an ecological or other perspective. Furthermore, as the insect populations evolve to minimize the effects of the applied pesticides, greater amounts of pesticides must be applied, causing significant direct and indirect effects on other animals, including humans. Thus, an important need exists for both highly specific and highly active pesticides which are biodegradable. Novel insect hormones which, like the ecdysteroids, act by complexing with insect members of the steroid receptor superfamily to control insect development, are likely candidates for pesticides with these desirable properties. The use of insect hormones may also have other important applications. Many medically and commercially important proteins can be produced in a usable form by genetically engineered bacteria. However, many expressed proteins are processed incorrectly in bacteria and are preferably produced by genetically engineered eucaryotic cells. Typically, yeast cells or mammalian tissue- culture cells are used. Because it has been observed that protein processing of foreign proteins in yeast cells is also frequently inappropriate, mammalian cultured cells have become the central focus for the production of many proteins. It is commonly known that the production of large amounts of foreign proteins makes these cells unhealthy, which may affect adversely the yield of the desired protein. This problem may be circumvented, in part, by using an inducible expression system. In such a system, the cells are engineered so that they do not express the foreign protein until an inducing agent is added to the growth medium. In this way, large quantities of healthy cells can be produced and then induced to produce large amounts of the foreign protein. Unfortunately, in the presently available systems, the inducing agents themselves, such as metal ions or high temperature, adversely affect the cells, thus again lowering the yield of the desired foreign protein the cells produce. A need therefore exists for the development of benign inducing factors for efficient production of recombinant proteins. Such factors could also prove invaluable for the therapy of human patients suffering from inability to produce particular proteins, treatment with these factors controlling both the timing and the abundance of the protein produced in the affected individual. The hormones that complex with mammalian or other vertebrate members of the steroid receptor superfamily are unlikely candidates as such benign factors because they would alter the expression of many target genes in cells bearing these receptors, thereby adversely affecting the host cells. For these and other reasons, obtaining steroid receptors or nucleic acid information about them has been a goal of researchers for several years. Unfortunately, efforts have been unsuccessful despite a significant investment of resources. The absence of information on the structure and molecular biology of steroid receptors has significantly hindered the ability to produce such products. Thus, there exists a need for detailed sequence information on insect members of the steroid receptor superfamily, and the genes that encode these receptors and for resulting reagents. Reagents are provided which are useful in finding new molecules which may act as agonists or antagonists of natural insect members of the steroid receptor superfamily, or as components of systems for highly specific regulation of recombinant proteins in mammalian cells. SUMMARY OF THE INVENTION In accordance with the present invention, isolated recombinant nucleic acids are provided which, upon expression, are capable of coding for other than a native vertebrate steroid receptor or fragment thereof. These nucleic acids typically comprise a segment having a sequence substantially homologous to one or more coding regions of domains A, B, D, E, or F from an insect steroid receptor superfamily member gene having steroid binding domain homology, e.g., EcR, DHR3, E75A, or E75B. Preferably, the .nucleic acids encode a polypeptide capable of binding to a ligand for an insect steroid receptor superfamily member and are capable of hybridizing to an insect steroid receptor superfamily member gene segment under selective hybridization conditions, usually stringent hybridization conditions. Mammalian cells transformed with the nucleic acids are also provided. In another embodiment, isolated recombinant nucleic acids are included that have sequence exhibiting identity over about 20 nucleotides of a coding segment of an insect steroid receptor superfamily member having steroid binding domain homology. The nucleic acids can be transformed into cells to express a polypeptide which binds to a control element responsive to a ligand of an insect steroid receptor superfamily. Alternatively, an isolated DNA molecule is provided comprising a DNA sequence capable of binding to an insect steroid receptor superfamily member other than 20-OH ecdysone receptor, such as DHR3, E75A, or E75B. The DNA sequence will generally be present in an expression vector and promote transcription of an operably linked sequence (e.g., encoding a polypeptide) in response to binding by an insect steroid receptor superfamily member. Cells comprising the nucleic acids are provided, as are cells expressing the polypeptides. In certain embodiments, non-insect cells will be used, including mammalian cells. Also contemplated are recombinant nucleic acids comprising a controlling element responsive to a ligand, e.g., a ligand which binds to an insect steroid receptor superfamily member ligand responsive controlling element, a non-heat shock promoter sequence (e.g., an alcohol dehydrogenase promoter) and a sequence comprising a reporter gene. Usually the controlling element will operate to make transcription of the reporter gene responsive to the presence of the ligand. Additional embodiments of the present invention include polypeptides comprising an insect steroid receptor superfamily member or fragment thereof, wherein such polypeptide is substantially free of naturally- associated insect cell components and exhibits a biological activity characteristic of an insect steroid receptor superfamily member with a hormone binding domain. Preferably, the insect steroid receptor superfamily member or fragment thereof also comprises a DNA binding domain and the polypeptide is capable of binding to a hormone analogue selected from the group consisting of an insect hormone, an insect hormone agonist and an insect hormone antagonist. The polypeptide can comprise a zinc-finger domain and usually is capable of binding to a DNA controlling element responsive to an insect hormone. As desired, the polypeptide will be fused to a second polypeptide, typically a heterologous polypeptide which comprises a second steroid receptor superfamily member. Cells, often mammalian cells, comprising the protein are provided. Fragments of such polypeptides can have a sequence substantially homologous to consensus El, E2 or E3 region sequences. By way of example, a preferred fragment has a sequence comprising: a segment at least about 25% homologous to a consensus El region sequence; a segment at least about 30% homologous to a consensus E2 region sequence; and a segment at least about 30% homologous to a consensus E3 region sequence. The polypeptides of the present invention have a variety of utilities. For example, a method for selecting DNA sequences capable of being specifically bound by an insect steroid receptor superfamily member can comprise the steps of screening DNA sequences for binding to such polypeptides and selecting DNA sequences exhibiting such binding. Alternatively, methods for selecting ligands, e.g., ecdysteroid analogues, specific for binding to a hormone binding domain of an insect steroid receptor superfamily member can comprise the steps of screening compounds for binding to one or more superfamily members and selecting compounds exhibiting specific binding to the members. Also included are methods for modulating insect physiology or development (e.g., killing) comprising the steps of screening compounds for binding to an insect steroid receptor superfamily member, selecting compounds exhibiting said binding and administering the ligand to an insect. Additionally provided are methods for selecting ligands specific for binding to a ligand binding domain of an insect steroid receptor superfamily member comprising combining: (i) a fusion polypeptide which comprises a ligand binding domain functionally linked to a DNA binding domain of a second steroid receptor superfamily member; and (ii) a second nucleic acid sequence encoding a second polypeptide, wherein expression of the second nucleic acid sequence is responsive to binding by the DNA binding domain; screening compounds for an activity of inducing expression of the second polypeptide; and selecting those compounds which do so. This will often be performed in a cell, e.g., with cells transformed with DNA encoding a fusion protein. This method allows selction of analogues which are useful in modulating insect physiology or development. Also provided are methods for producing a polypeptide comprising the steps of: selecting a cell, typically a mammalian or plant cell which is substantially insensitive to exposure of an insect steroid receptor superfamily ligand; introducing into said cell: (i) a receptor for the ligand; and (ii) a nucleic acid sequence encoding the polypeptide, the nucleic acid sequence operably linked to a controlling element responsive to presence of the selected ligand, wherein a transformed cell is produced; and exposing the transformed cell to the ligand. Usually the cell will be a mammalian cell, and will sometimes be introduced into a whole organism, e.g., a plant or animal. Kits for the determination of expression levels of the nucleic acids and proteins provided herein are made available. Typically, the kit will have at least one compartment which contains a reagent which specifically binds to the desired target molecule, e.g., ligand analogues, receptors, or nucleic acids. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. pMTEcR, a Cu 2+ -inducible EcR expression plasmid. The P MT , EcR ORF and Act 5c poly A elements are defined in Experimental Example III, part A. The HYG r ORF confers hygromycin resistance and is under control of the promoter in the LTR of Drosophila transposable elements, copia. The SV40 intron/poly A element provides an intron for a possible splicing requirement, as well as a polyadenylation/cleavage sequence for the HYG r ORF mRNA. The pAT153 DNA derives from a bacterial plasmid. Figure 2. The ecdysone-inducible pEcRE/Adh/βgal reporter plasmid. See the text of Experimental Example III, part B, for the construction of this plasmid and the definitions of all symbols (except the SV40 splice and poly A) which are defined in the figure legend. Figure 3. The constitutive EcR expression plasmid, pActEcR. The construction of this plasmid and the definition of the symbols are given in Experimental Example III, part B. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention provides novel isolated nucleic acid sequences encoding polypeptide products exhibiting the structure and/or activities of insect members of the steroid receptor superfamily. Having elucidated the structures of these insect steroid receptors from their genes, the separate ligand-binding domains and DNA-binding domains are used individually or in combination to screen for new ligands or DNA sequences which bind to these domains. Thus, for example, by binding to promotor sequences incorporating a DNA binding site, these receptors will usually control expression of reporter genes for which sensitive assays exist. Or, the hormone-binding domains serve as reagents for screening for agonists or antagonists of steroid receptor superfamily members. Either new classes of molecules, or selected modifications of known ligands will be screened for receptor binding. New ligands obtained in this way find use as highly specific and highly active naturally occurring pesticides. Alternatively, structural information about interactions between the ligand and binding domains directs methods for mutagenizing or substituting particular residues in the binding domains, thereby providing for altered binding specificity. Thus, inter alia, the present invention provides for screening for new ligand molecules, for the design of new ligand- binding domain interactions, for producing novel chimeric steroid receptor superfamily members and for generating new combinations of ligands and binding domains. The present invention also provides for the isolation or identification of new steroid hormone- responsive elements and associated genes. By appropriate operable linkage of selected sequences to DNA controlling elements which are responsive to binding by the DNA- binding domains of steroid receptor superfamily members, new regulatory combinations result. The present invention further provides for the design of either a binding domain in a member of the insect steroid receptor superfamily that will recognize given DNA sequences, or conversely for the modification of DNA sequences which will bind to particular receptor DNA-binding domains. Both the DNA-binding domain of a superfamily-member polypeptide and its DNA recognition sequence can be coordinately modified to produce wholly new receptor-DNA interactions. In an alternative embodiment, a DNA-binding sequence recognized by a selected receptor will be operably linked to a desired genetic sequence for inducible expression. Thus, upon administration of a ligand specific for that selected receptor, the genetic sequence is appropriately regulated. Expression systems are constructed that are responsive to administration of insect steroid receptor superfamily-specific ligands. By identifying and isolating new members of the insect steroid receptor superfamily, new, useful regulatory reagents become available, both hormones and controlling elements. In another embodiment, highly regulatable expression of a gene is achieved by use of regulatory elements responsive to ligands specific to the superfamily members. If transformed cells are grown under conditions where expression is repressed or not induced, the cells will grow to higher densities and enjoy less stressful conditions. Upon reaching high density, the regulatory ligand molecule is added to cause high expression. Selected cells otherwise insensitive to the inducing ligand will not be affected by exposure to the ligand used to regulate expression. This provides a means both for highly efficient regulatable expression of genes, and for introduction of these genes into intact organisms. In accordance with specific embodiments of the present invention, nucleic acid sequences encoding portions of insect steroid hormone receptor superfamily members have been elucidated. DNA encoding four different members of the Drosophila steroid receptor superfamily have been characterized: (1) the 20-OH ecdysone receptor, also called the ecdysone receptor (EcR) , for which a full-length encoding sequence has been determined; (2) Drosophila hormone receptor 3 (DHR3) , a protein with sequence homology to various steroid receptor superfamily members; (3 and 4) E75A and E75B, closely related proteins, encoded by segments of the same gene, and each possessing sequence homology to other steroid receptor superfamily members. The DNA sequences encoding each of these members of the insect steroid receptor superfamily provide probes for screening for homologous nucleic acid sequences, both in Drosophila and other sources. This screening allows isolation of homologous genes from both vertebrates and invertebrates. Production of large amounts of the encoded proteins is effected by inserting those sequences into expression systems. The EcR, DHR3, E75A, and E75B genes are each linked to similar DNA sequences which likely function as controlling, or regulatory elements which are responsive to insect steroids. The present invention provides for the isolation of these hormone-responsive control elements, and for their use in regulating gene expression. One embodiment of a DNA construct comprises: (1) multiple copies of an insect steroid receptor superfamily controlling element linked to (2) a minimal gene promoter, preferably not a heat shock gene promoter, which provides highly inducible expression of (3) an operably linked gene. This construct provides a very sensitive assay for the presence of the controlling molecule of the receptor. Another aspect of the present invention involves cells comprising: (1) isolated recombinant gene segments encoding biologically active fragments of insect steroid receptor superfamily proteins; (2) DNA sequences which bind insect steroid receptors, e.g., the elements involved in hormone-responsive control; or (3) modified receptor proteins. Transformed cells are understood to include their progeny. In particular, the present invention provides for a system whereby expression of polypeptides is responsive to steroid induction. For instance, a system which expresses a desired protein in response to exposure to ecdysone analogues is constructed by operably linking a promoter having an ecdysone- responsive enhancer to a peptide encoding segment. The present invention also provides insect steroid receptor proteins substantially free from naturally- associated insect cell components. Such receptors will typically be either full-length proteins, functional fragments, or fusion proteins comprising segments from an insect steroid receptor protein fused to a heterologous, or normally non-contiguous, protein domain. The present invention further provides a number of methods for utilizing the subject receptor proteins. One aspect of the present invention is a method for selecting new hormone analogues. The isolated hormone-binding domains specifically bind hormone ligands, thereby providing a means to screen for new molecules possessing the property of binding with high affinity to the ligand- binding region. Thus, a binding domain of an insect steroid receptor superfamily member will be used as a reagent to develop a binding assay. On one level, the binding domains are useful as affinity reagents for a batch or a column selective process, i.e., to selectively retain ligands which bind. Alternatively, a functional assay is preferred for its greater sensitivity to ligand- binding, whether a direct binding assay or an indirect assay in which binding is linked to an easily assayed function. For example, by operable linkage of an easily assayable reporter gene to a controlling element responsive to binding by an insect steroid receptor superfamily member, in which ligand-binding induces protein synthesis, an extremely sensitive assay for the presence of a ligand or of a receptor results. Such a construct useful for assaying the presence of 20-OH ecdysone is described below. This construct is useful for screening for agonists or antagonists of the 20-OH ecdysone ligand. In particular, this method allows selecting for ligands which bind to an "orphan" receptor, i.e., a receptor whose ligand is unknown. Binding domains for "unknown" ligands will often originate from either newly identified insect steroid receptor superfamily members, or from mutagenesis. A hybrid receptor will be created with a ligand-binding domain and DNA-binding domain from different sources. For example, a hybrid receptor between a putative binding domain and a known DNA-binding domain would allow screening for ligands. An "orphan receptor" binding domain will be functionally linked to a known DNA-binding domain which will control a known reporter gene construct whose expression will be easily detected. This system for ligand-receptor binding provides an extremely sensitive assay for ligand-receptor interactions. Alternatively, the recognition of important features of tertiary structure and spatial interactions between a ligand-binding domain from an insect steroid receptor superfamily member and its ligand will allow selection of new combinations of ligand-binding domains with ligands. Either method provides for selecting unusual ligands which specifically bind a modified polypeptide-binding domain of a receptor. This approach allows selection of novel steroid hormone analogues which exhibit modified specificity for binding to a subgroup of steroid receptors. The present invention also provides for new and useful combinations of the various related components: the recombinant nucleic acid sequences encoding the polypeptides, the polypeptide sequences, and the DNA sites to which the receptors bind (i.e., the regulatory, or control, elements) . For instance, fusing portions of nucleic acid sequences encoding peptides from different sources will provide polypeptides exhibiting hybrid properties, e.g., unusual control and expression characteristics. In particular, hybrid receptors comprising segments from other members of the superfamily, or from other sources, will be made. Combining an insect steroid receptor-responsive enhancer segment with a different polypeptide encoding segment will produce a steroid-responsive expression system for that polypeptide. The isolation of insect steroid receptors provides for isolation or screening of new ligands for receptor binding. Some of these will interfere with, or disrupt, normal insect development. These reagents will allow the user to accelerate or decelerate insect development, for instance, in preparing sterile adults for release. Alternatively, a delay or change in the timing of development will often be lethal or will dramatically modify the ability of an insect to affect an agricultural crop. Thus, naturally occurring biodegradable and highly active molecules able to disrupt the timing of insect development will result. Furthermore, these polypeptides provide the means by which have been raised antibodies possessing specificity for binding to particular steroid receptor classes. Thus, reagents will be produced for determining, qualitatively or quantitatively the presence of these or homologous polypeptides. Alternatively, these antibodies will be used to separate or purify receptor polypeptides. Transcription sequences of insect steroid receptor superfamily members The ecdysone receptor gene is a member of the steroid and thyroid hormone receptor gene superfamily, a group of ligand-responsive transcription factors. See. Evans (1988) Science 240:889-895; and Segraves, Molecular and Genetic Analysis of the E75 Ecdysone-Responsive Gene of Drosophila melanogaster (Ph.D. thesis, Stanford University 1988) , both of which are hereby incorporated herein by reference for all purposes. These receptors show extensive sequence similarity, especially in their "zinc finger" DNA-binding domains, and also in a ligand (or hormone or steroid) binding domain. Modulation of gene expression apparently occurs in response to binding of a receptor to specific control, or regulatory, DNA elements. The cloning of receptor cDNAs provides the first opportunity to study the molecular bases of steroid action. The steroid receptor superfamily is a class of receptors which exhibit similar structural and functional features. While the term insect is used herein, it will be recognized that the same methods and molecules will be derived from other species of animals, in particular, those of the class Insecta. or, more broadly, members of the phylum Arthropoda which use ecdysteroids as hormones. Members of the insect steroid receptor superfamily are characterized by functional ligand-binding and DNA binding domains, both of which interact to effect a change in the regulatory state of a gene operably linked to the DNA-binding site of the receptor. Thus, the receptors of the insect steroid receptor superfamily seem to be ligand-responsive transcription factors. The receptors of the present invention exhibit at least a hormone-binding domain characterized by sequence homology to particular regions, designated El, E2 and E3. The members of the insect steroid receptor superfamily are typically characterized by structural homology of particular domains, as defined initially in the estrogen receptor. Specifically, a DNA-binding domain, C, and a ligand-binding domain, E, are separated and flanked by additional domains as identified by Krust et al. (1986) EMBO J. 5:891-897, which is hereby incorporated herein by reference. The C domain, or zinc-finger DNA-binding domain, is usually hydrophilic, having high cysteine, lysine and arginine content — a sequence suitable for the required tight DNA binding. The E domain is usually hydrophobic and further characterized as regions El, E2 and E3. The ligand-binding domains of the present invention are typically characterized by having significant homology in sequence and structure to these three regions. Amino proximal to the C domain is a region initially defined as separate A and B domains. Region D separates the more conserved domains C and E. Region D typically has a hydrophilic region whose predicted secondary structure is rich in turns and coils. The F region is carboxy proximal to the E region (see, Krust et al., supra) . The ligand-binding domain of the members of the insect steroid receptor superfamily is typically carboxyl-proximal, relative to a DNA-binding domain described below. See, Evans (1988) Science 240:889-895. The entire hormone-binding domain is typically between about 200 and 250 amino acids but is potentially shorter. This domain has the subregions of high homology, designated the El, E2 and E3 regions. See, e.g.. Table 4. The El region is 19 amino acids long with a consensus sequence AKX(L/I)PGFXXLT(L/I) (D/E)DQITLL, where X represents any amino acid and the other letters are the standard single-letter code. Positions in parentheses are alternatives. Typically, members of the insect steroid receptor superfamily will have at least about five matches out of the sixteen assigned positions, preferably at least about nine matches, and in more preferred embodiments, at least about ten matches. Alternatively, these insect steroid receptor superfamily members will have homologous sequences exhibiting at least about 25% homology, normally at least about 30% homology, more normally at least about 35% homology, generally at least about 40% homology, more generally at least about 45% homology, typically at least about 50% homology, more typically at least about 55% homology, usually at least about 60% homology, more usually at least about 70% homology, preferably at least about 80% homology, and more preferably at least about 90% homology at positions assigned preferred amino acids. The E2 region is a 19 amino-acid segment with a consensus sequence: E(F/Y) (A/V) (L/C) (L/M)KA(I/L) (V/L)L(L/I) (N/S) (S/P)D(P/-) (R/K) (P/D)GL where - represents an optional absence of an amino acid. Typically, an insect steroid receptor superfamily member will exhibit at least about six matches, preferably at least about eight matches and more preferably at least about nine matches. Alternatively, E2 sequences of insect steroid receptor superfamily members exhibit at least about about 25% homology, normally at least about 30% homology, more normally at least about 35% homology, generally at least about 40% homology, more generally at least about 45% homology, typically at least about 50% homology, more typically at least about 55% homology, usually at least about 60% homology, more usually at least about 70% homology, preferably at least about 80% homology, and more preferably at least about 90% homology at positions assigned preferred amino acids. The E3 region is a 12 amino-acid segment with a consensus sequence LXKLLXXLPDLR . The insect steroid receptor superfamily members will typically show at least about four matches out of the nine assigned preferences in the E3 region, preferably at least about five matches and more preferably at least about six matches. Alternatively, over the assigned positions, members of the insect steroid receptor superfamily will exhibit at least about 25% homology, normally at least about 30% homology, more normally at least about 35% homology, generally at least about 40% homology, more generally at least about 45% homology, typically at least about 50% homology, more typically at least about 55% homology, usually at least about 60% homology, more usually at least about 70% homology, preferably at least about 80% homology, and more preferably at least about 90% homology at positions assigned preferred amino acids. In preferred embodiments, the insect steroid receptor superfamily members will exhibit matching of at least about five positions in an El region, at least about six positions in an E3 region and at least about four positions in an E3 region. The El, E2, and E3 regions are defined, e.g., in Table 4. The DNA-binding domain of these insect steroid receptor superfamily members is characterized by a "zinc fingers" motif. See, Evans (1988) Science 240:889-895. The domain is typically amino proximal to the ligand, or hormone, binding site. Typically, the DNA-binding domain of the insect steroid receptor superfamily members is characterized by clustering of basic residues, a cysteine-rich composition and sequence homology. See. Evans, R. M. (1988) Science 240:889-89; and Experimental section below. Significant polypeptide sequence homology among superfamily members exists. The insect steroid receptor superfamily members will exhibit at least about 30% homology in the 67 + 1 amino acid region of this domain, normally at least about 40% homology, usually at least about 45% homology, and preferably at least about 55% homology. Steroids are derivatives of the saturated tetracyclic hydrocarbon perhydrocyclopentanophenanthrene. Among the molecules in the group "steroids" are: the bile acids, e.g., cholic acid, and deoxycholic acid; the adrenocortical steroids, e.g., corticosterone and aldosterone; the estrogens, e.g., estrone and β- estradiol; the androgens, e.g., testosterone and progesterone; and the ecdysteroids. The terms steroid or steroid hormones are used interchangeably herein and are intended to include all steroid analogues. Typically, steroid analogues are molecules which have minor modifications of various peripheral chemical groups. See. Koolman (ed. ) (1989), cited above, for details on ecdysteroids. Although ligands for the insect steroid receptor superfamily members have historically been characterized as steroids, the term "steroid" as in "insect steroid receptor superfamily" is not meant only literally. The use of "steroid" has resulted from a historical designation of members of a group recognized initially to include only molecules having specific defined molecular structures. However, this limitation is no longer applicable since functions are no longer only correlated with precise structures. Thus, there will be members of the insect steroid receptor superfamily, as defined herein, whose ligand-binding specificities are not directed to classically defined "steroids." Typically, the ligands for members of the insect steroid receptor superfamily are lipophilic molecules which are structural analogues of steroid molecules. The term ligand is meant to refer to the molecules that bind the domain described here as the "hormone- binding domain." Also, a ligand for an insect steroid receptor superfamily member is a ligand which serves either as the natural ligand to which the member binds, or a functional analogue which serves as an agonist or antagonist. The classical definition of "hormone" has been defined functionally by physiologists, see, e.g., Guyton, Textbook of Medical Physiology, Saunders, Philadelphia. The functional term "hormone" is employed because of historic usage, but is meant to apply to other chemical messengers used to communicate between cell types. Recently the distinction between hormones and neurotransmitters has been eroded as various peptide neurotransmitters have been shown to exhibit properties of classically defined hormones. These molecules are typically used in intercellular signal transduction, but are not limited to those molecules having slow or systemic effects, or which act at remote sites. Substantial homology in the nucleic acid context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 40% of the residues, generally at least about 45%, more generally at least about 50%, normally at least about 55%, more normally at least about 60%, typically at least about 65%, more typically at least about 70%, usually at least about 75%, more usually at least about 80%, preferably at least about 85%, and more preferably at least about 95% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand or its complement,, typically using a sequence derived from Table 1, 2 or 3. Selectivity of hybridization exists when hybridization occurs which is more selective than total lack of specificity. Normally, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 to 25 nucleotides, generally at least about 65%, typically at least about 75%, usually at least about 85%, preferably at least about 90%, and more preferably at least about 95% or more. See, Kanehisa, M. (1984), Nucleic Acids Res. 12:203-213, which is incorporated herein by reference. Stringent hybridization conditions will include salt concentrations of less than about 2.5 M, generally less than about 1.5 M, typically less than about 1 M, usually less than about 500 mM, and preferably less than about 200 mM. Temperature conditions will normally be greater than 20 β C, more normally greater than about 25 β C, generally greater than about 30 β C, more generally greater than about 35"C, typically greater than about 40 β C, more typically greater than about 45 β C, usually greater than about 50°C, more usually greater than about 55°C, and in particular embodiments will be greater than 60 β C, even as high as 80 β C or more. As other factors may significantly affect the stringency of hybridization, including, among others, base composition and size of the complementary strands, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one. A gene for an insect steroid receptor superfamily member gene includes its upstream (e.g., promoter) and downstream operably linked controlling elements, as well as the complementary strands. See, generally, Watson et al. (1987) The Molecular Biology of the Gene. Benjamin, Menlo Park, which is hereby incorporated herein by reference. A gene geneally also comprises the segment encoding the transcription unit, including both introns and exons. Thus, an isolated gene allows for screening for new steroid receptor genes by probing for genetic sequences which hybridize to either controlling or transcribed segments of a receptor gene of the present invention. Three segments of particular interest are the controlling elements, both upstream and downstream, and segments encoding the DNA-binding segments and the hormone-binding segments. Methods applicable to such screening are analogous to those generally used in hybridization or affinity labeling. Nucleic acid probes will often be labeled using radioactive or non-radioactive labels, many of which are listed in the section on polypeptide labeling. Standard procedures for nucleic acid labeling are described, e.g., in Sambrook et al. (1989); and Ausubel et al. (1987 and supplements) . Insect steroid receptor superfamily member polypeptides A polypeptide sequence of the ecdysone receptor is represented in Table 2. Other insect steroid receptor superfamily member polypeptide sequences are set forth in Tables 1 and 3. Preferred nucleic acid sequences of the cDNAs encoding these insect steroid receptor superfamily member polypeptides are also provided in the corresponding tables. Other nucleic acids will be used to encode the proteins, making use of the degeneracy or non-universality of the genetic code. As used herein, the term "substantially pure" describes a protein or other material, e.g., nucleic acid, which has been separated from its native contaminants. Typically, a monomeric protein is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide backbone. Minor variants or chemical modifications typically share the same polypeptide sequence. Usually a substantially pure protein will comprise over about 85 to 90% of a protein sample, and preferably will be over about 99% pure. Normally, purity is measured on a polyacrylamide gel, with homogeneity determined by staining. Alternatively, for certain purposes high resolution will be necessary and HPLC or a similar means for purification will be used. For most purposes, a simple chromatography column or polyacrylamide gel will be used to determine purity. The term "substantially free of naturally-associated insect cell components" describes a protein or other material, e.g., nucleic acid, which is separated from the native contaminants which accompany it in its natural insect cell state. Thus, a protein which is chemically synthesized or synthesized in a cellular system different from the insect cell from which it naturally originates will be free from its naturally-associated insect cell components. The term is used to describe insect steroid receptor superfamily members and nucleic acids which have been synthesized in mammalian cells or plant cells, E. coli and other procaryotes. The present invention also provides for analogues of the insect steroid receptor superfamily members. Such analogues include both modifications to a polypeptide backbone, e.g., insertions and deletions, genetic variants, and mutants of the polypeptides. Modifications include chemical derivatizations of polypeptides, such as acetylations, carboxylations and the like. They also include glycosylation modifications and processing variants of a typical polypeptide. These processing steps specifically include enzymatic modifications, such as ubiquitinylation. See, e.g., Hershko and Ciechanover (1982), "Mechanisms of Intracellular Protein Breakdown," Ann. Rev. Bioch.. 51:335-364. Other analogues include genetic variants, both natural and induced. Induced mutants are derived from various techniques, e.g., random utagenesis using reagents such as irradiation or exposure to EMS, or engineered changes using site-specific mutagenesis techniques or other techniques of modern molecular biology. See, e.g., Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), CSH Press; and Ausubel et al. (1987 and supplements) Current Protocols in Molecular Biology. Greene/Wiley, New York, each of which is hereby incorporated herein by reference. As described above, the DNA-binding zinc fingers segment of a receptor shows high specificity of recognition of specific target DNA sequences. An understanding of the DNA-protein binding interactions provides for the modification in a rational manner of either DNA or protein characteristics, or both, to effect specificity of binding for modulation of enhancer activity. More importantly, isolation of genes for new members of the insect steroid receptor superfamily allows their use to produce the receptor polypeptides and to isolate new controlling elements. By using the DNA- binding domains, as described above, controlling elements which are responsive to the ligands bound by the corresponding superfamily members are identified and isolated. This procedure shall yield a variety of controlling elements responsive to ligands. By the methods described above, the ligands for any particular member of the insect steroid receptor superfamily will be identified. The controlling elements typically are enhancers, but also include silencers or various other types of ligand-responsive elements. They usually operate over large distances, but will typically be within about 50 kb, usually within about 35 kb, more usually within about 20 kb and preferably within about 7 kb of the genes that these elements regulate. Polypeptide fragments and fusions Besides substantially full-length polypeptides, the present invention provides for biologically active fragments of the polypeptides. Significant biological activities include ligand-binding, DNA binding, immunological activity and other biological activities characteristic of steroid receptor superfamily members. Immunological activities include both immunogenic function in a target immune system, as well as sharing of immunological epitopes for binding, serving as either a competitor or substitute antigen for a steroid receptor epitope. For example, ligand-binding or DNA-binding domains from different polypeptides will be exchanged to form different or new fusion polypeptides or fragments. Thus, new chimaeric polypeptides exhibiting new combinations of specificities result from the functional linkage of ligand-binding specificities to DNA-binding domains. This is extremely useful in the design of inducible expression systems. For immunological purposes, immunogens will sometimes be produced from tandemly repeated polypeptide segments, thereby producing highly antigenic proteins. Alternatively, such polypeptides will serve as highly efficient competitors for specific binding. Production of antibodies to insect steroid receptor superfamily members is described below. The present invention also provides for other polypeptides comprising fragments of steroid receptor superfamily members. Fusion polypeptides between the steroid receptor segments and other homologous or heterologous proteins are provided, e.g., polypeptide comprising contiguous peptide sequences from different proteins. Homologous polypeptides will often be fusions between different steroid receptor superfamily members, resulting in, for instance, a hybrid protein exhibiting ligand specificity of one member and DNA-binding specificity of another. Likewise, heterologous fusions, derived from different polypeptides, will be constructed which would exhibit a combination of properties or activities of the parental proteins. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with another domain of a receptor, e.g., a DNA-binding domain, so that the presence or location of a desired ligand is easily determined. See, e.g., Dull et al., U.S. No. 4,859,609, which is hereby incorporated herein by reference. Other typical gene fusion partners include "zinc finger" segment swapping between DNA-binding proteins, bacterial β-galactosidase, trpE Protein A, β-lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski et al. (1988) , Science 241:812-816; and Experimental section below. Insect steroid receptor superfamily member expression With the sequence of the receptor polypeptides and the recombinant DNA sequences encoding them, large quantities of members of the insect steroid receptor superfamily will be prepared. By the appropriate expression of vectors in cells, high efficiency protein production will be achieved. Thereafter, standard protein purification methods are available, such as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Deutscher (1990) "Guide to Protein Purification" Methods in Enzymoloqy. vol 182 and others; and Ausubel et al. (1987 and supplements) Current Protocols in Molecular Biology, for techniques typically used for protein purification. Alternatively, in some embodiments high efficiency of production is unnecessary, but the presence of a known inducing protein within a carefully engineered expression system is quite valuable. For instance, a combination of: (1) a ligand-responsive enhancer of this type operably linked to (2) a desired gene sequence with (3) the corresponding insect steroid receptor superfamily member will be placed together in an expression system provides a specifically inducible expression system. The desired gene sequence will encode a protein of interest, and the corresponding steroid receptor member will often be the ecdysone receptor. Typically, the expression system will be a cell, but in vitro expression systems will also be constructed. The desired genes will be inserted into any of a wide selection of expression vectors. The selection of an appropriate vector and cell line depends upon the constraints of the desired product. Typical expression vectors are described in Sambrook et al. (1989) and Ausubel et al. (1987 and supplements) . Suitable cell lines are available from a depository, such as the ATCC. See. ATCC Catalogue of Cell Lines and Hybridomas (6th ed.) (1988); ATCC Cell Lines, Viruses, and Antisera, each of which is hereby incorporated herein by reference. The vectors are introduced to the desired cells by standard transformation or transfection procedures as described, for instance, in Sambrook et al. (1989) . Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation are described generally, for example, in Sambrook et al. (1989) , Molecular Cloning: A Laboratory Manual (2d ed.), Vols. 1-3, Cold Spring Harbor Laboratory, which are incorporated herein by reference. Techniques for synthesis of polypeptides are described, for example, in Merrifield, J. Amer. Chem. Soc. 85:2149- 2156 (1963) . The recombinant nucleic acid sequences used to produce fusion proteins of the present invention will typically be derived from natural or synthetic sequences. Many natural gene sequences are obtainable from various cDNA or from genomic libraries using appropriate probes. See. GenBank m , National Institutes of Health. Typical probes for steroid receptors are selected from the sequences of Tables 1, 2 or 3 in accordance with standard procedures. The phosphoramidite method described by Beaucage and Carruthers, Tetra. Letts. 22:1859-1862 (1981) will produce suitable synthetic DNA fragments. A double stranded fragment is then obtainable either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence. With the isolated steroid receptor genes, segments of the transcribed segments are available as probes for isolating homologous sequences usually from different sources, e.g., different animals. By selection of the segment used as a probe, particular functionally associated segments will be isolated. Thus, for example, other nucleic acid segments encoding either ligand- binding or DNA-binding domains of new receptors will be isolated. Alternatively, by using steroid-responsive controlling elements as a probe, new steroid-responsive elements will be isolated, along with the associated segment of DNA whose expression is regulated. This method allows for the isolation of ligand-responsive genes, many of which are, themselves, also members of the insect steroid receptor superfamily. The natural or synthetic DNA fragments coding for a desired steroid receptor fragment will be incorporated into DNA constructs capable of introduction to and expression in an .in vitro cell culture. Usually the DNA constructs will be suitable for replication in a unicellular host, such as yeast or bacteria, but alternatively are intended for introduction to, with or without integration into the genome, cultured mammalian or plant or other eucaryotic cell lines. DNA constructs prepared for introduction into bacteria or yeast will typically include a replication system recognized by the host, the intended DNA fragment encoding the desired receptor polypeptide, transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment and transcriptional and translational termination regulatory sequences operably linked to the polypeptide encoding segment. The transcriptional regulatory sequences will typically include a heterologous enhancer or promoter which is recognized by the host. The selection of an appropriate promoter will depend upon the host, but promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters are known. See. Sambrook et al. (1989) . Conveniently available expression vectors which include the replication system and transcriptional and translational regulatory sequences together with the insertion site for the steroid receptor DNA sequence will generally be employed. Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al. (1989); see also. Metzger et al. (1988), Nature 334:31-36. Genetic constructs The DNA segments encoding the members of the insect steroid receptor superfamily will typically be utilized in a plasmid vector. In one embodiment an expression control DNA sequence is operably linked to the insect steroid receptor superfamily member coding sequences for expression of the insect steroid receptor superfamily member alone. In a second embodiment an insect steroid receptor superfamily member provides the capability to express another protein in response to the presence of an insect steroid receptor ligand. This latter embodiment is separately described below. The expression control sequences will commonly include eukaryotic enhancer or promoter systems in vectors capable of transforming or transfecting eucaryotic host cells. Once the vector has been introduced into the appropriate host, the host, depending on the use, will be maintained under conditions suitable for high level expression of the nucleotide sequences. Steroid-responsive expression of selected genes For steroid-responsive expression of other genes, the steroid receptor gene will typically be cotransformed with a recombinant construct comprising a desired gene for expression operably linked to the steroid-responsive enhancer or promoter element. In this use, a single expression system will typically comprise a combination of (1) a controlling element responsive to a ligand of an insect steroid receptor superfamily member, (2) a desired gene for expression, operably linked to the controlling element, and (3) an insect steroid receptor superfamily member which can bind to the controlling element. Usually, this system will be employed within a cell, but an in vitro system is also possible. The insect steroid receptor superfamily member will typically be provided by expression of a nucleic acid encoding it, though it need not be expressed at high levels. Thus, in one preferred embodiment, the system will be achieved through cotransformation of a cell with both the regulatable construct and another segment encoding the insect steroid receptor superfamily member. Usually, the controlling element will be an enhancer element, but some elements work to repress expression. In this embodiment, the ligand for the insect steroid receptor superfamily member will be provided or withheld as appropriate for the desired expression properties. A particularly useful genetic construct comprises an alcohol dehydrogenase promoter operably linked to an easily assayable reporter gene, e.g., β-galactosidase. In a preferred embodiment of this construct, a multiplicity of copies of the insect steroid receptor superfamily member is used. For example, operable linkage of controlling elements responsive to insect steroid receptor superfamily members, e,g. , EcR, DHR3, E75A and E75B, to the alcohol dehydrogenase (ADH) promoter, or others as described above, and protein coding sequences for a particular reporter protein, as described above, leads to steroid-responsive expression of β-galactosidase. Such a system provides highly sensitive detection of expression in response to ligand binding, allowing for detection of a productive ligand- receptor interaction. DNA sequences will normally be expressed in hosts after the sequences have been operably linked to (i.e., positioned to ensure the functioning of) an expression control sequence. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, e.g., U.S. Patent 4,704,362, which is incorporated herein by reference) . E. coli is one procaryotic host useful for cloning the DNA sequences of the present invention. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella. Serratia. and various Pseudomonas species. Other eucaryotic cells will often be used, including yeast cells, insect tissue culture cells, avian cells, or the like. Preferably, mammalian tissue cell culture will be used to produce the inducible polypeptides of the present invention (see. Winnacker, From Genes to Clones. VCH Publishers, N.Y. (1987) , which is incorporated herein by reference) . Mammalian cells are preferred cells in which to use the insect steroid receptor superfamily member ligand-responsive gene constructs, because they naturally lack the molecules which confer responses to the ligands for insect steroid receptor superfamily members. Mammalian cells are preferred because they are insensitive to many ligands for insect steroid receptor superfamily member. Thus, exposure of these cells to the ligands of the insect steroid receptor superfamily members typically will have negligible physiological or other effects on the cells, or on a whole organism. Therefore, cells can grow and express the desired product, substantially unaffected by the presence of the ligand itself. The ligand will function to cause response either in the positive or negative direction. For example, it is often desirable to grow cells to high density before expression. In a positive induction system, the inducing ligand would be added upon reaching high cell density, but since the ligand itself is benign to the cells, the only physiological imbalances result from the expression, e.g., the product, itself. Alternatively, in a negative repression system, the ligand is supplied until the cells reach a high density. Upon reaching a high density, the ligand would be removed. Introduction of these cells into a whole organism, e.g., a plant or animal, will provide the products of expression to that organism. In this circumstance, the natural insensitivity of cells to the ligands will also be advantageous. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferably, the enhancers or promoters will be those naturally associated with genes encoding the steroid receptors, although it will be understood that in many cases others will be equally or more appropriate. Other preferred expression control sequences are enhancers or promoters derived from viruses, such as SV40, Adenovirus, Bovine Papilloma Virus, and the like. Similarly, preferred promoters are those found naturally in immunoglobulin-producing cells (see. U.S. Patent No. 4,663,281, which is incorporated herein by reference) , but SV40, polyoma virus, cytomegalovirus (human or murine) and the LTR from various retroviruses (such as murine leukemia virus, murine or Rous sarcoma virus and HIV) are also available. See. Enhancers and Eukaryotic Gene Expression. Cold Spring Harbor Press, N.Y., 1983, which is incorporated herein by reference. The vectors containing the DNA segments of interest (e.g., the steroid receptor gene, the recombinant steroid-responsive gene, or both) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for procaryotic cells, whereas calcium phosphate treatment is often used for other cellular hosts. See, generally, Sambrook et al. (1989) , Molecular Cloning: A Laboratory Manual (2d ed.), Cold Spring Harbor Press; Ausubel et al. (1987 and supplements) Cement Protocls in Molecular Biology. Greene/Wiley, New York; and Potrykus (1990) "Gene Transfer to Cereals: An Assessment," Bio/Technology 8:535-542, each of which is incorporated herein by reference. Other transformation techniques include electroporation, DEAE-dextran, microprojectile bombardment, lipofeetion, microinjection, and others. The term "transformed cell" is meant to also include the progeny of a transformed cell. As with the purified polypeptides, the nucleic acid segments associated with the ligand-binding segment and the DNA-binding segment are particularly useful. These gene segments will be used as probes for screening for new genes exhibiting similar biological activities, though the controlling elements of these genes are of equal importance, as described below. Many types of proteins are preferentially produced in eucaryotic cell types because of abnormal processing or modification in other cell types. Thus, mammalian proteins are preferably expressed in mammalian cell cultures. Efficient expression of a desired protein is often achieved, as described above, by placing: (1) a desired protein encoding DNA sequence adjacent to controlling elements responsive to ligands for insect steroid receptor superfamily members and an appropriate promoter. Cyclic pulses of ligands in a cell culture may provide periods for cells to recover from effects of production of large amounts of exogenous protein. Upon recovery, the ligand will often be reinduced. Additional steroid responsive gene elements have also been isolated, e.g., substantially purified, using the techniques of the present invention. Other genes adjacent to, and operably linked to, steroid responsive gene control elements are selectable by locating DNA segments to which steroid receptors specifically bind or by hybridization to homologous controlling elements. For example, other steroid responsive genes have been isolated. Many of the genes which are ligand-responsive will also be new members of the insect steroid receptor superfamily. Having provided for the substantially pure polypeptides, biologically active fragments thereof and recombinant nucleic acids comprising genes for them, the present invention also provides cells comprising each of them. By appropriate introduction techniques well known in the field, cells comprising them will be produced. See, e.g., Sambrook et al. (1989). In particular, cells comprising the steroid responsive controlling elements are provided, and operable linkage of standard protein encoding segments to said controlling elements produce steroid responsive systems for gene expression. Cells so produced will often be part of, or be introduced into, intact organisms, for example, plants, insects (including caterpillars and larvae), and higher animals, e.g., mammals. This provides for regulatable expression of desired genes where the regulating ligand has no other effects on the cells because the cells otherwise lack the receptors and responsive genes. For example, plants will be induced to fruit at desired times by administration of the appropriate ligand, or animals will be ligand- responsive in production of particular products. And, in fact, biochemical deficiencies may be overcome by ligand- responsive expression of cells introduced into an intact organism which, itself, also otherwise lacks genes responsive to the presence of such a ligand. Multiple repeats of the control elements will lead, often, to at least additive or synergistic control. Cells containing these expression systems will be used in gene therapy procedures, including in humans. Once a sufficient quantity of the desired steroid receptor polypeptide has been obtained, the protein is useful for many purposes. A typical use is the production of antibodies specific for binding to steroid receptors. These antibodies, either polyclonal or monoclonal, will be produced by available in vitro or in vivo techniques. For production of polyclonal antibodies, an appropriate target immune system is selected, typically a mouse or rabbit. The substantially purified antigen is presented to the immune system in a fashion determined by methods appropriate for the animal and other parameters well known to immunologists. Typical sites for injection are in the footpads, intramuscularly, intraperitoneally, or intradermally. Of course, another species will often be substituted for a mouse or rabbit. An immunological response is usually assayed with an immunoassay. Normally such immunoassays involve some purification of a source of antigen, for example, produced by the same cells and in the same fashion as the antigen was produced. The immunoassay will generally be a radioimmunoassay, an enzyme-linked assay (ELISA) , a fluorescent assay, or any of many other choices, most of which are functionally equivalent but each will exhibit advantages under specific conditions. Monoclonal antibodies with affinities of 10 8 M—1 preferably 10 9 to 1010 , or stronger will typically be made by standard procedures as described, e.g., in Harlow and Lane (1988) , Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; or Goding (1986) , Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York, which are hereby incorporated herein by reference. Briefly, appropriate animals will be selected and the desired immunization protocol followed. After the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused, typically, to immortalized myeloma cells under appropriate selection conditions. Thereafter the cells are clonally separated and the supernatants of each clone are tested for their production of an appropriate antibody specific for the desired region of the antigen. Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse et al., (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281, hereby incorporated herein by reference. The polypeptides and antibodies of the present invention will be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescens, chemiluminescers, magnetic particles and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant, chimeric, or humanized, immunoglobulins will be produced, see, e.g., Cabilly, U.S. Patent No. 4,816,567; Jones et al., 1986, Nature 321, 522-526; and published UK patent application No. 8707252; each of which is hereby incorporated herein by reference. Another use of purified receptor polypeptides is for determination of the structural and biosynthetic aspects of the polypeptides. Structural studies of interactions of the ligand-binding domains with selected ligands are performed by various methods. The preferred method for structural determination is X-ray crystallography but may include various other forms of spectroscopy or chromatography. See, e.g., Connolly, M.L., . Appl. Crvstall.. 16:548 (1983); Connolly, M.L., Science 221:709 (1983) ; and Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York; each of which is hereby incorporated herein by reference. For example, the structure of the interaction between hormone ligand and hormone-binding segments is determined to high resolution. From this information, minor substitutions or modifications to either or both of the ligand and ligand-binding segment are made based upon, e.g., the contact regions between the two. This information enables the generation of modified interactions between a ligand and its binding segment to either increase or decrease affinity of binding and perhaps increase or decrease response to binding. Likewise, the interaction between the zinc finger DNA-binding segments with the specific nucleic acid-binding sequence will be similarly modified. As a separate and additional approach, isolated ligand-binding polypeptide domains will be utilized to screen for new ligands. Binding assays will be developed, analogous, e.g., to immunoassays. This procedure permits screening for new agonists or antagonists of a particular steroid receptor. Isolated DNA-binding segments will be used to screen for new DNA sequences which will specifically bind to a particular receptor-binding segment. Typically, these receptor- specific binding sites will be controlling elements for steroid responsive genes. Thus, having isolated these DNA-binding sequences, genes which are responsive to the binding of a given receptor can be isolated. This provides a method for isolating genes which are responsive to induction or inhibition by a given hormone receptor. In another aspect of the present invention, means for disrupting insect development are provided where new ligand agonists or antagonists are discovered. These compounds are prime candidates as agonists or antagonists to interfere with normal insect development. By application of new steroid analogues of ligands for insect steroid receptor superfamily members, it is possible to modify the normal temporal sequence of developmental events. For example, accelerating insect development will minimize generation time. This will be very important in circumstances where large numbers of insects are desired finally, for instance, in producing sterile males in Mediterranean fly infestations. Alternatively, it is useful to slow development in some pest infestations, such that the insects reach destructive stages of development only after commercial crops have passed sensitive stages. In another commercial application, ligands discovered by methods provided by the present invention will be used in the silk-production industry. Here, the silkworms are artificially maintained in a silk-producing larvae stage, thereby being silk productive for extended time periods. The development of larvae will also be susceptible to acceleration to silk-production in a shorter time period than than naturally. Other analogues of ligands for insect steroid receptor superfamily members will be selected which, upon application, will completely disrupt normal development and, preferably, lead to a lethal result. Slightly modified natural substances will often have greater specificity of action and much higher activities, allowing for lower levels of application. For example, more lipophilic ligands are more readily absorbed directly into the insect surface or cuticle. Thus, extremely low concentrations of natural ligands should be effective in controlling pests. Furthermore, many of these ligands are likely to be relatively easily manufactured, taking advantage of enzymatic production methods. New ligands for insect steroid receptor superfamily members will sometimes be more species specific or will exhibit particularly useful characteristics, for example, being lethal to specific harmful insects. The greater specificity of the hormones will allow avoidance of the use of non-specific pesticides possessing undesired deleterious ecological side effects, e.g., pesticide residue accumulation in food, often having deleterious effects on humans. Furthermore, compounds having structures closely analogous to natural compounds should be susceptible to natural mechanisms of biological degradation. Another aspect of the present invention provides for the isolation or design of new gene segments which are responsive to ligands for insect steroid receptor superfamily members. For example, use of the nucleic acids to screen for homologous sequences by standard techniques will provide genes having similar structural features. Similarly arranged intron structures will typically be characteristic of larger superfamily categories. The preferred domains for screening will be the ligand-binding or DNA-binding segments, although the DNA segments which are recognized by the DNA-binding domains, i.e., the controlling elements, will also be of particular interest. Screening for new controlling elements will usually take advantage of known similarities, e.g., sequence homology to other known elements, or homology to the DNA zinc finger-binding domains of other receptors. Receptors and genes important in the general developmental sequence of expression will be discovered. Using this set of developmentally regulated genes will allow selection of particular molecules which are responsible for controlling expression of developmentally regulated genes. Kits for the determination of expression levels of the nucleic acids and proteins provided herein are made available. Typically, the kit will have at least one compartment which contains a reagent which specifically binds to the desired target molecule, e.g., ligand analogues, receptors, or nucleic acids. These reagents will be used in techniques for assays, e.g., using methods typically used in screening protocols. See, e.g., Sambrook et al. (1989) and Ausubel et al. (1987 and supplements) . The following experimental section is offered by way of example and not by limitation. EXPERIMENTAL EXAMPLE I CLONING STRUCTURE AND EXPRESSION OF THE DROSOPHILA E75 GENE THAT ENCODES TWO MEMBERS OF THE STEROID RECEPTOR SUPERFAMILY. The following experiments demonstrate that the E75 gene encodes two members of the steroid receptor superfamily. The proteins it encodes share amino acid sequence homology with the conserved DNA-binding and ligand-binding domains of this superfamily. The E75 gene is ecdysone-inducible, and it occupies and causes the ecdysone-inducible early puff at the 75B locus in the Drosophila polytene chromosome. A. Cloning of Genomic DNA Encompassing the Ecdysone-inducible 75B Puff Locus We have used the method of chromosomal walking (Bender, W. , P. Spierer, and D. S. Hogness, 1983. Chromosomal walking and jumping to isolate DNA from the Ace and rosy loci and the Bithorax complex in Drosophila melanogaster. J. Mol. Biol. 168:17-33) to isolate the genomic DNA encompassing the 75B puff region. The starting point for the walk was a genomic clone, designated A8253, which had been localized by in situ hybridization to the proximal end of 75B. Isolated restriction fragments of A8253 were used to screen a library of genomic DNA from the Canton S (C s ) strain of D. melanogaster. See (Maniatis, T., R. C. Hardison, E. Lacy, J. Lauer, C. O'Connell, D. Quon, G. K. Sim, and A. Efstradiatis, 1978, "The isolation of structural genes from libraries of eucaryotic DNA." Cell 15:687-701). Genomic clones λcDm3504 and λcDm3505 were isolated by homology to A8253. The walk was then extended in both directions until -100 kb of genomic DNA had been isolated, and the orientation of the walk was determined by in situ hybridization of the terminal segments to polytene chromosomes. Thereafter, the walk was extended in the rightward direction on the molecular map, or distally relative to the centromere. The 350 kb of genomic DNA encompassed by the walk corresponds to the chromosomal region between bands 75A6-7 and 75B11-13, as determined by in situ hybridization. This region includes the 75B puff, which appears to initiate by simultaneous decondensation of chromosomal bands 75B3-5 and then spreads to surrounding bands. Methods Genomic DNA libraries Canton S genomic DNAs were isolated from a library of sheared, EcoRI-linkered Canton S DNA cloned into the Charon 4 λ phage vector. See (Maniatis, T. , R. C. Hardison, E. Lacy, J. Lauer, C. O'Connell, D. Quon, G. K. Sim, and A. Efstradiatis, 1978. The isolation of structural genes from libraries of eucaryotic DNA. Cell 15:687-701). 0 r genomic DNAs were isolated from a library of sheared DNA, GC-tailed into the sep6 λ vector. See (Meyerowitz, F. M. , and D. S. Hogness, 1982. "Molecular organization of a Drosophila puff site that responds to ecdysone." Cell 28:165-176). One step in the chromosomal walk was taken using a cosmid library of SauIIIA partially digested 0 r DNA cloned into the cosmid pl4Bl by the method of Ish-Horowicz and Burke (Ish- Horowicz, D. , and J. F. Burke, 1982. Rapid and efficient cosmid cloning. Nucleic Acids Res. 9:2989-2998). In situ hybridization In situ hybridization to polytene chromosomes was carried out with DNA probes that were nick-translated in the presence of 3 H-labeled TTP (NEN) , as described by Bonner and Pardue (Bonner, J. J., and M. L. Pardue, 1976. Ecdysone-stimulated RNA synthesis in imaginal discs of Drosophila melanogaster. Assay by in situ hybridization. Chromosoma 58:87-99), with the following modifications: Heat and RNAase treatments of the slides were omitted, and hybridization and washing were at 63 β C in 2XSSPE for 18 and 2 hours, respectively. B. Identification of a 50 kb Region of Cloned Genomic DNA that Contains Sequences Homologous to Ecdysone-induced Transcripts Restriction fragments of the above genomic clones were tested for their ability to hybridize with each of two cDNA probes, one derived from the RNA in ecdysone- induced cells, and the other from the RNA in noninduced cells. Two differential screens were carried out. In the first, genomic DNA covering the entire 350 kb walk was examined with cDNA probes synthesized with reverse transcriptase from an oligo(dT) primer annealed to poly(A)+ RNA. The poly(A)+ RNA was prepared from total inner tissues that were mass-isolated from late third instar larvae and incubated in the presence of ecdysone plus cycloheximide, or cycloheximide alone. (See Methods, below. Cycloheximide was included because higher levels of ecdysone-induced transcripts accumulate in its presence.) Each of the 32 P-labeled cDNA probes made from these two poly(A)+ RNAs was applied to one of two duplicate Southern blots that contained, in addition to the genomic fragments from the walk, a control DNA consisting of sequences from the ribosomal protein 49 gene (O'Connell, P., and M. Rosbash, 1984. Sequence, structure and codon preference of the Drosophila ribosomal protein 49 gene. Nucleic Acids Res. 12:5495-5513), which was used to normalize the hybridization intensities of the duplicate blots. This screen revealed sequences specific to ecdysone-induced RNAs only within the λcDm3522 genomic clone that is centered at approximately +220 kb on the molecular map. Because the above probes will preferentially detect sequences near the 3' termini of the RNAs, particularly in the case of long transcripts, a second differential screen was carried out with cDNA probes primed with random hexamers (see Methods, below) . This screen, which was restricted to the 135 kb of genomic DNA between +105 kb and +240 kb, revealed ecdysone-inducible sequences in fragments spread out over an -50 kb region between +170 kb and +220 kb. This region represents the E75 gene. Methods Organ culture and RNA isolation Late third instar O r larvae were harvested, washed in 0.7% NaCl, resuspended in Robb's phosphate-buffered saline (PBS) (Robb, J. A., 1968. Maintenance of imaginal discs of Drosophila melanogaster in chemically defined media. J. Cell. Biol. 41:876-885), preaerated with a blender, and passed through a set of rollers to extrude the organs. This "grindate" was filtered through a coarse Nitex screen to remove carcasses, and settled five times (3-5 minutes per settling) by gravity to remove floating and microscopic debris. Isolated tissues (primarily salivary glands, imaginal discs, gut, and Malphigian tubules) were cultured at 25 β C in plastic petri dishes in aerated Robb's PBS. β-ecdysone (Sigma) (0.2 μl/ml of 10 mg/ml) in ethanol and/or cycloheximide (2 μl/ml of 35 mM) in water was added to the appropriate cultures. Incubations in the presence of cycloheximide were for ~8 hours. Isolated tissues were homogenized in 10 volumes of 6 M guanidine-HCl/0.6 M sodium acetate (pH 5.2), centrifuged at 5000 g for 10 minutes to remove debris, and layered onto a 5.7 M CaCl shelf, as described previously (Chirgwin, J. M. , A. E. Przbyla, R. J. MacDonald, and W. J. Rutter, 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299). Poly(A)+ RNA was purified by oligo(dT) chromatography. Southern blot analysis Southern blots were performed on nitrocellulose, as described previously (Segraves, W. A., C. Louis, S. Tsubota, P. Schedl, J. M. Rawls, and B. P. Jarry, 1984. The rudimentary locus of Drosophila melanogaster. J. Mol. Biol. 175:1-17). cDNA probes were prepared by reverse transcription (AMV reverse transcriptase; Seikagaku) of 2 μg of poly(A)+ RNA with 700 ng of oligo(dT) 12~16 (Collaborative Research) or 15 μg of random hexamers (Pharmacia) in a 20 μl reaction mixture containing 80 mM Tris Cl (pH 8.3 at 42°C), 10 mM MgCl 2 , 100 mM KC1, 0.4 mM DTT, 0.25 mM each of dATP, dGTP, and dTTP, and 100 μCi of [ 32 P]dCTP (800 Ci/mole; Amersham) . After incubation at 37 e C for 45 minutes, 80 μl of 10 mM EDTA and 2 μl of 5 N NaOH were added before incubation at 70 β C for 10 minutes to denature the products and hydrolyze the RNA. After the addition of 10 μl of 1 M Tris-Cl (pH 7.5) and 5 μl of 1 N HC1, unincorporated label was removed by chromatography on Biogel P60. C. The E75 Gene Contains Two Overlapping Transcription Units: E75A and E75B Northern blot analysis of ecdysone-induced and noninduced RNAs, prepared as described above and hybridized with strand-specific DNA probes derived from cloned restriction fragments in the 60 kb region (+166 to +226 kb) containing the E75 gene, demonstrated that this gene produces two classes of ecdysone-inducible mRNAs, both derived from rightward transcription. The E75A class of mRNAs hybridized with probes from both the 5' (left) and 3* (right) ends of the 50 kb E75 gene. The E75B class hybridized only with probes from the 3'- proximal 20 kb of the gene. These results suggest that the A and B classes of ecdysone-inducible RNAs are initiated by different promoters, located about 30 kb apart, and that the two transcription units defined by these promoters overlap in the region downstream from the B promoter. This suggestion was confirmed by analysis of the structure of cloned cDNAs from the E75A and E75B mRNAs. Approximately IO 6 clones from an early pupal cDNA library (Poole, S. J., L. M. Kauvar, B. Drees, and T. Kornberg, 1985. The engrailed locus of Drosophila: Structural analysis of an embryonic transcript. Cell 40:37-40) were screened at low resolution with genomic DNA probes from the E75 gene region. The 116 cDNA clones identified by this screen were analyzed by restriction digestion and hybridization to a panel of probes derived from the 60 kb (+166 to +226 kb) region. One of the clones, λDm4925, was thereby selected as a representative of the E75A class of mRNAs, and another, λDm4745, as a representative of the E75B mRNA class. The genomic regions homologous to these two cDNA clones were further localized by Southern blot analysis, and the nucleotide sequence of these regions and of both cDNA clones was determined. These sequences are given in Table 1, along with those derived from 5• and 3' terminal sequence determinations for each transcription unit. These data demonstrate that the 50 kb E75A transcription unit consists of six exons, labeled in 5' to 3' order: A0, Al, 2, 3, 4 and 5, of which exons A0 and Al are specific to this unit, while the remaining four are shared with the 20 kb E75B transcription unit. Similarly, the E75B unit contains a specific exon, labeled Bl, at its 5' end, which is located just upstream of the shared exon 2. Thus, the E75 gene consists of two transcription units, of which the shorter E75B unit occupies the 3' proximal 20 kb of the longer E75A unit. Table 1. Sequences of the E75 exons and flanking DNA. The sequence is that of the C s genomic DNA, which was identical to that of the cDNAs, except for the T→G change indicated at position +2691. This change would convert a leucine to an arginine in the protein sequences. The Dm4925 cDNA extends from just 5' of the EcoRV site at +939 to +4267 in A. The Dm4745 cDNA extends from +804 in B to a point near the Hindlll site at +4246 in A. (A) The E75 A exons and flanking DNA. The sequences of the A0, Al, and common exons 2-5 are interrupted by intron sequences (lowercase) , which are limited to those near the splice sites and are in agreement with consensus sequences for donor (5•) and acceptor (3') splice sites. Negative numbers at the right end of each line refer to the number of base pairs upstream of the E75 A initiation site, positive numbers refer to positions in the E75 A mRNAs, continuing into the 3* flanking DNA. Numbers at the left end of each line refer to amino acid residues in the E75 A protein. The underlined 14 bp sequence at -159 to -172 exhibits a 13/14 bp match to a sequence (CGTAGCGGGTCTC) found 47 bp upstream of the ecdysone-inducible E74 A transcription unit responsible for the early puff at 74EF. This sequence represents the proximal part of a 19 bp sequence in the E74 A promoter that binds the protein encoded by the D. me1anogaster zeste gene. Another underlined sequence in the E75 A promoter at -74 to -82 is also found in the E75 B promoter, where it is part of a tandemly repeated octanucleotide (GAGAGAGC) located at -106 to -121 in B. This repeat matches the consensus sequence for the binding sites of the GAGA transcription factor which also binds to the E74 A promoter. Other underlined sequences represent, at -27 to -33, the best match to the TATA box consensus at an appropriate position, three AUG codons that are closely followed by in-frame stop codons in the 5'-leader sequence of the E75 mRNAs, and alternative polyadenylation-cleavage signals at 4591 and 5365 that are used by both E75 A and E75B mRNAs. (B) The Bl exon and its 5'-flanking DNA. The numbering at the right and left ends of the lines follows the same convention as in A. Exons 2-5 shown in A are also used in E75 B, but the amino acid residues and base pair numbers shown in A must be increased by 157 and 375, respectively, to apply to the E75 B protein and mRNA. The first ten nucleotides of the 136-nucleotide E75 B-intron linking the Bl exon to Exon 2 are gtaggttag, whereas the last ten are shown upstream of nucleotide 1178 in A. The underlined sequences represent, in order, the region of homology to a sequence upstream of E75 A, noted above, the best match to the TATA box consensus at -21 to -27, and three AUG codons followed by in-frame stop codons in the 5' leader of the E75 B mRNA. Panels 1 and 2 are shown in detail in panels 3-8, and 9-10, respectively. Methods cDNA libraries The λDm4925 and λDm4745 cDNAs were isolated from an 0 r early pupal cDNA library in λgtlO (Poole, S. J., L. M. Kauvar, B. Drees, and T. Kornberg, 1985. The engrailed locus of Drosophila: structural analysis of an embryonic transcript. Cell 40:37-40). The two cDNAs (ADm4927 and λDm4928) that were used for 3'-end mapping were isolated from an ecdysone-induced salivary gland cDNA library in A607 prepared by C. W. Jones. (Our strain collection names for the cDNA clones used in these studies are λfDm4925, λfDm4745, AeDm4927, and λeDm4928.) Northern blot analysis Probes to be used for Northern blots were cloned into the vector pøX (from R. Mulligan) , containing the 0X174 origin of replication cloned in between the Hindlll and BamHI sites of pBR322. This allowed the synthesis of single-stranded probe DNA (Arai, K. , N. Arai, J. Schlomai, and A. Kornberg, 1980. Replication of duplex DNA of phage φX174 reconstituted with purified enzymes. Proc. Natl. Acad. Sci. 77:3322-3326), which was performed by the incubation of .supercoiled plasmid DNA with gene A protein. rep and ssb proteins, and DNA polymerase III holoenzyme in a reaction containing 20 M Tris Cl (pH 7.5), 80 μg/ml BSA, 4% glycerol, 20 mM DTT, 1 mM ATP, 16 mM concentrations of the three unlabeled deoxynucleotides and 1.6 mM concentrations of the labeled deoxynucleotide for 1 hour at 30 β C. EDTA was then added to 20 mM, SDS to 0.1%, and proteinase K to 50 μg/ml. The reactions were digested for 30 minutes at 37°C, and unincorporated label was removed by gel filtration. SI nuclease protection and primer extension analysis Single-stranded probes, prepared as described above by the φX in vitro replication system, were purified by electrophoresis on low melting point agarose gels for use as SI probes. All other probes were prepared by extension of the -20, 17-mer sequencing primer (New England Biolabs) on single-stranded M13mp (Messing, J. , 1983. New M13 vectors for cloning. Methods Enzymol. 101:20-78) or pEMBL (Dente, L. , G. Cesareni, and R. Cortes, 1983. pEMBL: A new family of single-stranded plasmids. Nucleic Acids Res. 11:1645-1654) recombinant templates using 32 P-labeled nucleotides, followed by cleavage with the appropriate restriction enzyme and purification of the probe on denaturing polyacrylamide gels. Labeled probe (100,000-300,000 cpm) was incubated with 1 μg of poly(A)+ RNA in a 5 μl reaction mixture containing 5 μg of yeast tRNA, 0.4 M NaCl, 40 mM PIPES (pH 6.8), and 1 mM EDTA at 60 β C under oil. Reactions were cooled and diluted 1:10 into either SI digestion or primer extension buffer. SI nuclease digestions were performed in 50 mM acetate buffer (Na) , 400 mM NaCl, and 4 mM ZnS0 4 at 20 β C for 1 hour with -15 - 150 Vogt units of SI nuclease (Boehringer) per 50 μl reaction. Primer extensions were performed at 42*C in 50 mM Tris Cl (pH 8.3 at 42 β C), 80 mM KC1, 2 mM DTT, 1 mM of dATP, dCTP, dGTP, and dTTP, with 20 units of AMV reverse transcriptase (Seikagaku) per 50 μl reaction. Reactions were terminated by the addition of EDTA, tRNA carrier was added to the SI nuclease digestions, and samples were ethanol-precipitated and either electrophoresed directly on 5% or 6% denaturing polyacrylamide gels or glyoxalated (McMaster, G. K. , and G. C. Carmichael, 1977. Analysis of single and double-stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal and acridine orange. Proc. Natl. Acad. Sci. 74:4835-4838) and electrophoresed on 1% agarose gels run in 10 mM sodium phosphate buffer (pH 6.8). DNA sequence analysis The cDNA clones λDm4927 and λDm4928 were sequenced by chemical degradation (Maxam, A. M. , and W. Gilbert, 1980. Sequencing end-labeled DNA with base-specific chemical cleavage. Methods Enzymol. 65:499-560) . All other sequencing was performed using the dideoxynucleotide chain termination method (Sanger, F., A. R. Coulson, B. F. Barrell, A. J. H. Smith, and B. A. Roe, 1980. Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J. Mol. Biol. 143:161-178). Fragments were cloned into M13mp vectors (Messing, J., 1983. New M13 vectors for cloning. Methods Enzymol. 101:20-78) or pEMBL (Dente, L. , G. Cesareni, and R. Cortes, 1983. pEMBL: A new family of single-stranded plasmids. Nucleic Acids Res. 11:1645- 1654) and sequenced directly or following the generation of a set of overlapping deletions using exonuclease III (Henikoff, S., 1984. Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing. Gene 28:351-359). Sequencing was performed on both strands of the λDm4925 cDNA, the B-specific region of λDm4745 cDNA, the A- and B-specific 5' genomic regions not represented in the cDNAs, and the 3'-flanking region. The remaining exon boundaries of λDm4745 and genomic regions represented within the cDNA clones were sequenced on one strand. D. The E75 Gene Encodes Two Members of the Steroid Receptor Superfamily The coding and noncoding sequences of the E75 A and B mRNAs, their splice junctions, and the 5' and 3' flanking sequences are shown in Table 1. Certain sequences of potential interest within the 5' flanking DNA and in the 5' leader mRNA sequences are indicated in the legend to Table 1. We focus here on the large open reading frames of the E75 A and B mRNAs that begin at 380 bp and 284 bp downstream from their respective mRNA start sites, each continuing into the common final exon. The termination codon in exon 5 lies upstream of both alternative polyadenylation sites; thus, the sequence of the encoded protein is not affected by which site is selected. Since the open reading frames in the E75 A and B mRNAs begin in the AO and Bl exons and merge at the beginning of exon 2, the proteins encoded by the two transcription units differ in the amino-terminal region and are the same in the carboxy-terminal region. The specific amino-terminal regions contain 266 and 423 amino acid residues in the E75 A and B proteins, respectively, while their common carboxy-terminal region consists of 971 residues. The predicted molecular weights of the A and B proteins are thus 132,000 and 151,000. The open reading frames display characteristic D. melanogaster codon usage, and their extents have been confirmed by in vitro translation of mRNAs transcribed in vitro from cDNA constructs and by expression of fusion proteins in E. coli. The predicted protein sequence for each protein is punctuated by homopolymeric tracts of amino acids, which are noted in Table 1 and its legend. Analysis of the sequences of E75 proteins and comparison to the sequences of known proteins have revealed similarity between the E75 proteins and members of the steroid receptor superfamily (Evans, R. M. , 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895;- Green, S., and P. Chambon, 1988. Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 4:309-314). We have used the nomenclature of Krust el al. (Krust, A., S. Green, P. Argos, V. Kumar, P. Walter, J. Bornert, and P. Chambon, 1986. The chicken oestrogen receptor sequence: Homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J. 5:891-897) in dividing the proteins into six regions, A to F, in the amino- to carboxy-terminal direction. Similarity between E75A and other members of this superfamily is strongest in the C region, a cysteine- lysine-arginine-rich region that is necessary and sufficient for the binding of these receptors to DNA (for review, see, Evans, R. M. , 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895; Green, S., and P. Chambon, 1988. Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 4:309-314). The C region consists of 66-68 amino acids, of which 20 residues are invariant within this family. Among these are nine invariant cysteine residues, eight are believed to coordinate zinc in the formation of two zinc finger-like structures (Miller, J., A. D. McLachlan, and A. Klug, 1985. Representative zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J. 4:1609-1614; Freedman, L. P., B. F. Luisi, Z. R. Korszun, R. Basavappa, P. B. Sigler, and K. R. Yamamoto, 1988. The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334:543-546; Severne, Y., S. Wieland, W. Schaffner, and S. Rusconi, 1988. Metal binding finger structure of the glucocorticoid receptor defined by site- directed mutagenesis. EMBO J. 9:2503-2508). Within the C region, E75A contains all of the highly conserved residues and is approximately as closely related to other members of the steroid receptor superfamily as they are to one another. The closest relative of E75 appears to be the human ear-1 gene, which has nearly 80% amino acid identity to E75 A in the DNA-binding domain. The other region conserved among members of the steroid receptor superfamily is the E region, which is required for steroid binding and for the linkage of steroid-binding and trans-activation functions (for review, see. Evans, R. M. , 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895; Green, S., and P. Chambon, 1988. Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 4:309-314). Although overall E-region similarity is clearly significant for the comparison of E75 A to the thyroid hormone, vitamin D, and retinoic acid receptors, and ear-1, similarity to the glucocorticoid and estrogen receptors is considerably lower. However, the plots of local similarities show a clear similarity to each of these proteins within three subregions of the E region, denoted El, E2 and E3. The El subregion is the most highly conserved and corresponds to a region shown by m vitro mutagenesis to be essential for steroid binding and steroid-dependent trans- activation (Giguere, V., S. M. Hollenberg, M. G. Rosenfield, and R. M. Evans, 1986. Functional domains of the human glucocorticoid receptor. Cell 46:645-652; Danielson, M. , J. P. Northrop, J. Jonklaas, and G. M. Ringold, 1987. Domains of the glucocorticoid receptor involved in specific and nonspecific deoxyribonucleic acid binding, hormone activation and transcriptional enhancement. Mol. Endocrinol. 1:816- 822) . Region E2 is less highly conserved in primary amino acid sequence, but can, in part, be seen as a conserved hydrophobic region in the hydropathy plots of several of these proteins. A deletion of 14 amino acids within this region abolished steroid binding (Rusconi, S., and K. R. Yamamoto, 1987. Functional dissection of the hormone and DNA binding activities of the glucocorticoid receptor. EMBO J. 6:1309-1315). E3 falls close to the end of the region that is absolutely required for steroid binding. While the characteristic structural features of the steroid receptor superfamily are well conserved in E75, two novel variations are seen. The first of these concerns the structure of the E75 B protein, which contains a major alteration within its putative DNA- binding domain. The steroid receptor superfamily DNA- binding domain consists of two DNA-binding zinc fingers separated by a less conserved linker region. In E75, as in nearly all other genes of this family, an intron is found between the two fingers. In E75, this splice marks the beginning of the region held in common between the E75 A and B proteins. This results in the E75 A protein having two fingers, while the E75 B protein has unrelated B-specific sequences in place of the first finger. Other sequences within the B-specific amino-proximal region may contribute to the DNA-binding domain of the E74B protein. Alternatively, the B protein might bind DNA with only one finger, as GAL4 transcription factor of yeast appears to do. It is possible that these structural differences imply a functional difference in the DNA- binding properties of the E75 A and B proteins that might allow them to differentially regulate the transcription of the late genes that characterize the secondary response to ecdysone in different target tissues. In this respect, it should be emphasized that the putative hormone- or ligand-binding domain is represented by the E region that is common to the E75A and E75B proteins. Thus, these proteins appear to be receptors for the same hormone, which may regulate the transcription of different sets of genes. These proteins represent "orphan" receptors, in that their hormone, or binding ligand, has not yet been identified. Because ecdysteroids are the only known steroid hormones in Drosophila. the most obvious candidate for an E75 ligand would be ecdysone itself. However, it is unlikely that this is the case, since the putative hormone-binding domain of the E75 proteins does not exhibit the high sequence homology to that of the known Drosophila ecdysone receptor encoded by the EcR gene (see Experimental Example III and Table 2) that would be expected if the E75 proteins were also ecdysone receptors. It, therefore, seems likely that the E75 proteins would bind either a terpenoid juvenile hormone or a novel Drosophila hormone. The second unusual feature of the E75 proteins is the presence of a large F region, encompassing nearly one half of the proteins. Many of the other receptors have very small F regions, and no function has yet been ascribed to this region. Methods Protein sequence analysis Sequence data were compiled using the Bionet system. Protein sequence comparison was performed using FASTP (Lipman, D. J. , and W. R. Pearson, 1985. Rapid and sensitive protein similarity searches. Science 227:1435- 1441) and Bionet IFIND programs. E. Expression Vectors for E75 Proteins In order to express the E75 proteins, portions of cDNAs and genomic clones were fused in order to generate cassettes containing the entire E75 A and E75 B protein coding regions. First, BamHI sites were introduced into genomic clones upstream of the initial AUGs of the large open reading frames. Then, E75 A0 exon sequences were fused to sequences of a nearly full-length E75 A cDNA, and E75 Bl exon sequences were fused to sequences of a nearly full-length E75 B cDNA. These cassettes were cloned into pGEM3 (Promega) , and transcripts of the open reading frames were prepared using T7 polymerase. These were then translated in the presence of 35 S-methionine, and shown to give rise to proteins of appropriate size. These cassettes have been placed into a variety of expression vectors, including pUCHsneo/Act for expression in Drosophila cells, pSV2 for expression in mammalian cells, and pOTS for expression in bacterial cells. Methods BamHI sites were introduced directly upstream of the initial ATGs of the E75A and E75B coding sequence — at the Sspl site upstream of the E75A initial ATG, and at the SacII site upstream of the E75B initial ATG. cDNA and genomic sequences were joined at the EcoRV site in the AO exon to construct an E75A cassette, and at the Mlul in exon 3 to construct an E75B cassette. EXAMPLE II CLONING, STRUCTURE AND EXPRESSION OF THE EcR AND DHR3 GENES THAT ENCODE ADDITIONAL MEMBERS OF THE STEROID RECEPTOR SUPERFAMILY. The following experiments were carried out after the primary structure of the E75 gene, and of the two members of the steroid receptor superfamily that it encodes, was determined (Experimental, Example I) . The purpose of these experiments was to clone and determine the primary structure of other steroid receptor superfamily genes from Drosophila. and of the proteins they encode. The aim was to identify the gene that encodes a Drosophila ecdysone receptor, given that the characteristics of the E75 gene indicated that it did not encode an ecdysone receptor. The first stage of the experimental plan was to use the conserved sequences in the E75A transcription unit that encode the putative DNA-binding domain of the E75A receptor protein as a probe to screen a Drosophila genomic library to identify sequences encoding the putative DNA-binding domains of other Drosophila members of the steroid receptor superfamily. The second stage was to isolate cDNA clones corresponding to the identified genes, as well as additional genomic DNA clones, to obtain the nucleotide sequence of the complete coding region (i.e., the open reading frame encoding the respective receptors) and the exon-intron organization of these genes. The experiments described below resulted in the cloning and structural characterization of two genes that satisfy the criteria for bona fide members of the steroid receptor superfamily: encoding proteins that exhibit amino acid sequence homology to both the DNA-binding and the hormone-binding domains that are conserved among members of this superfamily. The two genes are called EcR and DHR3. The EcR gene was originally called DHR23, but was renamed EcR after it was shown to encode an ecdysone receptor (see Experimental Example III) . The DHR3 designation stands for Drosophila Hormone Receptor 3. A. Identification and Chromosomal Mapping of EcR and DHR3 Genomic Clones Initially, Southern blots of total Drosophila genomic DNA, digested with one or more restriction endonucleases, were probed with a 530 bp fragment of the E75A cDNA containing the sequences encoding the putative DNA-binding domain of the E75A receptor protein (see Experimental Example I) at low and high stringency hybridization conditions. To isolate the sequences responsible for these low stringency bands, this E75A probe was used to screen a Drosophila genomic library under the same low stringency conditions, counterscreening duplicate filters with E75 intron probes to eliminate phage containing inserts from the E75 gene. Five genome equivalents were screened and 39 non-E75 containing phage were isolated. The 25 most strongly hybridizing clones were divided into six classes on the basis of restriction patterns and cross hybridization, each class containing between one and six independent overlapping genomic inserts. For each class, a restriction fragment containing the region of hybridization to the E75A probe was localized by Southern blotting. Hybridization of probes derived from these fragments to genomic Southern blots showed that each of the low stringency bands detectable by the E75A probe could be accounted for by one of the six isolated fragments. The nucleotide sequences of the six restriction fragments were determined to test whether they represent candidate receptor genes. In all cases, DNA sequence similarities with the E75A probe were observed that are sufficient to account for the hybridization of these fragments with the probe. When the DNA sequences were conceptually translated in all six reading frames, four of the fragments yielded no significant sequence similarity with E75A at the protein level. The remaining two clones, however, showed predicted amino acid sequences with strong similarity to the DNA binding domains of the E75A protein and other steroid superfamily receptors. These two clones represent the EcR and DHR3 genes, as will become apparent. Probes from these clones were used to map the position of these genes in the polytene chromosomes by m situ hybridization. The EcR and DHR3 chromosomal loci were mapped to positions 42A and 46F, respectively, in the right arm of the second chromosome. B. Structure of the EcR and DHR3 Genes and Their cDNAs The DHR3 and EcR genomic clones described above were used to screen a cDNA library prepared from third instar tissues treated with ecdysone and cycloheximide. This procedure allowed the isolation of a large number of cDNA clones, since both genes have a peak period of transcription in late third instar after the rise in ecdysone titer. For each gene, 20 cloned cDNAs were purified and their lengths determined. Restriction maps for the 10 longest cDNAs from each gene were determined and found to be colinear. For EcR, a 5534 bp cDNA sequence was obtained from two overlapping cDNA clones. It contains an 878 codon open reading frame (ORF) which yields a predicted amino acid sequence expected for a member of the steroid receptor superfamily (Table 2) , as described in more detail below. The length of the largest DHR3 cDNA that was isolated (clone DHR3-9) is 4.2 kb. The nucleotide sequence of this cDNA was determined and found to contain a 487 codon AUG-initiated open reading frame (Table 3) . As described below, the amino acid sequence of the DHR3 protein predicted from this sequence demonstrates that this protein is also a bona fide member of the steroid receptor superfamily. Table 2. The cDNA sequence of the EcR gene. Numerals at the left refer to the nucleotide sequences; those on the right to the amino acid sequence in the EcR protein. Nucleotides 1-5194 are the sequence of EcR-17 cDNA, while nucleotides 5195-5534 derive from the EcR-9 cDNA. The underlined sequences in the 5' and 3' untranslated regions refer, respectively, to the ATG codons and the AATAAA consensus polyadenylation signals. Positions of the introns and the donor and acceptor splice sequences are indicated above the cDNA sequence in small type. The amino acid sequences homologous to the conceived DNA-binding (C region) and hormone-binding (E region) domains of the steroid receptor superfamily are underlined. Panel 1 is shown in detail in panels 2 and 3. Table 3. The cDNA sequence of the DHR3 gene. The numbering and underlining of the nucleotide and amino acid sequences have the same meaning as in Table 2, and the intron positions and donor and acceptor splice sequences are similarly indicated. The sequence of the 5' proximal 2338 nucleotides of the DHR3-9 cDNA is shown. The sequence of the remainder of this 4.2 kb cDNA was determined for only one strand and is not shown. Four silent, third-position differences between the cDNA and genomic DNA sequences are indicated above the cDNA sequence. The genomic structure of the EcR and DHR3 genes was investigated by isolating additional genomic DNA clones that form overlapping sets that contain all of the sequences found in the respective cDNA clones. The exons contained in these cDNAs were mapped within the genomic DNA by comparison of cDNA and genomic clones via Southern blot analysis, mapping of restriction cleavage sites, and finally, by determination of the nucleotide sequence of the genomic DNA in regions that contain the exon/intron boundaries. Table 2 and 3 show these boundaries and the sequence of the splice junctions for the EcR and DHR3 genes, respectively. All of these splice junctions conform to the splice donor and acceptor consensus sequences. For EcR. the cDNA sequence shown in Table 2 is split into six exons spread over 36 kb of genomic DNA, with the ORF beginning in the second exon and ending in the sixth. For DHR3, the cDNA sequence derives from nine exons spread over 18 kb, with the ORF beginning in the first exon and ending in the ninth. Because the 5' and 3' ends of the respective mRNAs were not mapped, it should be emphasized that these genes may have additional noncoding exons at their 5* or 3* ends. The EcR and DHR3 gene structures differ significantly from those of all previously examined steroid receptor superfamily genes. Comparison with the genes for 11 other receptor homologues for which at least partial structural information is available reveals that the positions of certain exon boundaries have been conserved in evolution. This conservation is most striking in the portion of the genes encoding DNA-binding domains. In the nine other cases where the structure of this region has been examined, the two halves of the DNA- binding domain are always encoded by separate exons. If we exclude the Drosophila genes knirps. knirps-related. and egon (which are not bona fide receptor homologues since they lack the hormone-binding domain sequence similarity) , these are always small exons, the second one invariably ending in the fourth codon beyond the conserved Met codon at the end of the C region. Thus, these exons each encode one of the two predicted zinc fingers of the DNA-binding domain. In contrast, both zinc fingers of the putative DNA-binding domain of the EcR and DHR3 receptors are encoded by a single exon. It is possible that our screen specifically selected for genes lacking the above intron. The screen selected genomic clones that hybridize to an E75A cDNA probe that, of course, lacks this intron. Genomic sequences containing a contiguous sequence encoding the DNA-binding domain would be expected to hybridize to this probe better than clones from genes containing the intron. This would explain the successful isolation of the EcR and DHR3 genes, and the failure to isolate the genes of other Drosophila members of the steroid receptor superfamily. Methods Isolation of cDNA and additional genomic clones Subclones of the originally isolated DHR3 and EcR genomic clones were used to screen a cDNA library prepared from third instar tissues treated with ecdysone and cycloheximide. This library was chosen because both genes are relatively highly expressed at the end of third instar, and because of the high quality of the library. Of the 270,000 primary plaques screened, 20 positives for DHR3 and 220 for EcR were detected. Twenty cDNAs for each gene were purified, of which the ten largest for each were restriction mapped and found to be colinear. cDNA DHR3-9, which extends further in both the 5' and 3' directions than our other DHR3 cDNAs, was chosen for sequencing. For EcR. the longest cDNA, EcR-17, extended the farthest 5' and was sequenced in its entirety. An additional cDNA clone, EcR-9, was found to extend 300 bp farther 3' than EcR-17, and this 3' extension was also sequenced. Additional genomic DNA clones covering the EcR and DHR3 genes were obtained by screening the Drosophila Canton S genomic library referred to in part A above, either with probes from the respective cDNA clones, or, for overlapping clones, by the chromosomal walk method described in Experimental Example I. DNA seguence analysis cDNAs were subcloned into BlueScript vectors (Stratagene) , and clones for sequencing were generated by exonuclease III digestion (Henikoff, S., 1984. Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing. Gene 28:351-359) . Double-stranded plasmids were denatured (Gatermann, K. B., G. H. Rosenberg, and N. F. Kaufer, 1988. Double- stranded sequencing, using mini-prep plasmids, in 11 hours. BioTechnicrues 6:951-952) and sequenced by the dideoxy chain terminating method (Sanger, F. , S. Nicklen, and A. R. Coulson, 1977. DNA sequencing with chain- terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467), using the enzyme Sequenase (U.S. Biochemical) . cDNA EcR-17 was completely sequenced on both strands, as was the EcR-9 3' extension. cDNA DHR3- 9 was sequenced on both strands for the 5' most 2338 bp, which contains the entire ORF, and the remainder of the long 3' untranslated region was sequenced on one strand. The exon/intron boundaries in genomic DNA clones were first mapped at low resolution by Southern blot analysis of their restriction fragments probed with labeled cDNAs. Genomic DNA surrounding each exon/intron boundary was subcloned and the nucleotide sequence of these subclones determined as above. Genomic exons were either sequenced entirely, or for the longer exons, were digested and electrophoresed in parallel with cDNA clones to confirm the colinearity of the genomic and cDNA clones. Shorter exons were completely sequenced from genomic clones. Longer exons had their boundaries sequenced from genomic clones, and were confirmed to be colinear with the cDNA clones by parallel digestion and electrophoresis of the cDNA and genomic clones. C. The Predicted Amino Acid Sequence of the EcR and DHR3 Proteins and their Implications Comparison of the predicted EcR and DHR3 protein sequences to the sequence database and to individual members of the steroid receptor superfamily shows that these proteins share the two conserved domains characteristic of this superfamily (Evans, R. M. , 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895; Green, S., and P. Chambon, 1988. Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 4:309-314). We refer to the domains as the C and E regions, for the more amino-terminal and more carboxy-terminal homologies, respectively, according to the nomenclature of Krust et al. (Krust, A., S. Green, P. Argos, V. Kumar, P. Walter, J. M. Bornert, and P. Chambon, 1986. The chicken oestrogen receptor sequence; homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J. 5:891-897). These domains are underlined in Tables 2 and 3, and Table 4A-C presents a comparison of these domains from EcR and DHR3 with those from representative members of the superfamily. Table 4. Sequence comparison of the conserved C and E regions in DHR3, EcR, and some representative nuclear receptor homologues. (A) C-region alignment. Numbers at the left indicate the amino acid positions within the individual receptors; dashes indicate gaps introduced to obtain maximal alignment. Dots indicate three positions important in determining the DNA binding specificity of this domain. (B) E-region alignment. Bars indicate the three most highly conserved stretches within this domain. (C) Computed percent identities among the C-region sequences (lower left) and among the E-region sequences (upper right) . The kni sequence shows no significant E-region homology and is, therefore, not included in this comparison. Sequences shown are from: E75A, Drosophila ecdysone-inducible gene at 75B; kni, Drosophila segmentation gene knirps; hRARα, human retinoic acid receptor alpha; htRβ, human thyroid receptor beta; hVDR, human vitamin D receptor; cOUP-TF, chicken ovalbumin upstream promoter transcription factor; hERRl and hERR2, human estrogen-related receptors 1 and 2; hER, human estrogen receptor; hGR, human glucocorticoid receptor; hMR, human mineralocorticoid receptor; hGR, human progesterone receptor. Panel 1 is shown in detail in panels 2-6. The C region is a 66-68 amino acid domain that has been shown to function as a zinc finger DNA binding domain in vertebrate receptors. This domain has also been implicated in receptor dimerization (Kumar, V. , and P. Chambon, 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156). As shown in Table 4A, all 19 C-region residues that are absolutely conserved in the other receptor homologues are also conserved in DHR3 and EcR, including the nine invariant Cys residues, eight of which coordinate two zinc ions (Freedman, L. P. , B. F. Luisi, Z. R. Korszun, R. Basavappa, P. B. Sigler, and K. R. Yamamoto, 1988. The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334:543-546). As seen in Table 4C, the Drosophila C-region sequences (including those of E75A) are not more closely related to each other than they are to those from the vertebrate receptor homologues. The C region of DHR3 is most similar to that of the human retinoic acid receptor α (hRARα) , and the C region of EcR is most similar to that of the human thyroid receptor β (hTRβ) . Studies on the human glucocorticoid receptor (hGR) and human estrogen receptor (hER) have identified three C-region residues (indicated by dots in Table 4A) that are critical for determining the differential DNA binding specificity of these receptors (Mader, S., V. Kumar, H. de Verneuil, and P. Chambon, 1989. Three amino acids of the estrogen receptor are essential to its ability to distinguish an estrogen from a glucocorticoid-responsive element. Nature 338:271-274; Umesono, K. , and R. M. Evans, 1989. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57:1139-46). The three Drosophila proteins DHR3, EcR, and E75A, as well as the vertebrate receptors hRARα, hTRβ, and the human vitamin D receptor (hVDR) , all have identical amino acids at these three positions; thus, these proteins may all have similar DNA binding specificities, as has already been shown for hRARα and hTRβ (Umesono, K. , V. Giguere, C. K. Glass, M. G. Rosenfeld, and R. M. Evans, 1988. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 336:262-265). The E-region is an -225 amino acid domain that functions as a hormone-binding domain in vertebrate receptors. This domain has also been implicated in hormone dependent receptor dimerization (Kumar, V. and P. Chambon, 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156; Guiochon, M. A., H. Loosfelt, P. Lescop, S. Sar, M. Atger, A. M. Perrot, and E. Milgrom, 1989. Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers. Cell 57:1147-1154), hormone dependent nuclear localization of the glucocorticoid receptor (Picard, D. , and K. R. Yamamoto, 1987. Two signals mediate hormone- dependent nuclear localization of the glucocorticoid receptor. EMBO J. 6:3333-3340), and binding of the glucocorticoid receptor to the 90 kDa heat shock protein (Pratt, W. B., D. J. Jolly, D. V. Pratt, W. M. Hollenberg, V. Giguere, F. M. Cadepond, G. G. Schweizer, M. G. Catelli, R. M. Evans, and E. E. Baulieu, 1988. A region in the steroid binding domain determines formation of the non-DNA-binding, 9 S glucocorticoid receptor complex. J. Biol. Chem. 263:267- 273) . Table 4B shows an alignment of the E regions of the DHR3 and EcR proteins with those of other receptor homologues. The three relatively highly conserved stretches within this region noted in Experimental Example I are overlined; each contains a cluster of residues conserved in all or most of the receptor sequences. DHR3 and EcR show strong similarity to each other and to the other proteins in these stretches, and a lower similarity outside of them. The presence of this E-region homology establishes these proteins as bona fide members of the nuclear receptor family, in contrast to the Drosophila knirps (Nauber, U. , M. J. Pankratz, A. Kienlin, E. Seifert, U. Klemm, and H. Jackie, 1988. Abdominal segmentation of the Drosophila embryo requires a hormone receptor-like protein encoded by the gap gene knirps. Nature 336:489-492), knirps-related (Oro, A. E., E. S. Ong, J. S. Margolis, J. W. Posakony, M. McKeown, and R. M. Evans, 1988. The Drosophila gene knirps- related is a member of the steroid-receptor gene superfamily. Nature 336:493-496), and egon (Rothe, M. , U. Nauber, and H. Jackie, 1989. Three hormone receptor¬ like Drosophila genes encode an identical DNA-binding finger. EMBO J. 8:3087-3094) proteins, which show C- region homology but no E-region homology. The E region in DHR3 is most similar to that of E75A, and the E region of EcR is most similar to that of hTRβ, although the level of these similarities is lower than those found among E regions of many other receptors (Table 4C) . Thus, DHR3 and EcR are not especially close homologues of any previously cloned receptors. Comparison of E-region sequences allows division of the nuclear receptors into subfamilies (Petkovich, M. , N. J. Brand, A. Krust, and P. Chambon, 1987. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444-450), the members of any one subfamily being more related to each other than to those in other subfamilies. The DHR3 and EcR receptors fall into a subfamily with the E75A, E75B, hRARα, hTRβ, and hVDR receptors. D. In Situ Labeling of the EcR and DHR3 Proteins with Antibodies Induced by Proteins Produced in E. coli To determine the intracellular and tissue distribution of the EcR and DHR3 proteins in Drosophila. affinity-purified polyclonal antibodies directed against those proteins were produced in the following manner. The region of about 120 amino acid residues located between the conserved DNA-binding and hormone-binding domains of these proteins was used as the immunogen to produce antibodies against each protein. Thus, the coding sequences for amino acids 335-447 of the EcR protein and for amino acids 164-289 of the DHR3 protein (see Tables 2 and 3, respectively) were cloned into the appropriate pATH (Dieckmann, C, and A. Tzagaloff, 1985. J. Biol. Chem. 260:1513-1520) or pUR expression vectors, so as to fuse these coding sequences to those encoding E. coli β-galactosidase (βgal) or to E. coli tryptophan E protein (trpE) , respectively. The βgal fusion proteins were produced in E. coli by the addition of the IPTG inducer to exponential cultures, while the production of trpE fusion proteins were induced by dilution into tryptophan-free media and subsequent addition of indoleacetic acid. For EcR, the trpE fusion protein was used as an immunogen and the βgal fusion protein was used on i munoblots to test sera for immunoreactivity to the EcR portion of the fusions. For DHR3, the βgal fusion protein was injected, and sera were checked against the trpE fusion protein. For immunization the appropriate fusion protein was prepared by electrophoresis on SDS-PAGE gels and visualized by staining in ice-cold 0.25 M KC1, after which the fusion protein band was cut out. Approximately 100 μg of fusion protein in 0.25 ml of gel slice was crushed by passing through successively smaller hypodermic needles, and mixed with 0.25 ml of a sterile saline solution and 0.5 ml of Freund's complete adjuvant. For each immunogen, two New Zealand White rabbits were injected at multiple intramuscular sites, and after one month, boosted at two-week intervals, omitting the Freund's adjuvant. While the βgal fusion proteins were subject to the above gel electrophoresis without prior purification, the trpE fusion proteins were first purified by the following method which takes advantage of their insolubility in vivo. E. coli from a two-liter culture of induced cells were washed, and the cell pellet was subjected to several freeze/thaw cycles. The cells were resuspended in 18 ml of 50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, and 1.8 ml of 10 mg/ml lysozyme was added. After 15 minutes on ice, the cells were lysed by passing three times through a french pressure cell at 10,000 psi. The insoluble fraction was collected by centrifugation at 27,000 x g for 15 minutes, and washed by resuspension, using a Dounce homogenizer, in ice-cold 50 mM Tris-HCl, 0.5 mM EDTA, 0.3 M NaCl, followed by centrifugation as above. The washing step was repeated, and the final pellet dissolved in 10 ml of 4M urea, 2% (w/v) SDS, 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5% (v/v) 2-mercaptoethanol. Material remaining insoluble was centrifuged out and discarded. The antisera was affinity purified in a two-step procedure by successive passage through "nonspecific" and "specific" affinity columns. In the case of antibodies raised against the trpE fusion proteins, the nonspecific column consisted of resin coupled to the insoluble protein derived from E. coli expressing unmodified trpE protein, and was used to remove antibodies directed against trpE epitopes, as well as against insoluble E. coli protein impurities. The specific column consisted of resin coupled to the EcR-trpE fusion protein (purified as described above) and was used to absorb the desired antibodies directed against the EcR epitopes, antibodies that were subsequently released from the column. In the case of antibodies raised against the βgal fusion proteins, the same general procedure was used, except that the resin in the nonspecific column was coupled to β-galactosidase, while that in the specific column was coupled to the DHR3-βgal fusion protein. Western blot analysis of the appropriate E. coli extracts demonstrated that these affinity-purified antibodies exhibited the desired specificity. The intracellular distribution of the EcR protein in late third instar salivary glands was examined by in situ labeling of this protein with the anti-EcR antibody. The EcR protein was thereby shown to be highly localized in the nuclei of these glands. Indeed, when the polytene chromosomes in these nuclei were examined by the antibody-labeling method of Zink and Paro (Zinc, B. , and R. Paro, 1989. Nature 337:468-471), specific loci within these chromosomes exhibited strong binding of the EcR protein. In particular, the EcR protein was bound to the early puff loci, including those occupied by the E75 and E74 genes. This is the result expected if the ecdysone receptor encoded by the EcR gene is that which induces the transcription of the early genes, as anticipated by the Ashburner model. Another prediction of the Ashburner model is that the ecdysone-receptor complex initially represses the genes responsible for the later puff, so that the transcription of the late genes induced by the early gene proteins is delayed until these proteins accumulate sufficiently to overcome this initial repression. If the EcR receptor is involved in this postulated initial repression, then one would expect the EcR protein to bind to the late puff loci in the salivary glands. This expectation was met by the observation that EcR protein also binds to the late puff loci in the polytene chromosomes. Additional in situ antibody labeling experiments demonstrated that the EcR protein is present in the nuclei of all ecdysone target tissues examined in late third instar larvae. It is also present in most, if not all, cells during embryogenesis and other stages of Drosophila development that have been examined. In this respect, the EcR protein was not detected by anti-EcR antibody labeling of embryos in which the EcR gene was eliminated by a chromosomal deletion, further demonstrating the specificity of this antibody. In contrast to the widespread distribution of the EcR protein, anti-DHR3 antibody labeling of embryos demonstrated that the distribution of the DHR3 protein is highly restricted during this stage of development. During the brief embryonic period of expression, the protein is restricted to the peripheral nervous system, and to cells surrounding the spiracles at the posterior end of the embryo. Finally, it should be noted that affinity-purified antibodies against the E75A protein have also been prepared by the same technique described above for anti- EcR and anti-DHR3 antibodies. In situ antibody labeling of the E75A protein in larval salivary glands has also demonstrated that this protein is localized in the nucleus and is bound to specific loci in the polytene chromosomes. EXAMPLE III THE ECDYSTEROID-BINDING, DNA-BINDING AND GENETIC REGULATORY PROPERTIES OF THE EcR PROTEIN DEMONSTRATE THAT IT IS AN ECDYSONE RECEPTOR. The following experiments demonstrate that the protein encoded by the EcR gene is an ecdysone receptor by the following three criteria. (1) The EcR protein binds ecdysteroids and accounts for a large proportion, if not all, of the ecdysteroid-binding activity present in Drosophila embryos and in a variety of cultured Drosophila cells. (2) The EcR protein binds with high specificity to a DNA sequence that functions as an ecdysone response element (EcRE) , i.e., an enhancer that confers ecdysone inducibility to a promoter. (3) Cells that do not respond to ecdysone because they lack functional ecdysone receptors are transformed to the ecdysone-responsive state by transfection with an EcR expression plasmid. A. The EcR Protein Binds Ecdysteroids The EcR expression plasmid, pMTEcR, shown in Figure 1 contains the open reading frame encoding the EcR protein (EcR ORF; see Experimental Example II) fused to the Drosophila metallothionine promoter (P MT ) at its 5' end, and the polyadenylation-cleavage sequences of the Drosophila Actin 5C gene at its 3' end. Because transcription of the EcR ORF is under the control of this metallothionine, that transcription is induced by Cu 2+ ion to yield an mRNA that, in turn, produces the EcR protein. A cell line, MtEcRHy, that overproduces this protein upon Cu 2+ induction, as determined by Western blot analysis using the affinity-purified anti-EcR antibody (see Experimental Example II) , was constructed by the stable integration of the pMTEcR plasmid DNA into the genome of Drosophila Sch-2 cell line. A control cell line, MtHy, was similarly constructed by the integration of the expression vector DNA lacking the EcR ORF. Whole cell extracts were prepared from both the MtEcRHy and MtHy cell lines after Cu 2+ induction, and were assayed for ecdysteroid-binding activity using the high affinity ecdysone analogue [ I] lodoponasterone A. The MtEcRHy extract contained sevenfold more saturable ecdysteroid-binding activity than the MtHy control extract. To see if the induced ecdysteroid-binding activity was due to the EcR polypeptide itself, the EcR protein was depleted from the MtEcRHy extract by immunoprecipitation using an affinity-purified anti-EcR polyclonal antibody, or, as a control, the extract was mock-depleted with preimmune serum. The treated extracts were then assayed for ecdysteroid-binding activity. Comparison of the immuno-depleted extract with the mock- depleted extract showed that most of the binding activity was removed by the anti-EcR antibody treatment, indicating that the induced ecdysteroid-binding activity results from the EcR protein. The endogenous ecdysteroid-binding activity in the control cell line, MtHy, was unchanged by Cu 2+ exposure, and was approximately the same as that in the Sch-2 cell from which it derives. The question arises as to whether the endogenous activity in these and other Drosophila cell lines, as well as in embryonic extracts, results from the expression of the EcR gene in their respective genomes. To answer this question, extracts from embryos and several cell lines were immuno-depleted and mock- depleted, as described above, and assayed for ecdysteroid-binding activity. Again, comparison of these treated extracts showed that the large majority of the endogenous binding activity was removed in each case by treatment with the anti-EcR antibody. Thus, it appears that most, if not all, of the endogenous binding activity in embryos and cell lines results form the resident EcR gene. Methods Extracts Tissue culture cell extracts for hormone and DNA- binding experiments were prepared as follows. Cells were grown in spinner flasks to a density of 5-7xl0 6 cells/ml, and were washed once in EcR buffer (25 mM Hepes, pH 7.0, 40 mM KC1, 10% (v/v) glycerol, 1 mM EDTA, 1 mM dithiothreitol, and the following cocktail of protease inhibitors: 10 mM Na 2 S 2 0 5 , 500 μM PMSF, 1 μM leupeptin, 1 μM pepstatin) . All further manipulations were at 4 β C. Cells were resuspended in EcR buffer at 2% of the original culture volume, divided into 3 ml aliquots, and sonicated using 30 1/2 second pulses with a probe sonicator (Bronson Sonifier 450) , resulting in disruptions of -95% of the cells. After centrifugation at 100,000 x g for 1 hour, 100 μl aliquots of supernatant were frozen in liquid nitrogen, and stored at -80 β C. Protein concentration was determined using bovine serum albumin as the standard, and was typically 6-11 mg/ml. Embryo extracts were prepared by a similar protocol: 3-6 hour Canton S embryos were dechorionated in 55% commercial bleach for 2 minutes, washed extensively in 0.7% NaCl, and resuspended using 2 grams of embryos per ml of EcR buffer. Embryos were broken with 20 strokes in a Dounce homogenizer using a B pestle, and lysis was completed with the probe sonicator using the same settings as used for the tissue culture cells. The extract was adjusted to 400 mM KCl, centrifuged 1 hour at 100,000 x g, and aliquots of supernatant were frozen. This extract contained 13.4 mg/ml protein. Before use in hormone binding, it was diluted tenfold in EcR buffer lacking KCl to bring the final KCl concentration to 40 mM. Hormone-binding assays For hormone-binding experiments, extracts were first diluted to the following concentrations in EcR buffer: 0.9 mg/ml for MtHy and MtEcRHy extracts, 3 mg/ml for S2 and SRS 1.5 extracts, 4 mg/ml for the Kc cell extracts, and 1.3 mg/ml for the embryo extract. All manipulations were done on duplicate samples in order to quantify variability in the results. For immunoprecipitation experiments, extracts were immuno-depleted, mock- depleted, or left untreated. For depletions, 300 μl of diluted extract was incubated for 30 minutes at 25°C with 3.5 μl affinity-purified anti-EcR antibody, or with 3.5 μl preimmune serum for the mock-depletion control. Then 38 μl 10% Staphylococcus aureus (Pansorbin, Calbiochem) in EcR buffer was added, and incubation was continued for 15 minutes at 25 β C. After centrifugation for 3 minutes in a microcentrifuge, the supernatant (depleted extract) was recovered. The immunoprecipitation was repeated, except in the case of the embryo extract, which was subjected to only one round of precipitation. The "untreated" extract aliquots were left at 4 β C for the duration of the depletion procedure, and were diluted with EcR buffer to match the final concentration of the depleted aliquots. A modification of the hormone-binding assay of P. Cherbas was used (Cherbas, P. 1988. Proc. Nat'l Acad. Sci.. U.S.A. 85:2096-2100). Assay tubes contained 140 μl extract, 14 μl [ I] lodoponasterone, and either 14 μl EcR buffer or 14 μl unlabelled 20-OH ecdysone in EcR buffer as a competitor. [ I] lodoponasterone was 2177 Ci/mM and was used at a final concentration of 5x10 "10 M in the assay; 20-OH ecdysone was 2xl0 "5 M final concentration in the assay. After incubation for 1 hour at 25 β C, each reaction was spotted on a dry Whatman GF/C filter (2.4 cm), and after 30 seconds the filter was washed by using a vacuum to draw 10 ml EcR buffer through the filter over a period of 1 minute. Filters were placed in 800 μl 4% SDS, and radioactivity was measured in a counter. The hormone-binding activities shown are saturable binding activities, calculated as the total binding activity, as measured in assays with no added competitor, minus the unsaturable binding activity, which was measured in the assays with excess unlabelled ecdysone added. In the most active extracts, the unsaturable activity (representing the large number of low affinity binding sites in the extract) was less than 10% of the total activity. B. Genetic Regulatory Activity of the EcR Protein in vivo An ecdysone-inducible reporter plasmid, pEcRE/Adh/βgal (Figure 2) , was constructed to test the regulatory functions of the EcR protein in vivo. The reporter gene in this plasmid consists of the sequence that encodes the E. coli β-galactosidase (βgal ORF) linked through the 5' leader sequence of the Drosophila Ultrabithorax gene (UBX leader and AUG) to an ecdysone- inducible promoter. This promoter was created by fusing a truncated version of the proximal promoter for the Drosophila Adh gene (P DA d h - 3 +53 , the numbers indicating that it consists of the sequence from base pair positions -34 to +53, which just includes the TATA box) to seven repeats of a 34 bp synthetic oligonucleotide ( EcRE OLIGOS) which contains the ecdysone response element (EcRE) from the ecdysone-inducible heat shock gene hsp 27 (Riddihough and Pelham, 1987. EMBO J. 6:3729-3734). The seven EcREs should confer ecdysone-inducibility to the truncated promoter, provided that the cells transfected with this reporter plasmid contain the appropriate ecdysone receptor. This ecdysone-inducible reporter plasmid was constructed by insertion of the 7 EcRE OLIGOS into plasmid pAdh/βgal, which is identical to pEcRE/Adh/βgal except that it lacks the array of ecdysone response elements. The pAdh/βgal plasmid should therefore not be ecdysone inducible and can serve as a control. To test these expectations, Sch-2 cultured cells (which were shown above to contain endogenous ecdysone-binding activity) were transfected with each plasmid and examined for β-galactosidase activity in the presence and absence of ecdysone. The ecdysone-induced β-galactosidase activity in the pEcRE/Adh/βgal transfected cells was 2000-fold greater than when such cells were not exposed to ecdysone, whereas ecdysone had little effect on the pAdh/βgal transfected cells. These results indicate that the EcREs confer ecdysone-inducibility on the P DA d h -3 4+ 5 3 promoter, as expected, and that the Sch-2 cells contain functional ecdysone receptors. To test the function of the EcR receptor in such a system, host cells lacking functional ecdysone receptors are required. "Ecdysone-resistant" cells lacking ecdysone-binding activity, and hence, presumably functional receptors, can be produced by continuously exposing ecdysone-responsive cells to ecdysone during a period of several weeks. This ecdysone-resistant state is then maintained in ecdysone-free media for several months. An ecdysone-resistant cell line, SRS 1.5, was therefore generated by growing Sch-2 cells in 3xl0 "6 M ecdysone. The SRS 1.5 cells lack significant ecdysone- binding activity. When these cells were transfected with the pEcRE/Adh/βgal plasmid and subsequently exposed to ecdysone, very little ecdysone-induced β-galactosidase activity was observed, indicating that the cells have only trace amounts, if any, of functional receptors. To test whether the expression of the EcR gene can "rescue" this deficiency, the SRS 1.5 cells were cotransfected with two plasmids: the ecdysone-inducible reporter plasmid, PEcRE/Adh/βgal, and a constitutive expression plasmid for the EcR gene, pActEcR, in which transcription of the EcR ORF is .controlled by the Drosophila Actin 5C promoter, P A ^ SC (Figure 3) . Cotransfeetion with these two plasmids, followed by exposure to ecdysone, resulted in a dramatic induction of β-galactosidase activity. Thus, introduction of this EcR expression plasmid into the SRS 1.5 cells regenerated the ecdysone-inducibility they had lost. Methods Construction of the pAdh/βgal, pEcRE/Adh/βgal and pActEcR plasmids Plasmid pAdh/βgal was constructed in two steps. The Bglll-Scal fragment of pDΔ5'-34, containing nucleotides - 34 to +53 of the Drosophila Adh distal promoter, was cloned into pUC18 cut with Seal and BamHI. The resulting plasmid was cut with EcoRl, and the EcoRl fragment of cPβbxd6.2 (containing the Ubx untranslated leader and AUG, the βgal open reading frame, and the SV40 splice and poly A signals) inserted. To construct pEcRE/Adh/βgal from pAdh/βgal, two 34- residue oligonucleotides were synthesized: 5'TCGAGAGACAAGGGTTCAATGCACTTGTCCAATG3' 3'CTCTGTTCCCAAGTTACGTGAACAGGTTACAGCT5' These will anneal to form 30 bp duplexes with Sail compatible four nucleotide overhangs at their 5' ends, as shown. Further annealing via the 5' overhangs allows formation of tandem arrays that can be inserted into pAdh/βgal at its Sail site just upstream from the TATA box of the truncated Adh promoter. When these oligonucleotides were kinased, annealed, ligated into Sail-cut pAdh/βgal and cloned, pEcRE/Adh/βgal was obtained. Restriction mapping showed that it contained a tandem array of seven 34 bp repeats, each of which contains the 23 bp ecdysone response element (EcRE) present in the hsp 27 gene, the remaining 11 bp representing flanking hsp 27 sequences and the 5' overhangs. The constitutive EcR expression plasmid, pActEcR, was formed by inserting the Fspl-Hpal fragment of an EcR cDNA containing bp 851-4123 that contains the ORF encoding the EcR protein (Table 2) , into the EcoRV site of the ActSV40BS plasmid. This expression vector was constructed in two steps by inserting the Xbal-EcoRl fragment of cosPneoβ-gal, containing the SV40 splice and poly A signals, into BlueScript+KS (Stratagene) cut with SacII and Xbal, blunting the EcoRl and SacII ends. The resulting plasmid was digested with BamHI and Apal, and the BamHl-EcoRl fragment of pPAc was inserted, with the Apal and EcoRl ends being blunted. Transfection and generation of the cell line SRS 1.5 The cell line SRS 1.5 was obtained by growing Schneider line 2 (Sch-2) cells in the presence of 3xl0 "6 M 20-OH ecdysone (Sigma) . This treatment initially halts growth of Sch-2 cells, but after several weeks the adapted cells grow well. SRS 1.5 cells were washed in hormone-free medium and passed several times in hormone- free medium prior to their use in transfection experiments. Cells were transfected by the calcium phosphate technique. Cells were transfected with 10 μg of each plasmid used; when only a single plasmid was being transfected, 10 μg of pUC18 DNA was added as a carrier. In general, all transfections were carried out in duplicate. Twenty-four hours after transfection, cells that were to undergo hormone treatment were split into two dishes, one of which was treated with 2xl0 "6 M 20-OH ecdysone. β-galactosidase assays Forty-eight hours after transfection, 2 ml of cells were washed once in PBS (137 mM NaCl, 27 mM KCl, 65 mM Na 2 HP0 4 , 15 mM KH 2 P0 4 , pH 6.8), and were resuspended in 50 μl of 0.25 M sucrose, 10 mM Tris, pH 7.4, 10 mM EDTA, and repeatedly frozen in liquid nitrogen and thawed in a 37 e C water bath for a total of 3 freeze/thaw cycles. Cell debris was removed by a 10-minute centrifugation in a microcentrifuge at 4°C. The concentration of protein in the supernatant (cell extract) was determined by the Bradford method, with bovine serum albumin as a standard, and was typically 1.5-2.5 mg/ml. Extracts were assayed immediately or frozen and assayed up to two weeks later with no loss in activity. To 10 μl of extract, or an appropriate dilution, 500 μl of assay buffer was added (0.6 mM 4-methylumbelliferyl-β-D-galactoside, 60 mM Na 2 HP0 4 , 40 mM NaH 2 P0 4 , 10 mM KCl, 1.0 mM MgS0 4 , pH 7.0) . After a 30-minute incubation at 37 e C, reactions were stopped with 500 μl of 300 mM glycine, 15 mM EDTA, pH 11.2. The fluorescent reaction product was quantified on a Perkin-Elmer LS-5B luminescence spectrometer, with λ ex =365 n and λ ern = 450 nm. βgal activities are given as fluorescence units per μg protein assayed. C. Specific Binding of the EcR Protein to Ecdysone Response Elements The simplest explanation of the results described in the preceding section is that the EcR protein generated by the EcR expression plasmid binds to the EcRE of the reporter plasmid and, in combination with ecdysone, activates the minimal Adh promoter in that plasmid. The following experiment was designed to test whether the EcR protein exhibits specific binding to this EcRE in vitro. Two plasmids were used: pUC18, which serves as the control, and pUC18-EcRE, which was generated by substituting the Hindll-Xbal fragment from pEcRE/Adh/βgal that contains the seven repeats of the 34 bp EcRE oligonucleotide, for the Hindll-Xbal fragment of pUC18. Because the only difference between these two fragments is the seven oligonucleotide repeats, this is also the only difference between the two plasmids. The two plasmids were digested with ApaLI and Hind III, end-labeled with P and mixed with an extract from MtEcRHy cells in which the EcR protein was overexpressed by Cu + induction (see section A, above) . After a 15-minute incubation at 25*C to allow EcR-DNA binding to occur, affinity-purified anti-EcR antibody was added. The 25 e C incubation was continued for an additional 40 minutes, at which time anti-rabbit Ig-coated magnetic beads (Dupont Magnasort-R) were added, and the incubation continued 15 minutes more. The beads were separated from the solution magnetically, similarly washed, and the DNA eluted from the beads in 1% SDS at 65"C. The eluted DNA was ethanol precipitated and fractionated by electrophoresis in an agarose gel, which was dried and autoradiographed. Only the fragment containing the EcRE oligonucleotide was specifically and efficiently registered on the autoradiographs, and that registration was dependent upon the anti-EcR antibody. Quantitative analysis of the autoradiographs demonstrated a 10 3 -fold preference for binding to the EcRE oligonucleotide over the average vector sequences, under the conditions of this assay (see Methods, below) . According to the criteria stated at the beginning of this Experimental Example, the EcR protein clearly satisfies the definition of an ecdysone receptor. Methods Conditions for the DNA binding assay A quantity of 0.2 mole of digested, labelled plasmid DNA was mixed with 2 μg (dl/dC) in 10 μl of TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and 90 μl of the MtEcRHy extract, diluted to 0.9 mg/ml in EcR buffer adjusted to 180 mM KCl, was added. After binding for 15 minutes at 25 β C, 2 ml of affinity-purified anti-EcR antibody, diluted 1.5x in EcR, was added, and this incubation was continued at 25 β C for 40 minutes, when 50 μl of anti-rabbit Ig-coated magnetic beads (Dupont Magnasort-R) , exchanged into 180 mM KCl EcR buffer, was added and the incubation continued for 15 minutes. The beads were washed twice in 400 μl 180 mM KCl EcR buffer, and DNA was eluted from the beads by soaking twice in 200 μl 1% SDS in TE at 65°C. The eluted DNA was ethanol precipitated and run on an agarose gel, which was dried and autoradiographed. As controls, one half of the input DNA (0.1 fmole) was run on the gel for comparison, and the binding assay was carried out, leaving out the antibody. EXAMPLE IV RECEPTOR GENE MUTAGENESIS. Mutations in the steroid receptor superfamily genes can alter their function in two ways. Most obviously, they alter the sequences encoding the receptor proteins and thus alter the receptor function. Alternatively, they can alter the expression of these genes — an alteration that can be at any level of that expression from transcription of the gene to the translation of its mRNA(s) . Such mutations can change the timing of gene expression during development or change the tissue and cell distribution of that expression, thus, profoundly changing the course of development. Furthermore, these mutations provide information about the regulation of receptor gene expression, just as mutations that alter the structure of the receptors encoded by these genes provide information about the genes whose expression these receptor proteins control. In particular, mutations that alter receptor gene expression can lead to the identification of the proteins and other regulatory molecules that control their expression. Clearly, mutagenesis of insect steroid receptor superfamily genes provides an important avenue leading to an ability to interfere in a highly specific manner with insect development, and thus to control insect infestations deleterious to human health and agriculture. We have carried out mutagenesis experiments for two Drosophila members of the steroid receptor superfamily genes, E75 and EcR, that we have cloned and characterized with respect to their expression. In this experimental example, mutagenesis of the E75 gene is described. A. Deletion Mutations In Drosophila, genetic analysis for a given locus - - in this case, the early puff locus at 75B that houses the E75 gene — generally depends upon the isolation of deletions of all or part of that locus. Such deletions greatly facilitate the subsequent isolation of point and other small mutations within the locus. By isolating mutations that are revertants to the neighboring dominant Wrinkled (W) mutations, we have isolated and molecularly mapped the boundaries within our chromosomal walk (see Experi •mental Example I) of two deletions, WR - and WT?10, generated by gamma ray mutagenesis, the preferred way of generating such large alterations of genomic structure. One of these, W , extends distally from Wrinkled to cover the entire E75 gene; and the other, W R4 , extends to a point about 90 kb upstream of the 5' end of the 50 kb E75A transcription unit and does not include the E75 gene. An F2 screen was then employed to screen for gamma ray-induced mutations mapping to the 200 kb distal region that is included in the W R1 ° deletion but not the W R4 deletion. This screen resulted in the isolation of five members of a single lethal complementation group that molecular mapping data demonstrate represents the E75 gene. The most useful of these five mutations is the E75 X4β mutation. Molecular mapping of this mutation demonstrated that it is a 105 kb region that includes all of the E75 gene. This method provides an extremely efficient screen for other E75 mutations, i.e., by screening for mutations that cannot complement this deletion mutation. B. E75 Mutations Generated by Ethyl Methane Sulfonate The chemical mutagen ethyl methane sulfonate (EMS) was used for this screen, as it is the preferred method for generating point or small mutations. An F2 screen of 15,000 lines resulted in the isolation of 23 penetrant mutations within the 105 kb region of the E75 X48 deletion, all of which turned out to be alleles of E75. It appears that this 105 kb region was saturated by this screen with respect to lethal complementation groups, and hence, E75 appears to be the only lethal complementation group in this region. Adding the five E75 mutations described above, a total of 28 penetrant E75 alleles have thus been isolated, several of which are temperature-sensitive alleles. Inter se complementation studies among these alleles and examination of their phenotypes reveal a complex complementation group — a complexity that probably results from the fact that the E75 gene contains two overlapping transcription units, a 50 kb E75A unit and a . 20 kb E75B unit that occupies the 3' end of the E75A unit (see Experimental Example I and Table 1) . These alleles can be roughly divided into two groups: (1) those that cause lethality in early development, during the latter part of embryogenesis or during early larval development, and (2) those that cause lethality late in development, during the prepupal or pupal stages. This division correlates with the stages when the E75A and E75B units are expressed. Thus, E75A transcription is associated with each of the six pulses of ecdysone, including those that mark the embryonic and early larval stages. By contrast, E75B mRNAs are not observed until the end of the last larval stage, being particularly abundant during the pupal stage. This correlation invites the speculation that the early lethal mutations affect the expression of the E75A unit and its E74A protein, and that the late lethal mutations specifically affect the expression of the E75B unit and its E75B protein. This proposition can be tested by detailed molecular mapping of these mutations and further examination of their phenotypes at the molecular level to determine the causes of lethality. The mutants described here provide a foundation for the further genetic analysis of the E75 gene that will allow exploration of the requirements for appropriate E75 expression and function and will identify structural and functional domains of E75. Some of the future E75 studies will best be performed by its m vitro manipulation, followed by transformation of the constructs back into Drosophila. Finally, it will be desirable to identify interacting genetic loci — interactions that may occur at the level of regulation of E75 expression or at the level of interaction of the E75 proteins with those encoded by other genes. Such interactive genetic loci can be identified via the isolation of mutations that act as suppressors or enhancers of the E75 mutations. Methods Strains, markers and chromosomes For this aspect of the invention, the following strains, markers and chromosomes were used. Tu 2 was described by Lindsley (Lindsley, 1973. PIS 50:21). All other strains and mutations are as described (Lindsley, and Grell, 1968. Genetic Variation of Drosophila melanogaster r Publication 627, Carnegie Institute of Washington, Washington, DC) . ru h W R4 e s ro ca was constructed by recombination between ru h W R4 sbd 2 Tu 2 and st sbd 2 e s ro ca. The st m ri p p sbd 2 chromosome was constructed by recombination of st in ri E P with sbd 2 , in order to allow marking of this chromosome over W R4 and W R.10, and homozygosed by crossing to TM3, backcrossmg to TM3, and mating of isogeneic sibling progeny. The st p_ p ell line was homozygosed by standard ionic procedures. Antpw and ns_ .c4 are descri•bed i•n Scott et al. (1984) Proc. Nat'l Acad. Sci. USA 81:4115-4119. The pupal lethals X19. g26. 013B. 8ml2, iX-14. 2612. m45. p4 , q30L. mz416. 13mll5. 052 and wg49 are described in Shearn (1974) Genetics 77:115-125. All strains used to construct the strains described above and other strains were obtained from the Bowling Green and Caltech stock centers. TM1, TM3 and TM6B (Lindsley, and Grell, 1968. Genetic Variation of Drosophila melanogaster. Publication 627, Carnegie Institute of Washington, Washington, DC) are balancer chromosomes carrying recessive lethal mutations along with multiple inversions to suppress recombination. This allows the maintenance, as a heterozygote, of a recessive lethal chromosome in its original state. These chromosomes are also marked with convenient visible markers. Quantitative Southern blot mapping for detection of mutant lesions DNA was prepared from adult flies (about 50) by douncing in 1 ml of 10 mM Tris-HCl, pH 7.5, 60 mM NaCl, 10 mM EDTA, 0.15 mM spermine, 0.2 mg/ml proteinase K. The homogenate was added to an equal volume of 0.2 M Tris-HCl, pH 9.0, 30 mM EDTA, 2% SDS, 0.2 mg/ml proteinase K, incubated at 37 β C for 1 hour, and then extracted twice with buffer-saturated phenol and once with 24:1 chloroform/isoamyl alcohol. DNA was EtOH precipitated twice, hooking the pellet out without centrifugation. Southern blot hybridization was as described (Segraves, W. et al., 1984. J. Mol. Biol. 175:1-17). Where restriction fragment length polymorphism was not used in order to distinguish the parental chromosome from the balancer chromosome, guantitation of band intensity on genomic Southerns was achieved using a scanning densitometer. By using a control probe outside the mutant region, the amount of DNA in each track was internally controlled. Comparison of deficiency heterozygote to wild type bands, when normalized to a control band in this way, gives little deviation from the expected 1:2 ratio. Molecular cloning of mutant lesions Restriction fragments of the appropriate size were isolated by preparative low melting agarose (FMC) electrophoresis of about 20 μg of restricted genomic DNA. The 6 kb W Xhol fragment was cloned into Xhol-cleaved λSE6DBam which is propagated as a plasmid in order to grow the vector and cannot be packaged without an insert. The 18 kb W R1 ° Sail fragment was cloned into the Sail site of AEMBL3, cleaved also with EcoRl for the biochemical selection method for the prevention of propagation of non-recombinant clones. The 7 kb EcoRl fragment containing the x37 breakpoint was cloned into EcoRI- cleaved A607. Plating of recombinants on the hflA strain RY1073 prevented plaque formation by non-recombinant phage. The 14 kb x48 EcoRl fragment was cloned into the EcoRl site of AEMBL4, which had been cleaved with BamHI to utilize the "biochemical selection" for recombinants. The breakpoint fragments of x44 and the recipient fragment were cloned into λSE6ΔBam. Libraries were packaged using λ in vitro packaging extracts prepared as described in Hohn (Hohn, B. , 1979. Methods Enzymol. 68:299-303). After demonstration that each of the libraries gave a significant number of plaques only when inserts were included in the ligation, they were screened using restriction fragments capable of detecting the breakpoint clones. Gamma ray mutagenesis AAcdult males of the strain ru h W sbd 2 Tu 2 or st in ri p_ p sbd 2 were irradiated in plastic vials with 5000 rad of gamma rays from a Cs37 source at a dose rate of 4300 rad/minute. These were then mated to virgins of the appropriate strain, which were allowed to lay eggs for five days. EMS mutagenesis The primary lesion in EMS-induced mutations of bacteria and yeast is an alkylation-induced transition of guanine to adenine; most EMS-induced point mutations in Drosophila can similarly be explained on this basis. This change would be expected to convert, on the complementary strand, a C in the opa repeat element to a T, creating an in-frame stop codon (CAGCAA to UAGCAA or CAGUAA) . (Ethylnitrosourea, ENU, which has been reported to yield a higher number of mutations for a given amount of sterility, is also an alkylator; however, considerably more stringent precautions must be taken in handling this mutagen.) EMS was administered at 0.025 M to unstarved 1.5-5 day-old males in 1% sucrose solution (1.5 ml on two slips of Whatman #2 in a 350 ml milk bottle) . Starvation of the males for 8 hours before EMS administration resulted in unacceptable levels of sterility, and males of the st p_ p eϋ strain readily fed upon the EMS/sucrose solution without starvation. Mutagenesis was monitored by crossing mutagenized males to attached-X FMA3 females. Other mutants seen in this screen included a large number of ca alleles (many mosaic) seen over TM6B in the Fl and F2 generations, a dominant brown allele, and two new mutants, Wink, a third chromosome dominant mutation resembling Bar, and a third chromosome dominant Curly- like mutation. Wink is easily scored (RK1) , has complete penetrance, and is quite healthy over TM6B. In the initial screen, vials were scored as mutant if they had fewer than 25% as many deficiency heterozygote as balancer heterozygote flies. On retesting, this was revised to 50% of the level seen in control crosses. Balancer heterozygotes were approximately two-thirds as viable as deficiency heterozygotes. In situ hybridization and cytological analysis In situ hybridization of polytene chromosomes was carried out as described in Experimental Example I (see Methods, section A) . Cytological analysis was performed by squashing larval salivary glands in lactoacetic orcein (2% orcein, 50% acetic acid, 30% lactic acid) . Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the claims. <cττ___-M-Tτ_m-r^g->-_Ai--i_3u*_rιττ^ CCO CTS AA CCC CCC CCI CAA CIS CM 1 S SAB CAS GAS TTC TCC cm CCT PCD lay Aaa reo Ala res Glu Lau Sin Sac Glu Gla Glu rna Sac Sin Arq CCC CAC OTA ATT COC OOC GIG ATC GAC TTTαCCθαe ATβATTCCC α_CTTC Ala ua Val Ila Acq Gly Val I la Aap rna Ala Gly MET tla rrβ Gly rna CTβ CTC ACC CAC GXC GAT AAC TTC ACE CTC CTG AAC OCC OGA CIC TTC OtC 'wι -_^τpττc-____t^^aacM_ι_ ^ __-_ι' _____'_,Iyτ __>rπ_α_M u ι jm Lau Lau TJir GIB Aap Aap Lya the Th Lau Lau Lya Ala Gly Lau rha Aap ...——-______-..uiij ι___<_r- _,τ CTS TT CTC COC CTB AIC TCC ATS TTTGAC TG- TCS AXA AAC -C ATC ATC Lau rna Va An Lau Ila Cy» MET rha Aap sac Sac Ila AM Sac Ila Ila ' ■ > afSU- aeaat alia Al^_^u_-L^__LllUllα_-llU-^ll^.ul _π.^.lli^_ll^-U--__.n^-^--U-^AC_^ CTΆ AAT ccc oβ βτo ATO ca COS GAT OCS ATC CK3 AAC USA ccc T σx Lau Aaa Gly Gin Val MET Acq Arq Aap Ala Ila Gin Asa Gly Ala Aan Ala TTC CTS GIB CTC TOC ACC TTC AAT TTC 035 GAG CCC ATG AAC TCG ATS AAC *2U Fha Lau Val Aap Sac Thr rha Aan rha Ala Glu * MET Aaa Sac MCT Aan πτrnτ-_'π-τr , **^***"ττπr**— — — TTΓ nnnr— *πτn. .nτ_ra_ι_τττr_ιτιr AO. GAT OOC GM AT» OOC CIO TTC TOC OCC ATC GTT CIO ATT ACO CCS GAT T.IY?T_T__.. τιy ■« < « -_- ■■ .y ■ ^Λyττav τr rwy_-π__ι_ τιτw»ττ_ Thr Aap Ala Glu Ila Gly Lau rha cya _u Ila Val lau lie Thr f co Aap *M.τrrττra»_n»iιn__τaaMiiMAτkm^ ^ CCCαST TISCGC λAC CTSGMCTGAT GλSAAOkTGTACTCGCGλCTCAA fro Gly Lau Arq Aaa Lau Glu Lau Ila Glu lya MB Tyr sax Are Lau Ly ATG TTΛ ATS ICC OSS GAC SOT TCλ GAT ACC OOC AAS ACT TCT CTG ATC TOC AOC MR Lau WT Sac Ala Aap Sac Sac Aap Sac Ala Lya The Sac val Ila Cya sac TOC CTG CAO TAC ATT SIC OCC CAC AAT AGO CCC GAT CAO CCC CM TTC CT Cys Lau Gin Tyr Ila Val Ua βla Aaa Aoj o Aap Cla tra Glu turn La AcsG-sλcrαcc>__:Aτsc_AαcAccAccAαcrcαc_Aα_scce__c__c<CA The val sac Ala Sar MET Lau Ala fro fro Ala Fro Glu βla t a Sac Thr The AAG TTG CTS SAG ACS ATG CCC SAT CTS COC ACC CTG AOC ACC CTS CAC AC Lya Lau Lau Glu Ihr MET res Aap Lau Arq Thr Lau sar Thr Lau Mia Th sα ccλ ccc ATT rrc ααs cut ACX GOT CCA TC CAC CTO SU AAT OCC CTO AAA Ala rro Pcα Ila Lau Gly Val Thr Gly Arq sar Mia Lau Glu Aaa Ala Lau Lya AAA CTS GTA GTT TTC COC ACC CAG CK AAG GAG CTS CTS COC CAS OO AT 54 Lya Lau Val val rha Aeq Thr Glu Rla Lya Glu Lau Law Arq Gla Gin ME 542 CTX CCS CCA AAC ACA ACT CTT TCS GCT TAC TAC OG <~*C AAC AOC AAG CTG CCC Lau fro rro Aan Thr Sac Val Sar Ala Tye Tyr Gla His Aaa sae Lya Lau Gly 21(2 TCC ATS GMS GAC OCC AAC AAC ACC GAT OCC CAG CAG AAC AAG TCS CCC TC Sar MET Glu Aap Sly Aaa Aaa Sar Aap Gly Gla Gla Aaa Lya sar rro sa ATS G-COG AAT TAC AAT CCSGAA TTC AGO ACC CTG OTA OCA CCT CTC ACA AT MET Gly Gin Aaa Tye Aaa rro Glu fee Arq sac Lau Val Ala res Val The Aap AOC TOO OOS GAT OCC ATO GAC CTS GAGSCSGCC AAG ACT CCS CTT OCC TC Sar Trp Ala Ala MCT Aap Val slu Ala Ala Lya Sae fro Lau Gly sa CTS GAT ACT CTS CO CCC ACA QCT CTG ACC ATS GCS ACT TCT TCS AAT TCT CCC Lau The val reo fro The Gly Val The MET Ala Sae Sac Sae Aan Sae fro TCS ACC ACT GAS TCC CCC GAC CTG GAC TAC OOC ACT CCS ADC ACT TCG CA in Sar sar Thr Glu sac Ala Aap Lau Aap Tye Gly sar rra smt Smt mt Gl _ΛC TCC TCC CTCλAGCT β CCC C«Cλ_C 6αCGT0 λTC TTTeTC _αCAAA TCSKT Aan Sac Sac val Lya Lau fro ma Sar Gly val Ila fha val Sar Lya ar Sac Sin Gly Val Sar Lau rro Sax rro rro Gin Gin Gla Irs Sar Ala Lau Al OCC CIC ACC ACC ACC GAT GOT CCC ACT OCA GIG TTO CU Oβ OO CAG CCS CAG Ala Val Sar Thr Thr Aap Gly fro Thr Ala Val Law βla Gla Gin Gla fro Gin TCO OCT CCT CTO CIO OCS OCC ACC CTC ICC OGA OCA TOT CCC CTO OOC AA Sar Ala rro Lau Lau Ala Ala Thr Lau Sar βly Gly cya rro Law t→zm Aa 112 c_Gc_AATGccccιβc_cττcG«GταccτGeccc]_:α_:σ_:ccce_βα-sαtA sin Gin MIT rro Gla Mia rka Glu Sae Lau reo Mia Ua Mia fro Gin Gla Glu SOC AAT TCC OOC TCC AGC OCT GAC TCC OGA OCA OCT GAG ATO GAT ATC G 1(2 Ala Aaa ar Gly Sar sar Sly Aap smt Gly Ala Ala αlu MET Aap Ila CAC C«_i CCA CAC C»G CAS CAC CAA CAA CAT CDC CTT CAG CAC CAC CCA CAT CCA Ua Gin fro Gin Gin Gin Gla Gin Gin Mia Ilia Lau βla Mia Mia reo Mia reo TCS CAC OCX CAT CTC CC CAS AAC CCC CTS ACA ATC ACS CCO ATT CTS C Sar Mia Ala Mia La Thr Sin Aan sly Lau Thr Ila Thr reo Ila Val A gAGTATCTT.. Incron S..-1HI'1AC_B His val MET Tye reo Ua Sly Tye Gin Gin Ala Aan Lau Hi- Hia ae Gly Gly CAO CAC CMS CAA CAA CAG CAC CAG CIC ATC OCA AtA CTC AAT AAT OCS C ATT OCT CTG GTT CCS GOB GAT TCS CCT CCC CAC ACT CCC α_3 TAC ATC AAO TCC Gin Gin Gin Gin Gin Gin Sin Gin Gin Ila Gly Ila Lau Aan Aan Ala H :ia Ala val val reo Ala Aap Sar Arq reo βln Thr rro Glu Tyr Ila Lya Sar 21« COC AAC TTG AAT OCS GGA CDC OCS ATS TOC CAG CAA CM CAC OS CAC C Arq Aan Lau Aan Gly Gly Hla Ala MIT Cya Gin Gin Gla Gin Gin Hla f Tyr rro val MCT Aap Thr Thr Val Ala sac ft Val Lya Gly Glu reo Glu Lau G___4*25 gTGA___l_H-..Incrsn 1..TTLI _.l_ j_t CTO CAC CAC CAC TTG ACA OCC GGA GCT OCC COC TAC AGk AA β CTA CAT T Lau Hla Mia Hla Lau The Ala Gly Ala Ala Arq Tye Arq Lya Lau Aap S 10(2 Arq ΛΛC ATA GAA TTC SAT OOC ACC AO. GTS CTS TOC CSC CTT TOC GSG at AAG OCC Aan Ila Glu rha Aap Gly Thr Thr Val Lau Cya Arq Val Cya Gly Aap Lya Ala 2702 ACS GAT TCS OOC ATT GAC TCS COC AAC GAG AAC AAC GAS TOC AAG OCS C The Aap Sac Gly Ila Glu Sac Gly Aan Glu Lya Aan Glu Cya Lya Ala v cTAλαrr π..incron 2..A Λ'U liiSjfi CS OCC OCR ACT TCC TCS TOC TCC CT CCS CCT TCC tOt GTG GAT GAT TCC OCT TTC CAT TAC OOC CS CAT TCC TOC 6» OST TOC AAG OGA TTC TTC CCC Sac Sly Gly Sac mt smt Cya Sac ac reo Arq smt sac val Aap Aap Sac Gly rha Mia Tyr Gly Val Hla Sar cya Glu Gly cya Lya Gly rha fha Aeq 270 GAC TOC AGC GAT OCC OOC CCC AAT CAC AAT CAC CTO 0-0 OO CAT CCC CSC TCC ATC CAC CAA AAS ATC CAG TAT COC CCS TOC ACC AAG AAT CAG CM TOC Aap Cya Smt Aap Ala Ala Ala Aan Mia Aan Gin Val Val Gin Hla reo Arq sat Ila Gin Gin Lya Ila Gla Tyr Arq reo Cys The Lya Aan Gin Gla Cya ACT GTS CTO TCC CTS TCA CCA CTT COC TCS CCC CAC CCC TCC ACC ACC AOC ATT CTS COC ATC AAT COC AAT CCT TOT CAA TAT TCC CCC CTC AAA AAO TOC Sar Val Val Sae val Sae rro val Arq sar rro Gin res Sac Thr Sae Sac Ila Lau Arq Ila Aan Aeq Aaa Aeq Cya βln Tye Cya Acq Lau Lya Lya Cya .Intron 3..CCAA' CTO AAS CGA CAC ATT GIG GAC GAT ATG CCC GTS CTG AAO CSC CTO CTG lau Lya Arq Gin Ila val Slu Aap MET rro Val Lau Lya Arq Val Lau ATT OCC GTS OCC ATS ACT COC GAT OCTT GTS CCT TTT OGA COC GTG rrr. nmj ejGC Ila Ala Val Gly MET Sac Acq Aap Ala Val Arq rna Gly Acq Val reo Lya Acq 2*72 Cαr CCT CIC TAC GAT Aαi AAC ICG CIG ATS βAC βAOβS TAC AACCCG 324 1352 rro fro Lau Tyr Aap The Aan sar Lau IT Aap slu Ala Tyr Lya rro SAA AAS OCS CCT ATC CTO OCS OCC ATS CAA CAC AOC ACC CAC AAT CSC OOC CAC Slu Lya Ala Acq Ila Lau Ala Ala MET Gin Sin Sar Thr Gin Aan Acq Gly Gin AAA TTC COS OCC CTC eOS CAT COC GAC TTC CACACC OCC GAC 0CG GAT Lya rha Acq Ala Lau Acq Hla Arq Slu fha Glu Thr Ala Glu Ala Aap CKCSA GCC CIC aCC ACCGICCTS GAT CAC CAC CCA COC CTC CTC GCC a-COTG Sin Acq Ala Lau Ala Thr Slu Lau Aap Aap Sin rro Arq Lau Lau Ala Ala Val ACT TCC ACT TCC OCC TCS AAC AOC CTG ACT OCC OCC ACT OCO COG CAC Sar Sar Thr Sac Gly Sac Aaa Sac Lau Sac Ala Sly Sac reo Arq Gin CTS cαeαec c*c er β *α ACC ICT GAG TTC ACC AAG α_> AAG GΓCTCG GCC ATS Lau Arq Ala Hia Lau Slu Thr cya Slu rna Thr Lya αlu Lya val sar Ala MET GIC CCG AAC ACT CTG OCC ACS CCC CCC CCA TCS OSS OCC ACC CCC COC 371 val rra Aan ac val Ala The reo res rro sar Ala Ala Sar Ala Ala gAACTCTC*..Intron 4..A h;TTTCTCC G AAT CCC OCC CAC ACC CAO CTC CAC ATG CAC CTS ACC CCC ACC AOC CCC Aan rra Ala Gin sar Gin Lau Mia MET Mia Lau The Aiq Sac smt reo COS CAC COS OCS COB GAT TOC OX TOC TAC TOC ATS CCC ACA CTT CTO CCC TCT Arq Gin Arq Ala Arq Aap cya res Sar Tyr sar MET rra Thr Lau Lau Ala Cya 3242 B TCG ATO OOC AOC TCS CAC TCS CTC CTS OCC AAC TCT CTC ATG OCC SAC CCS CCC sae H- Ala sae Sar Hla sae val Lau Ala Lya sar Lau MET Ala Glu rro Arq CSAUJU-l ■ ! ll_y .ll_U_XaU.lV_M-lT0_σ__M_AAAAAOMUUMIC»rM_J_T_ri__-WCA J72 -Ml ATS ACO CCC 9S CAO AISAAGCOC AaC GAT ATT ATC CλA AλC TAC -TS λλG eαC ,ι. ιu__ l -_._-._ i _-.__-'«-_!alι_ __.ι_jτ-j___j_ _n'i_n_____ _-_y__ «'Mf__ϊ___ MET Thr rra Glu Gla MET Lya An) sar Aap Ila Ila Gla Aan Tyr Lau Lya Arq yr_-^~^-n^^Λπ^r"•^ r '^* , ""~^^^*nn ' ^J ~ CT ~'',^ι ■ ι ι .. < ιi"" " ■ asAλc_αc(CAθ_Aα_cA__:_<_:AccλccAλTQαcsτsoαcAACcαcAcrccc Slu Aaa ae iti Ala Ala Sar Sar Thr Thr Aan Gly val Gly Aan An) Sar rro 1 MX MK ACC TCC ACACCS CCSCαS TCS SCO CTC CAC AAT CAC CAC CGT TOC COC ar sar ae sar The rra rra rra Sar Ala Val Gin Aan Gin Gin Arq Trp Gly mHHA acarc aica τ^_ra | r_τ^ _MMη r"^ AA »»"'^ A ^""^ A ccKKTCocrsATCACCAecλceiαccAOCM: ccc esc CMS TCC STS TOS COS Sar Sar Sac Val Ila Thr Thr Thr Cya sin Sin Aeq Sin Gin Smt Val mt rro Λ_W3__»CB__»__J__T>irJ-t _SnC I»0CAAtI»_AT-0C_,_IU.11 ■U-lU.lUUCA αtCA_CAACα_τ τcc___:ταcj_-rτσ:_αcτeτAαcτccAαe τecA_ιττα: τσι Hla Sar Aaa Gly Sar Sar sar Sar sar Sar Sar sar Sae sae Sae ae Sae sar Tαk__-XMΛ_n__ --IG_QClV|XSI_CCTTλ RC 1CC 1CC M_λ 1CC TCCA_C TαC AOC TαC ACC TCO OCC AOC CC TOC CAC TAT GIG-C_r--CG_ACCC_M_U____J--lTCTCTU_ -____r ATC CTT TCT OCA AT ae Sae Sae The Sae Smt Aaa cya sar Sar Sae smt Ala mt Smt Cya Gin Tyr MET Val Cys Ala (C 10t0 1 302 TTC CAC ICSO-O CAC TCC ACeACC AAC OOC ACC ACT OCA CCO OCS AOC TCC ACT CMS CTT OCT OCT CTG CAC CAT CAC C S CAC CAA CAC CM CTC CAC TTG C Fha βln Sar rro Mis Sar The Sae Aan Gly The sac Ala rro Ala Sar See smt Slu Val Ala Ala Val Gin His Sin Sin Sin Sin Gin βla Lau Gin Lau r ICG αsλ lCS AACAαC O-CACSCCC CTGCTSeMCTOCAOCTBGAC TTOCTeK: Sae Gly Sar Aaa Sar Ala The rro Lau Lau βlu Lau Gin Val Aap Ila Ala Aap Gin Gin Gin Gla Gin Gin Gin The Thr Gin Gla Gin Hla Ala Thr Thr I TCG OCC OO CCT CTC AAT TTS TCC AAC AAA TCO CCC ACS CCO CCS COC AOC AAC c-S CTGACooαe AAr ααe oαc αoT AλT CTsα TTβrcoccACA Cccc Sar Ala βla reo Lau Aaa Lau Sar Lya lya sar rro The reo reo reo Sae Lya Lau Lau Thr Gly Aan Gly Gly Gly Aan Lau Hla Ila Val Ala The rro G 1134 cτβcλCGCTcτGGTGαccαccαα_ λλταo_ Gτr CAA AOS TAT CCC AO. ITS TCE CAT CAC CCS ATG CAT CAC CIC CAC CAT CAG CAT CAC CAT OO CAT CAG C Lau Ila Ala Lau Val Ala Ala Ala Aaa Ala Val Gla Arq Tyr rro Thr Lau Sae Hia βln rro MET Ila βln Lau Hla Hla sm Hla Gin ua Gin Hla Gin H aCC CAC CTC ACA GIG ACA OCC ICC AAT OOC OOO TOC TOC CTC OOC OOC OOC GAS OUCMS OCC λAβ Aαc CλA CIC CTS AAC CAA CAA CAC ICS OCS CTSCTC A Ala Aap Val Ihr Val Thr Ala sar Aan Gly Gly sar sar val βly Gly Gly Glu Sin sin Ala Lya sar Gin Gin Lau Lya Gin Gin Hla ar Ala Lau val L TCcαoccαccλSCλβociccαccαsCGλOTOT cos ere ccc CAA TCC COB CCT CR CAC TOS OCS CCC ATC AAS CAC CAA CMS CAG ACE CCC AAG CAA ATT C Sar Gly Arq Gin Gin sin sar Ala sly βlu Cya βly Lau rro βln Sar βly rro Lau Slu Sae Ala rro Ila Lya Gin Gin Gin Gin Thr rro Lya Gin Ila v USS CMS COC COC CST OCA CAA OCT AAT OCT OGA OOC GTA ACA GOB GGA OCA OST ACC Slu Arq Arq Arq Ala Gin Gly Aan Ala Gly Gly val Arq Ala Gly βly Gly Aeq Lau Gin Gin βln βln βln βln rro βln Arq Lya Arq Lau Lya Aan Glu A TOG TTT TAC QCCCAαAAOTαSGMS AGλ CλGAGλCTβOGA CTβGCλ Crr CMS αSA ATCO_A CAA eAO CAA C_A CAAACA CCT aCA ACA CTA CTAA*O ACAACA A Tep rha Tye Ala Glu Lya Trp clu Arq βla Arq Lau βly val Ala Val βln Arq Ila Val Gla Gin βln Cln Gin Thr rro Ala Thr Lau Val Lya ar The c 40S2 AGC AGO AAC CAC GAT CAC ITS GAC COS COS GAC TTS AAT Tλλ A_CAAC __C A_C ACAC _J_: AC CAC __ ACAAAT Ae- A_ ACT CACC sar Arq Lya Gin Aap Hla Lau βlu Arq Arq βlu Lau Aan Sar Aan ar Asa Sae Aan Aaa Thr Cln The The Aan Sac Ila sae β la β 12.7 ΛTTΛTΓTTACCAT CMS CAC CAT CAS ATT STS TTS CAC CAC CAC CAC CCA CCC OCS OCA OCA A Oln Gla Hla βln Ila Val Lau βln Hla βln Gin rra Ala Ala Ala Ala T 3AC_Ulβr_ATTMITrAAλλAλC-_UC_J_______UU_: •42 AAC CCA TOT OCC GAT CTG ACC GO- AAA AAT GAC ACC GAC TCC OOC ATC G 4234 Lya rro Cya Ala Aap Lau Smt Ala Lya Aan Aap Sae Glu sae Gly Ila A AACAAAλλMXCλA___rTCλATαSnTTM ΛtATAAAtATATTTTA SAC TOC CCC AAC ACC SAT SAC GAT TOC CCC AAT OCC AAC CCS OCS COC A XMST_AAACT-TJ-l_X_r_f___^_»A_α_>A_A_-»TCAAll'l , Mlll l_l>_.lir U__πAA-TTTTC Aap cya rπ Aan Smt Aap Glu Aap Cya rra Aan Ala Aan reo Ala sly T TTCA-C1__-T_______-U---CCCCTCACCTO I.<.11 IΛ'.AAUXl HX'_I I'M'M.AfXAM.U.l l'VT tc aa at toc ccc tos Lau Glu Aap Sar Sar Tyr Glu Cln Tyr Gin cya rro Trp Lya Lya Ila A _CM-U-_l_.il U 11 lA_AM.m_AAt_.lU 1-1 l lAOTATIllATTAU-U 1A_-U.UM.IA._T αOS eOT GλS CIC CTC AAG CAG CC OλC TTG GMS CAC Cλβ C-WS ACC ACC α 4514 Ala Arq Glu Lau Lau Lya Gin Arq Clu Lau Glu Gin Gin Gin Ihr Thr TTAOCCCTTTACTTGTACTTOS«OCAAAA_rt_CUll_.lUUlULΛl lUlllt_>AAAAACTOOUUl TATTACT_LIIlLttTTTTTAAAIACCIAAAAJ>CAAAA-aAJ-l\-W.It-A lUlllA U ar Aan Ala Gin Gin Gin val Slu Ala Lya rro Ala Ala Ila rro Ihr s I » poly A alta cCaHtt. and ccartSM 1112 4454 ATC AAS CMS CTS CIC TOT GAT ACT CCC TTT TCC GOG CAC ACC CAC AAS G «AE_«_Aλn_AAβ_ocx__cιταc_j__λA_τrrλA___ια^ Ila Lya Gin Lau Hla Cya Aap Sar rro rha Sar Ala Gin The Hla Lya G ArTTAACTAλll -TATOAAI 1' .Uϊ IΛTACI πitXACLLTT lAIM2AX TTC_AXl.tl_l-CλTCTAαcT GCC AAT CTC CTS COS CAA CAC TCC CAC CAA CAA CAC CTT CTO OCC ACO C Ala Aan Lau Lau Arq Gin βln Sar βln Gin Gin Gin val val Ala Thr G 'λ_r__TAΛJ__M_CAAGTT___AT__u.TAT CAG CAC CAA CAC CAC CAS O CAC CAC CAC CMS CAA CAA CCA ACC GAT A Gin Gin Gin Gin Gin βln βln Hla βln Hla Gin Gin cln Acq Arq Aap S rcττττCTλλτrτrλAAACT_α__cjuu\MTλ-__k-Ti^ 4.34 GAC ACC AAC TOC TCC e-S ATO AαC AAC TCO AαC AAC TCC ACT OCO O-C A AIO-TTAAA_»TITACrArrAArrACTAMACT_M_SA-^UK_M>C>CAAA_CCAACSITAAM Aap Sar Aan cya Sar Lau _KT Sar Aan sar Sar Aan sar Sar Ala Gly A TT_TOTM__TA_rrTAAAK_rrAM.T_Λ*_«CΛAAAACATAmAΛ TCC ACC TOC AAC CCT COC CM. GAC CAC CMS CTS GAC GAC ATS SAC GAG G Cya Thr cya Aan Ala Gly Aap Aap Gin Gin Lau Glu Glu MET Aap Glu A £074 ^_a_ri_.»_MT _!____ .__-__-._ττr._ι___-!^_.τ<_^ 1312 GAT TαS OαC IGC CM- GAT GAA CTT TOC GAG CAG CAT CAC CAC CCA CTS Ajp ar Gly Cya Aap Aap Glu Lau Cya Glu Cln Hla Hla Cln Arq Lau A AAAAAAAAik-CAACMA__UAAΛTTAICATλTATTATTnAAA__AλλβTλT___«TTI^ .214 TCC CAA CTO AAr TAC CTO TOC CAC AAO TTCGAT GAG AAA CTO CSkC ACO α AAOU>AA_-H-A»AA-TiqCOSrA_aA_-WUtACTAITAT»TTMTTMCAIT^ Sar Gin Lau Aan Tyr Lau cya Gin Lya rha Ajp Glu Lya Lau Aap Thr A _»_.. _ l a.τ l aA_ l τa.τa.l_-.__Aτraaw » _ι ui.jnmi '[ <-rf**^^ynuv;jvftAft_-__.M_|. sar Aan smt Sar Ala Aan Thr Sly Arq Aan rnr Fro Ala Val Thr Ala A .354 T IVΛW-II mmiium mum mu ii iii 1544 SAT OCC SAT qeaqqcttaq l__^ put, aciva polyinanylatlon aiqnal tor lonq ceanaeelpca Aap Ala Aap *"^ ACTTACTAGTGAAAAACATGATAATAAAC_AACTTO:CAAAAAA^ CTTATCTTAAAAAAArAOGTG-t-GATTGTAACCGTTCATGT -141 τσσGτr__ATt_αcAGCAC GTTcr_AAσα_;^ AAAACTGΔ_____£________TCCαCCC-GAATT_;TT^ ' »** mRNA start site ATCC CC _CTCCGCTTt_rTCCC TCCGTTCGT^ TTTAACCAGTCTAGTGAGTGCCCCGTGAAAAαGATAACCC^ + 211 TTTTATCAGTGTGAAGAAAACATGTAAACTTGGCTX_AAAAAGGGCTT^ C_AAGGATAAAATAATATC_OC_ACCAGTGCTTCAAAAArc AAATTTTTTTAATAAATATTCCAAAAATATTGCCCCTGAAAAGTGTTGAT 380 ATG TTA ATG TCC GCG GAC AGT TCA GAT AGC GCC AAG ACT TCT GTG ATC TGC AG MET Leu MET Sβr Ala Asp Sβr Sβr Asp Sβr Ala Lys Thr Sβr Val lie Cys Sβ ACG GTG AGT GCC AGC ATG CTA GCA CCA CCA GCT CCA GAA CAG CCC AGC ACC A Thr Vai Sβr Ala Ser MET Leu Ala Pro Pro Al Pro Glu Gin Pro Sβr Thr T GCA CCA CCC ATT TTG GGG GTA ACA GGT CGA TCT CAC CTG GAA AAT Q3C CTG A Aia Pro Pro lie Leu Giy Val Thr Gly Arq Ser His Leu Glu Asn Ala Leu L 54 542 CTA CCG CCA AAC ACA AGT GTT TCG GCT TAC TAC CAG CAC AAC AGC AAG CTG G Leu Pro Pro Asn Thr Sex Val Ser Ala Tyr Tyr Gin His Asn Ser Lys Leu G ATG GGC CAG AAT TAC AAT CCG GAA TTC AGG AGC CTG GTA GCA CCT GTC ACA G MET Giy Gin Asn Tyr Asn Pro Glu Phe Arg Ser Leu Val Ala Pro Val Thr A CTG GAT ACT GTG CCA CCC ACA GGT GTG ACC ATG GCG AGT TCT TCG AAT TCT C Leu Asp Thr Val Pro Pro Thr Gly Val Thr MET Ala Ser Ser Ser Asn Ser P 1 AAC TCC TCC GTC AAG CTG CCC CAC AGC GGC GTG ATC TTT GTC AGC AAA TCG A Asn Ser Ser Vai Lys Leu Pro His Sβr Gly Val lie Phe Val Ser Lys Ser S GCC GTC AGC ACC ACC GAT GGT CCC ACT GCA GTG TTG CAA CAG CAG CAG CCG C Ala Val Sβr Thr Thr Asp Gly Pro Thr Ala Val Leu Gin Gin Gin Gin Pro G 812 CAG CAA ATG CCC CAG CAC TTC GAG TCC CTG CCC CAC CAC CAC CCC CAG CAG G Gin Gin MET Pro Gin His Phe Giu Ser Leu Pro His His His Pro Gin Gin G 1 CAG CAA ATG CCC CAG CAC TTC GAG TCC CTG CCC CAC CAC CAC CCC CAG CAG G Gin Gin MET Pro Gin His Phe Glu Ser Leu Pro His His His Pro Gin Gin G 1 CAC CAG CCA CAG CAG CAG CAG CAA CAA CAT CAC CTT CAG CAC CAC CCA CAT C His Gin Pro Gin Gin Gin Gin Gin Gin His His Leu Gin His His Pro His P CAT GTG ATG TAT CCG CAC GGA TAT CAG CAG GCC AAT CTG CAC CAC TCG GGT G His Val MET Tyr Pro His Giy Tyr Gin Gin Ala Asn Leu His His Ser Gly G ATT GCT GTG GTT CCG GCG GAT TCG CGT CCC CAG ACT CCC GAG TAC ATC AAG Ile Ala Val Val Pro Ala Asp Ser Arg Pro Gin Thr Pro Glu Tyr lie Lys S 2 TAC CCA GTT ATG GAT ACA ACT GTG GCT AGT TCG GTA AAG GGG GAA CCA GAA C Tyr Pro Val MET Asp Thr Thr Vai Ala Ser Ser Val Lys Gly Glu Pro Glu L CTG TGC CCC GTT TGC GG GAT AAG G Asn lie Glu Phe Asp Gly Thr Thr Val Leu Cys Arg Val Cys Gly Asp Lys A CGC ATC CAG CAA AAG ATC CAG TAT CGC CCG TGC ACC AAG AAT CAG CAG T Arg Ser He Gin Gin Lys He Gin Tyr Arg P ro Cys Thr Lys Asn Gin Gin C AGC ATT CTG CCC ATC AAT CGC AAT CGT TGT CAA TAT TGC CGC CTG AAA AAG T Sβr l ie Leu Arg l ie Asn Arg Asn Arg Cys Gin Tyr Cys Arg Leu Lys Lys C ΛTT GCC GTG GGC CGC GTG CCG AAG C lie Aia Val Gly MET Ser Arg Asp Ala Vai Arg Phe Gly Arq Val Pro Lys 3 1352 GAA AAG GCG CGT ATC CTG GCG GCC ATC CAA CAG AGC ACC CAG AAT CGC GGC C Gl u Ly3 Al a Arg l ie Leu Ala Ala MET Gin Gin Ser Thr Gin Asn Arg Gl y G CAG CGA GCC CTC GCC ACC GAG CTG GAT GAC CAG CCA CGC CTC CTC GCC CCC '. in Arg Ala Leu Ala Thr Glu Leu Asp Asp G in P ro Arg Leu Leu Aia Aia CTG CGC GCC CAC CTC GAG ACC TGT GAG TTC ACC AAG GAG AAG GTC TCG GCG Leu Arg Ala Hi s Leu Glu Thr Cys Glu Phe Thr Lys Glu Lys Va l Ser Al a GT^AGTCTCA. . i nt ron 4 . . ATTTCTT, CGG CAG CGG GCG COG GAT TGC CCC TCC TAC TCC ATG CCC ACA CTT CTG GCC A rg Gin Arg Ala Arg Asp Cys P ro Ser Tyr Ser MET Pro Thr Leu Leu Aia CCG CTG AA v, JC GCC CCT GAA * CTC CAA TCG GAG CAG GAG TTC TCC CAG CCT TTC Pro Leu Asn Pro Aia Pro Glu Leu Gin Se r Glu Gin Gl u Pnβ Se r Gi n Arg ?nβ 1622 GCC CAC GTA ATT CGC GGC GTC ATC GAC TTT GCC GGC ATC ATT CCC CGC TTC CAG Ala His Val lie Arg Gly Val He Asp Phe Ala Gly MET He Pro Gly Phe Gin .32 CTC CTC ACC CAG GAC GAT AAG TTC ACG CTC CTC AAG GCG GGA CTC TTC GAC GCC Leu Leu Thr Gin Asp Asp Lys Phe Thr Leu Leu Lys Al a G_. y Leu Phe Asp Al a CTC TTT GTC CGC CTC ATC TCC ATC TTT GAC TCG TCG ATA AAC TCA ATC ATC TCT Leu Phe Vai Arg Leu He Cys MET Phe Asp Ser Sβr He Asn Sβr He He Cys CTA AAT GGC CAG GTC ATC CGA CGG GAT GCG ATC CAG AAC GGA OCC AAT GCC CGC Leu Asn Giy Gin Val MET Arg Arg Asp Ala He Gin Asn Giy Ala Asn Ala Arq 486 TTC CTG GTC GAC TCC ACC TTC AAT TTC GCG GAG CGC ATG AAC TCG ATG AAC CTG P_» Leu Val Asp Ser Thr Phe Asn Phe Ala Glu Arg MET Asn Ser MET Asn Leu 1892 ACA GAT GCC GAG ATA GGC CTG TTC TGC GCC ATC GTT CTG ATT ACG CCG GAT CGC Thr Asp Aia Glu He Gly Leu Phe Cys Ala He Val Leu He Thr Pro Asp Arq CCC GGT TTC CGC AAC CTG GAG CTC ATC GAG AAG ATG TAC TCG CGA CTC AAG GGC Pro Gly Leu Arg Asn Leu Glu Leu He Glu Lys MET Tyr Ser Arq Leu Lys Gly 540 TGC CTG CAG TAC ATT GTC GCC CAG AAT AGG CCC GAT CAG CCC GAG TTC CTG GCC Cys Leu Gin Tyr He Val Ala Gin Asn Arg Pro Asp Gin Pro Glu Phe Leu Ala AAG TTC CTC GAG ACG ATC CCC GAT CTG CGC ACC CTC AGC ACC CTG CAC ACC GAG Lys Leu Leu Glu Thr MET Pro Asp Leu Arg Thr Leu Ser Thr Leu His Thr Glu AAA CTC GTA GTT TTC CGC ACC GAG CAC AAG GAG CTC CTG CGC CAG CAG ATG TCG Lys Leu Val Val Phe Arg Thr Glu His Lys Glu Leu Leu Arg Gin Gin MET Trr> 594 2162 TCC ATG GAG GAC GGC AAC AAC AGC GAT GGC CAG CAG AAC AAG TCG CCC TCG GGC Ser MET Glu Asp Gly Asn Asn Ser Asp Gly Gin Gin Asn Lys Ser Pro Ser Gly ACC TOG GCG GAT GCC ATC GAC GTC GAG GCG GCC AAG AGT CCG CTT GGC TCG GTA Sβr Trp Ala Asp Ala MET Asp Val Glu Ala Ala Lys Ser Pro Leu Gly Ser Vai TCG AGC ACT GAG TCC GCC GAC CTC GAC TAC GGC AGT CCG AGC AGT TCG CAG CC Sβr Sβr Thr Glu Sβr Ala Asp Leu Asp Tyr Gly Ser Pro Se r Ser Ser Gin Pr 64 Θ CAG GOC GTG TCT CTG CCC TCG CCG CCT CAG CAA CAG CCC TCG GCT CTG GCC AG Gin Gly Val Ser Leu Pro Ser Pro Pro Gin Gin Gin Pro Sβr Aia Leu Ala Se TCG GCT CCT CTG CTG GCG GCC ACC CTC TCC GGA GGA TCT CCC CTG CGC AAC Ser Ala Pro Leu Leu Ala Ala Thr Leu Ser Gly Gly Cys Pro Leu Arg Asn Ar 2432 GCC AAT TOC GGC TCC AGC GGT GAC TCC GGA GCA GCT GAG ATG GAT ATC GTT GG Ala Asn Ser Gl Ser Ser Gl As Ser Gl Ala Ala Glu MET As He Val Gl 2432 GCC AAT TCC GGC TCC AGC GGT GAC TCC GGA GCA GCT GAG ATG GAT ATC GTT Ala Aan Ser Gly Ser Ser Gly Aso Ser Gly Ala Ala Glu MET AaD lie Val Giy 702 TCG CAC GCA CAT CTC ACC CAG AAC GGG CTG ACA ATC ACG CCG ATT GTG CGA CAC Ser Hla Ala Hia Leu Thr Gin Aan Gly Leu Thr lie Thr Pro lie Val Arq H a CAG CAG CAG CAA CAA CAG CAG CAG CAG ATC GGA ATA CTC AAT AAT GCG CAT TCC Gin Gin Gin Gin Gin Gin Gin Gin Gin l ie Gly l ie Leu Asn Aan Ala Hia Ser CGC AAC TTG AAT GGG GGA CAC GCG ATG TGC CAG CAA CAG CAG CAG CAC CCA CAA Arg Aan Leu Aan Gly Gly Hia Ala MET Cya Gin Gin Gin Gin Gin Hia Pro Gin 756 G (Dro4 925) CTG CAC CAC CAC TTG ACA GCC GGA GCT GCC CGC TAC AGA AAG CTA GAT TCG CCC Leu Hia His Hia Leu Thr Ala Gly Ala Ala Arg Tyr Arg Lys Leu Asp Ser Pro Arg 2702 ACG GAT TCG GGC ATT GAG TCG GGC AAC GAG AAG AAC GAG TGC AAG GCG GTG AGT Thr Aap Ser Giy l ie Glu Ser Gly Aan Glu Lya Aan Giu Cys Lya Ala Val Ser TCG GGG GGA AGT TCC TCG TGC TCC AGT CCG CGT TCC AGT GTG GAT GAT GCG CTG Ser Gly Gly Ser Ser Ser Cya Ser Ser Pro Arg Ser Ser Val Asp Asp Ala Leu 810 GAC TGC AGC GAT GCC GCC GCC AAT CAC AAT CAG GTG GTG CAG CAT CCG CAG CTG Asp Cya Ser Asp Aia Ala Ala Asn Hia Aan Gin Val Val Gi n Hia Pro Gin Leu AGT GTG GTG TCC GTG TCA CCA GTT CCC TCG CCC CAG CCC TCC ACC AGC AGC CAT Sβr Val Vai Ser Val Ser P ro Val Arg Ser P ro Gin P ro Ser Thr Sβr Sβr Hi s CTG AAG CGA CAG ATT GTG GAG GAT ATG CCC GTC CTC AAG CGC GTG CTG CAG GCT Leu Lys Arg Gin l ie Val Glu Asp MET P ro Val Leu I.ys Arg Va l Leu Gin Al a 364 2972 CCC CCT CTC TAC GAT ACC AAC TCG CTC ATG GAC GAG GCC TAC AAG CCG CAC AAG P ro P ro Leu Tyr Asp Thr Aan Ser Leu MET Asp Glu Al a Ty r Lys F ro Hia Lys AAA TTC CGG GCC CTC CGG CAT CGC GAG TTC GAG ACC GCC GAG GCG GAT GCC AGC Lya Phe Arg Ala Leu Arg His Arg Glu P he Giu Thr Ai a Gl u Aia Aap Al a Se r AGT TCC ACT TCC GGC TCG AAC AGC CTC AGT GCC GCC AGT CCG CGG CAG AGC CCA S β r Ser Thr Sβr Gly Sβr Aan Ser Leu Sβr Ala Giy Se r P ro Arg Gin Sβ r Pro 918 GTC CCG AAC AGT GTG GCC ACG CCC CCG CCA TCG GCG CCC AGC GCC GCC GCA GGT Val Pro Aan Se r Va l Al a Thr Pro P ro P ro Ser Ala Ala Ser Ala Ala Ala Giy AAT CCC GCC CAG AGC CAG CTC CAC ATG CAC CTC ACC CCC AGC AGC CCC AAG GCC Aan Pro Al a Gin Ser Gin Leu Hia MET Hia Leu Thr Arg Ser Ser P ro Lys Ai a 3242 TCG ATG GCC AGC TCG CAC TCG GTC CTC GCC AAG TCT CTC ATC GCC GAG CCG CGC Ser MET Aia Ser Ser His Ser Va i Leu Aia Lys Ser Leu MET Ala Giu P ro Arc 972 ATG ACG CCC GAG CAG ATG AAG COC AGC GAT ATT ATC CAA AAC TAC TTG AAG CGC MET Thr Pro Glu Gin MET Lys Arg Ser Asp l ie l ie Gin Asn Tyr Leu Lys Arg GAG AAC AGC ACA GCA GCC AGC AGC ACC ACC AAT GGC GTC GGC AAC CCC AGT CCC Glu Asn Sβr Thr Ala Ala Sβr Ser Thr Thr Asn Giy Vai Giy Asn Arg Ser P re AGC AGC AGC TCC ACA CCG CCG CCG TCG GCG GTC CAG AAT CAG CAG CGT TCG GCC Ser Ser Ser Ser Thr Pro P r P ro Ser Ala Val Gin Asn Gin Gin Arg Tro Gl y 102 AGC AGC TCC GTG ATC ACC ACC ACC TGC CAG CAG CGC CAG CAG TCC GTC TCG CCG Se r Ser Ser Val lie Thr Thr Thr Cys Gin Gin Arg Gin Gin Sβr Vai Sβr P ro 3512 CAC AGC AAC GGT TCC AGC TCC AGT TCG AGC TCT AGC TCC AGC TCC AGT TCG TCA His Sβr Aan Gly Ser Ser Ser Ser Ser Ser Sβr Sβr Ser Ser Ser Ser Sβr Ser TCC TCC TCC ACA TCC TCC AAC TGC AGC TCC AGC TCG GCC AGC AGC TGC CAG TAT Sβr Ser Ser Thr Sβr Ser Aan Cys Ser Ser Sβr Ser Ala Ser Ser Cys Gin Tyr 108 TTC CAG TCG CCG CAC TCC ACC AGC AAC GGC ACC AGT GCA CCG GCG AGC TCC AGT Phe Gin Ser Pro His Ser Thr Ser Asn Giy Thr Ser Ala Pro Ala Ser Ser Sβr TCG GGA TCG AAC AGC GCC ACG CCC CTG CTC GAA CTG CAG GTC GAC ATT GCT GAC Ser Gly Ser Aan Ser Al a Thr Pro Leu Leu- Glu Leu Gin Val Asp l ie Ala Asp TCG GCG CAG CCT CTC AAT TTC TCC AAG AAA TCG CCC ACG CCG CCG CCC AGC AA Ser Ala Gin Pro Leu Asn Leu Ser Lya Lys Ser Pro Thr Pro Pro Pro Ser Ly 11 3782 CTG CAC GCT CTG GTG GCC GCC GCC AAT GCC GTT CAA AGG TAT CCC ACA TTG TC Leu His Ala Leu Val Ala Ala Ala Aan Ala Val Gin Arg Tyr Pro Thr Leu Se GCC GAC GTC ACA GTG ACA GCC TCC AAT GGC GGG TCC TCC GTC GGC GGC GGC GA Ala Asp Val Thr Val Thr Ala Ser Asn Gly Gly Ser Ser Val Gly Gly Giy Gl TCC GGC CGC CAG CAG CAG TCC GCC GGC GAG TGT GGG CTC CCC CAA TCC GGG CC Ser Gly Arg Gin Gin Gin Sβr Ala Gly Glu Cys Gly Leu Pro Gin Ser Gly Pr 11 GAG CGC CGC CGT GCA CAA GGT AAT GCT GGA GGC GTA AGA GCG GGA GGA GGT AG Glu Arg Arg Arg Al a Gin Gly Asn Ala Gly Gly Val Arg Ala Gly Gly Giy Ar TCG TTT TAC GCG GAG AAG TOG GAG AGA CAG AGA CTG GGA GTG GCA GTT CAG CG Trp Phe Tyr Ala Glu Lys Trp Glu Arg Gin Arg Leu Gly Val Ala Vai Gin Ar 4052 AGC AGG AAG CAG GAT CAC TTG GAG CGG CGG GAG TTC AAT TAA Sβr Arg Lys Gin Asp H s Leu Glu Arg Arg Glu Leu Asn 1237 4052 AGC AGG AAG CAG GAT CAC TTC GAG CGG CGG GAG TTC AAT TAA Ser Arg Lys Gin Asp H a Leu Giu Arg Arg Giu Leu Asn 1237 ATTATCTTACCATTTAATTGAGACGTGTACAAAGTTTGAAAGCAAAACCAACATCC^ 7AATATTTAAAGCAACAACAAACAAAACAACTACAAGTTATTAATTTAA 4234 AACAAAAAACCCAAGCTTGAATGGTATTACAAAAGAAAAAGAAAAA^ OCAGTTAAACTTTAACGTAGCAAGAAACCAACAAACCCAAOG^ 4374 CAGCTCCTACCCAAAACGO-OCTCACCTCCCCCCC^ CGACCCCTGATTGT TATAAG TCAAGCTCTTGTTCTACA^ 4514 TTAGCGCTTCAGTTGTAGTTGGAG<_AAAACTACTTTCCTC TATTATTATTAAATTTTTAAATACCTAAAAACAAAACAATGTGTGTGAAA^ poly A site c m4927 and cDrt»4928 4654 AAGCAGAATCAAGTGCAGTTTGCAACAAATTTTAACTACGATTAAGTTGATAAC^ ATTTAACTAATTTTATGAATTTC TATAGTTTTCCΛCCCTTCTATAGATCTTCTATCTCATCATC 4794 ^CCGTATTCCTCATTTCTCCTTTGGCACAAAGCTCTTCTCTATGCTA^ TCTCTTCTAATTTCAAAACTACC_ACAAAAATACGATTAAAATATACACGAAGTAATCΛAAA ^ 34 ATGCTCAAAGTTTCAGCAGCAACCAGTAAAACGACGATCΛACIAAGAGAAA^ ΓTGTGTΛCATAGTCAAATGΓTAAATTAAACACΛAAAACATATTCAAAGTACATATAAATACA_^ 5074 TTMTGMGAAACCTATGCTTAAAAGATTCAATCTCTCATTCGCATCTTAGAAAACCMCCGAAAAA ΛAAAAAAAATCAACAAACAAAAATTATGATATATTATCTAAAAGTAAAGTATACATTTACATT 5214 AACAAAAGAGAAAACTTGCGGTAGCAACAAAAC ATTATATTAATCACATTTCAATC ATGATCATTAATTATTATGAT AATTAATTACGATCTTTATGCTTAGACAAACCAACAAAAA^ 5354 GCAAAAAO:AJI 2_&_y^AAAAAAACAAAAAACA^ putative polya enyla ion signal for long t ranscripts CGACGCGTCTCGAGTGAACCTCCTCAGTTGG _ACACAAAAAC_AAA^ TC - . 41 GGTGOGGGGAGTA__GAO -GGGATGCGGGTAATOGGGaGCACCC OGrAG^ .AGCGA__t-CGAAGCAACACAACACCAACA GAGSCCr^^ i it* mRNA sta rt s te TCCAGAGCAAGAAAAOCCCGCGAAAAACCAAGCAAAAAA AATACA^ AGAGC_AGAGTCAACAGCAACAAAT TTCAATAGCAAATCATATCC^ + 211 TGAGΛTCAAAGTGAAGTCTGCAA_^TCCTCATTAGCAAATCGTAGAGCA^ 284 GTCTCATTTCGAAGCCAAAAAGCAAAATCTCTAATTCAAAT ATG GTT TCT GCA ATG CAA MET Val Cys Ai a MET Z_. r. 3C2 GAG GTT GCT GCT GTG CAG CAT CAG CAG CAG CAA CAG CAA CTC CAG TTG CCC CAG Giu Val Ala Aia Vai Gin His Gin Gin Gin Gin Gin Gin Leu Gin Leu Pro Gin 24 CAG CAA CAG CAG CAG CAG CAG ACA ACA CAG CAG CAA CAT GCA ACA ACG ATA GTG Gin Gin Gin Gin Gin Gin Gin Thr Thr Gin Gin Gin His Ala Thr Thr lie Vai CTC CTG ACG GGC AAT GGC GGC GGT AAT CTG CAC ATT GTC GCC ACA CCG CAA CAG Leu Leu Thr Giy Asn Gly Gly Giy Asn Leu His lie Val Ala Thr Pro Gin Gi-n His Gin Pro MET His Gin Leu His His Gin His Gin His Gin his Gin His Gl . 78 CAG CAG GCC AAG AGC CAA CAG CTG AAG CAA CAA CAC TCG GCG CTG GTC AAG TTG Gin Gin Ala Lys Ser Gin Gin Leu Lys Gin Gin His Ser Aia Leu Vai Lys Leu 572 CTC GAG TCG GCG CCC ATC AAG CAG CAA CAG CAG ACG CCC AAG CAA ATT GTT TAC Leu Giu Ser Aia P ro l ie Lys Gin Gin Gin Gin Thr Pro Lys Gin lie Vai Ty r CTC CAG CAG CAG CAG CAG CAA CCG CAA CCC AAA AGA CTG AAA AAC GAA GCA GCΛ Leu Gin Gin Gin Gin Gin G in P ro Gin Arg Lys Arg Leu Lys Asn Giu Aia Ai d 132 ATC GTA CAA CAG CAA CAA CAA ACA CCT GCA ACA CTA GTA AAG ACA ACA ACC ACC lie Val Gin Gin Gin Gin Gin Thr Pro Ala Thr Leu Val Lys Thr Thr thr Th AGC AAC AGC AAC ACC AAC AAC ACC CAG ACA ACA AAT AGT ATT AGT CAG CAG CA Ser Asn Ser Asn Ser Aan Aan Thr Gin Thr Thr Aan Ser I_.e Ser Gin Gin Gi AGC AAC AGC AAC AGC AAC AAC ACC CAG ACA ACA AAT AGT ATT AGT CAG CAG CAA Sβr Asn ≤βr Asn Ser Asn Asn Thr Gin Thr Thr Aan Ser lie Ser Gin Gin Gin CAG CAG CAT CAG ATT GTC TTC CAG CAC CΛG CAG CCA GCC GCG GCA GCA ACA CCA Gin Gin His Gin lie Val Leu Gin His Gin Gin ? o Aia Aia Aia Ala Thr Pro 186 842 AAG CCA TGT GCC GAT CTC AGC GCC AAA AAT GAC AOC GAG TCG GGC ATC GAC GAG Lys Pro Cys Ala Asp Leu Ser Ala Lys Asn Asp Ser Giu Ser Giy lie Asp Giu GAC TGC CCC AAC ACC GAT GAG GAT TCC CCC AAT GCC AAC CCG CCG CCC ACA TCG Asp Cys Pro Asn Ser Asp Glu Asp Cys Pro Asn Ala Asn Pro Ala Gly Thr Ser CTC GAG GAC AGC AGC TAC GAG CAG TAT CAG TGC CCC TCG AAG AAG ATA CGC TAT Leu Glu Asp Ser Ser Tyr Glu Gin Tyr Gin Cys Pro Trp Lys Lys lie Arg Tyr 240 GCG CGT GAG CTC CTC AAG CAG CGC GAG TTG GAG CAG CAG CAG ACC ACC CGA GGC Ala Arg Glu Leu Leu Lys Gin Arg Glu Leu Giu Gin Gin Gin Thr Thr Giy Giy AGC AAC GCG CAG CAG CAA GTC GAG GCG AAG CCA GCT GCA ATA CCC ACC AGC AAC Ser Asn Ala Gin Gin Gin Val Glu Ala Lys Pro Ala A a He Pro Thr Ser Asn ATC AAG CAG CTC CAC TCT GAT AGT CCC TTT TCG GCG CAG ACC CAC AAG GAA ATC lie Lys Gin Leu His Cys Asp Ser Pro Phe Ser Ala Gin Thr His Lya Giu He 294 GCC AAT CTC CTC CGC CAA CAG TCC CAG CAA CAA CAG GTT GTG GCC ACG CAG CAG Ala Aan Leu Leu Arg Gin Gin Sβr Gin Gin Gin Gin Vai Val Ala Thr Gin Gin CAG CAG CAA CAG CAG CAG CAG CAC CAG CAC CAG CAA CAA CGA AGG GAT AGC TCC Gin Gin Gin Gin Gin Gin Gin His Gin His Gin Gin Gin Arg Arg Asp Ser Ser GAC AGC AAC TCC TCG CTC ATG AGC AAC TCG ACC AAC TCC AGT CCG CCC AAT TCT Asp Sβr Asn Cys Ser Leu MET Ser Asn Ser Ser Asn Ser Ser Aia Giy Asn Cys 348 TCC ACC TOC AAC GCT CA GAC GAC CAG CAG CTC GAG GAG ATG GAC GAG GCC CAC Cys Thr Cys Asn Ala Giy Asp Asp Gin Gin Leu Giu Glu MET Asp Giu Ala His 1382 GAT TCG GGC TGC CAC GAT GAA CTT TOC GAG CAG CAT CAC CAG CGA CTG GAC TCC Λsp Ser Gly Cys Asp Asp Giu Leu Cys GJ.U Gin His His Gin Arg Leu Asp Ser TCC CAA CTC AAT -"AC CTC TOC CAG AAG TTC GAT GAG AAA CTG GAC ACG GCG CTG Ser Gin Leu Asn Tyr Leu Qvs Gin Lys Phe Asp Giu Lys Leu Asp Thr Aia Leu 402 AGC AAC ACC AGC GCC AAC ACG GGG AGG AAC ACG CCA GCT GTA ACA GCT AAC GAA Ser Asn Ser Ser Aia Asn Thr Giy Arg Asn Thr Pro Aia Val Thr Aia Asn Giu 1544 GAT GCC CAT gtaggtttag Asp Ala Asp 1105 α_-C_AccGCAGGAGϊcGτo_ -CGGAeβTC_α.._cτccτcGAJCQoεcTCCTCCτGcceτcc as en__cλicτa: : a:τ__:cτsaι_: An lau . ro Clu Slu Sar tar Car Slu Val Thr Sar Sar Sar Aan Sly Lau Val lau Pro Sar Sly Val Aan Mat Sar Pro Sar Sar lau Aap mi τ_αc_te_*_τ». ττ__ -*τc_-;cccτ.τ∞cτc__c -α_m Sar Mia Aap Tyr Cya Aap Cln Aap Lau Trp Lau Cya Sar Pha Sly Sly Sar Aan Sly Mia Sly Lau Sar S n Sin S n 1211 CΛG __ -TC ATC A_C CTC GCC ATC CAC GG T_C TCC A_C A_. CTC CCr α_- CΛC _^ Sin Sar Val Ila Thr Lau Ala Mac Mia Gly Cya Sar Sar Thr Lau Pro Ala Cln Thr Thr Ila Ila Pro Ila Aan Sly Aan Ala Aan Sly Aan 1314 GCA OOC TCC ACC AAT GGC CAA TAT CTS CCC OCT CCC ACT AAT CTS OSA OCC TTS OCC AAC OCC ATC CTC MT OSS CGC TTC AAT CCA ATC CAC Sly Cly Sar Thr Aan Sly Sin Tyr Val pro Gly Ala Thr Aan Lau Cly Ala Lau Ala Aan βly Hat Lau Aan Gly Sly Pha Aan Sly Mac Cln 1477 CAACK ATT Cje jUl. GEC_C α-C CTC ATC J_t iα: __ΛA_= C!X TCA Am C_= K Sin Sin Ila Cln Aan Gly Mia Cly Lau Ila Aan Sar Thr Thr Pro Sar Thr Pro Thr Thr Pro Lau Hla Lau Gin Sin Aan Lau Sly Ely Ala 167 G_coαcα-Ccs Aτcα_c_GλλTGGsτλτ errαcc_ccα-Uτααcκs _λM QθccττλτcccACR_τsccAcκGccccc Sly Sly Cly Gly Ila Sly Gly Hac Gly Ila Lau Ila M a Ala Aan Sly Thr Pro Aan Sly Lau Ila Sly Val Val Ely Gly Giy Sly Gly Val 191 lϊcaaqa-' v "«aca«j! 1<(3 OCT CTT OSA CTA CSC OGA GCC Q EAC-C OGA OGC C-S αEA ATGCAC CAC ACA CCC CGA ACC SAT TCC CTS AAT TCT ATA TCT TCA CCT CCC GAT Gly Lau Gly Val Gly Gly Gly Cly Val Gly Cly Lau Gly Mac Gla Mu Thr Pro Ar« Sar Aap Sar Val Aan Sar Ila Sar Sar Cly Arq Aap 229 175S GAT TC TCS CCT TCC A-C >_C TTC AAC OGA TAC TCS OCC AAC SAA ACC TO. CAT DCS AAC AAC AC AAS AACαGλCCT CCS CCACGG CTGCAΛ Aap Lau Sar Pro Smt Sar Sar Lau Aan Cly Tyr Sar Ala Aaa Glu tar Cya Aap Ala Lya Lya tor Lya Lya Sly Pro Ala Pro An Val Eln 2(0 1141 GKCACCTC TGCCTS -Tr raC 0OCCAC A_C0O_ TCCα0C TA C_C TA AK: QX CTC __c nT CλS OOC TGC AAGGGG TTC TTT CGACSC ACC Clu Slu Lau <-.. i... v.l r.. cl. a__ _r_ _]. _.. r.l » τ»r m. ..- _.„ _ι. ι.„ τ_r _»« cl,. civ r». i.v. civ __. _.__. ι» am cr 291 1142 CTT AS AAG AOC Cα- CT TAC OC T Q C AAC TTC OSS COC OCC TGC GAA ATSCA TC TA ATC ACC CGA AAS TST CAS GAC TCC CCC CTCAAA V.l Thr I... Cr 11. V.l Tvr Cv. Cv. v. Mi. Civ In II. C». β\„ _.r »_.. _.r T.r MT In »n 1... _v. Cln _1„ r«. 1m !_.., I.. 2035 AΛS TOC CTSCCC CTS αCT λTS CαS COS GAA TGC GTC CTC CCG SAC AJC CAA TCT GC_. ATG λAS CGG CαCCAA AAG AAG Gα_ ClG AAG <_S λ_G ... r-v. __.„ -I. v.l cl. _-. Aro Pro Clu Cya Val Val Pro Clu Aan Gin Cya Ala Hac Lya Arq Aπj Slu Lya Lya A_a Sin Lya Glu Lys 2121 CAC AAA ATG ACC ACT TCG CCS J_ETCT CAC Ol GOC GCC _AT CGC A_C TTS OCC TCT α_T αGC G_C CAA GAC Tr- -T. AAG _AG GAG Ar. CT- Aap Lya Mac Thr Thr Sar Pro Sar Sar Gin Mia Gly Gly Aan Gly Sar Lau Ala Sar Cly Sly Gly Sin Aap Pba Vai Lya Lya Slu lit Lau 3i< Iβtaow * *v* 'vcaaa?) 2221 GAC CTT ATS ACA TGC GAC CCC CCC CAC CAT OCC ACT ATT CCC CTA CTA CCT GAT GAA ATA TTC OCC AAC TOT CAA GCC CSC AAT ATA CCT TC Aap Lau Mac Thr Cya Glu Pro Pro Gin Mia Ala Thr Ila Pro Lau Lau Pro Aap Glu Ila Lau Ala Lya Cya Gin Ala Arq Aan Ila Pro __. 415 l9-99-e--v--" i) c_-! 2314 TTA ACC TAC AAT CAC TTC GCC CTT ATA TAC AAC TTA ATT TGC TAC CAC GAT OOC TAT GAC CAG CCA TCT GAA GAC GAT CTC ACC CGT ATA ATC Lau Thr Tyr Aan Gin Lau Ala Val Ila Tyr Lya Lau Ila Trp Tyr _ι. _— «.ι y vr r. , cl. »n .-- cl.. cl.. a.-, ι... in in τι. _-- 446 2407 J_rr CA*α CAT C_G _AC C_« _-C αU- -X CAC CTC A_C -Tr α_- CAT A- A_C C_G ATA A^ Cr r.l. »-_ In Bl.. _._ Bt., Cr Cln Thr In V.l Cr »_. A,, _,. Tl. Thr Cl., Tl. Thr Tl. I.„ Thr U.I Cl„ I-, Tl. V.l Cl„ Ph. 477 2500 OCT __Jlβ_T CT CCλαCS T7_r _U _AG ATACCCUS GAC C_C C_S ATC «S T CTAAAC OCC TOC TCG Tθ: G_C STS ATC ATC al. l... Bl. !_.. »n ar. -_. Thr I... Tl. »n r.l. Cl.. a— cl. τι. Thr ι_». l._ ι._. al. f.. cr cr Clu v.l ___.. ___.. ι.„ n a.. 501 251X OCA CCA CGC TAT GAC CAC ACC TCG SAC TCA ATA TTC TTC OCS AAT AAT AGA TCA TAT ACS COC CAT TCT TAC AAA ATG OCC CGA ATG OCT GAT .1. In __, T.r In UI. Cr Cr Cr Tl. -_. »_. »1. ... ....— Cr Tvr Thr ._. In Cr T.r I... .r tl. Cl. «.r Al. .r, 539 2tl( AA ATT GMGAC CTG CTS CλT TTC TCC CαC CUlATC TTC TCC ATe ΛS C-GGAC AAC CTC CAA TA GCS eTT CTC MrT Q^ _._ Tl. Clu __-, 1__ I... UI. H_ C» __i Cl. _- _- l.f _. 1... U.I m a.. V.l Bl,. T...1. I... !_■_ Thr .1. Tl. V.l Tl. »h. 570 2779 TCO GAC COG CCO OCC CTO GAG AAC OCC CAA CTA CTC GAA CCC ATC CAS AOC TAC TAC ATC GAC ACC CTA COC ATT TAT ATA CTC AAC CGC CAC Cr an In Brr, cl. I... Bin I.v. Al. Sin l.„ V.l Clu Al. Tl. Cl. Cr Tvr Tvr Tl. In Thr ■ ._ In Tl. T r -;. l.„ l.r In Hi. (01 2172 TαC CαrGAC TCλATC CC CTCCTC TT TAC αCAAACCTC C-CTCC λT TC MZ SλG CTS αn ACS CTC αOC AK r». Bl.1__ Cr __r Cr !_-■ V.l Ph. T.r .1. I.v. I.„ I... Cr Tl. !_-, Thr Blu T.„ In Thr l._ SI. l-h Cl„ l.n Al. Cln Mr. .v. 632 11 ( 5 TTC TCA CTAAAS CTC AAA AKr COC AAACTG CCC AAC rrC CTC GAGCAG AT GS GIIC CTT CAT GC ATC CCS CCA TCC STCC ah. cr I... i.. i... ι.v. ... in I... l__, Pm I.v. »h- <__-_, Bl.. cl.. τι. π t^. Val _u Ala _i« Pro Pro Sar Val Sin Sar Hia lau ((3 305i CAC TτA_cαeEACCcλλcc>cccτcτcc__;coso_ταιcccτ TGcαcαcλτcG_τταoGαococcλττ__cαx Sin Ila Thr Gin Clu Glu Aan Glu Ana Lau Glu AT. Ala Clu n Mac Arq Ala Sar Val Sly Gly Ala Ila Thr Ala Giy I.. Aap Cya Aap 69< 3151 TCT GCC TCC ACT TCS GCC CCC OCA OCC OCC GCC CAC CAT CAC CCT CAC CCT CAC CCC CAG CCC CAA CCC TCC TCC CTC ACC CAC AAC GAT TCC Sar Ala Sar Thr Sar Ala Ala ia Ala Ala Ala Gin Mia Gin Pro Sin Pro Gin Pro Sin Pro Gin Pro Sar Sar Lau Thr Gin Aan Aap Sar 72S 3244 CAG CAC CAS ACλCAC Cα- CJC πλCAΛ CR CAC RACCλCCT CAGCTC CMGGT CλλeTG Gin Mia Sin Thr Eln Pro Sin Lau Sin Pro Eln Lau Pro Pro Gin Lau Gin Sly Sin Law Gin Pro Sin Lau Gin Pro Sin Lau Sin Thr Eln 756 3337 CTC CAC CCA CAC ATt CAA CCA CAC CCA CAC CTC CTT CCC GTC TCC OCT CCC CTC CCC OCC TCC GT CC OCACCT GOT TCC TTC TCC CCG CTC Lau Gin Pro Cln Ila Gin Pro Gin Pro Gin Lau Lau Pro Val Sar Ala Pro Val Pro Ala Sar Val Thr Ala Pro Gly Sar Lau Sar Ala Val 717 3430 __T __S __C >_CG_λTA ATC SCC GCA___r GCS QCC ATA Q -*CCC ATC _α:α_o α_A AK A_ε >_C __rt λTC I_S G^ Sar Thr tar Sar Clu Tyr Mac Gly Cly Sar Ala Ala Ila Cly Pro llm Thr Pro Ala Thr Thr Sar Sar Ila Thr Ala Ala Val Thr Ala Sar 111 3523 TCC ACC ACA TCA GCG CTA CCS ATS OOC AAC OGA GTT OGA GTC CCT CTT OOG CTC OOC OOC AAC CTC AOC ATG TAT G_S AAC OCC CAS ACS GCG Sar Thr Thr Sar Ala Val Pro Mac Sly Aan Gly Val Gly Val Cly Val Cly Val Gly Cly Aan Val Sar Hat Tyr Ala Aan Ala Gin Thr Ala 149 3 ( 1 ( ATS OX TTS ATG OCT CTA OCC CTC CAT TCG CAC CAA GAC CAC CTT ATC COS CCA CTS OCG GTT AAC TCSGKi CAC TCG KG ACT OCA TAG CAG Hat Ala lau Hat Cly Val Ala Lau Ila tar Mia Gin slu Cln Lau Ila Gly Cly Val Ala Val Lya Sar Glu Mia Sar Thr Thr Ala - 171 ϊ - 2407 ACT CMCα. GΛT GA β AK GAG J_X CM λC__ GI__ GIC ._X m αS CλT ATA AC_ tor Cln Pro Aan Clu ton Clu tor Cln Thr taw V.l _ar Ph. try Mia Tl. Thr Bin Tl_. Thr Tl. !__.. Thr Val Cln tail. TU Val Glu Pha 477 (gtgagt-'v'-ogttag. ■ 2500 OCT AAA OST CTA CCA OOG TTT ACA AAG ATA OOC CAB CAG GAC CAB ATC ACC TTA CTA AAS GOC TOC TOB TCG G*G GTC ATG ATG CTG CCT ATG Ala LOT Glu Uu Pro Al. Pha. Thr LOT Tla. »m Ala. Bl.. _r, Bl, Tl. Thr !__.. Tan. t.y. Ala COT tor tor Clu Val Hat Hat Uu Arn Hat 501 2593 OCA CGA COC TAT CAC CAC AOC TCG CAC TCA ATA TTC TTC OOG AAT AAT AGA TCA TAT ACG COG GAT TCT TAC AAA ATG OOC OGA ATG OCT GAT All Am Am Tvr Aan Hla tor tor Aan tor II. Pha. Pha Ala ton _..n fcm __.. Tyr Thr *m __m tor Tvr LOT Hat Al. Civ Hat Ala Aan 539 2 ( l ( AAC AT GM GAC CC CTG OlT m ταC CGC ( _AA ΛTC TTC TCG ATG AAG GTG GAC AK Aan Ila Glu Aan u Uu Bl. Ph. Cv Am Bin Ma. Pha tor Mai- !__. Val lar, Han V.l r.l.. Tvr Al. T.u Uu Thr Al. Tla Val Tie Pha 570 2779 TCG GAC COB CCG GOC CTC GAS AAG OCC CAA CTA CTC CAA OCC ATC CAC AOC TAC TAC ATC GAC ACG CTA COC ATT TAT ATA CTC AAC COC CAC Sar Aan Am Pm Glv Uu Clu l.va Al. Cln 1... Val Clu Ml. Tl. Cln tar Tvr Tvr Tl. frap Thr I_». Arn II. Tvr Ila Uu Aan Am Hla (01 2172 TOC OBCCK T ( _λ ATG AαC C_C GTC TTC TfCOCA AAGCTC(rTC TC6 λTC(πC λOC G»C^ fva Glv ian tor Hat tor Uu Val Pha Tvr Ala t.v. I__u lam «.r Tl. Uu Thr Clu Uu Am Thr Uu Civ Aan Gin Aan Ala Glu Met Cvi (32 29 ( 5 TTC TCACTA AAG CTC AM AAC COC AAA CTG ( X£ AAG TTO CTC G-_3 G«G ATC TOG GK Gn Pha tor Uu l.va Uu Lva Aan Am Lva Uu P I.v. Ph. I__u cι f . Bl.. Tl. Tr^ aap v.l Hla Ala Ila Pro Pro tor Val Gin tor Hla Uu ((3 3051 CAG ATT AC CK GAG G-_3 AAC G___ CCT CTC G-__ C-Xi 0CT CAG CCT ATGO9S a» Gin Ila Thr Gin Glu Glu Aan Clu λig Lau Glu Arg Ala Glu Arg Hat Arg Ala tor Val Gly Gly Ala lie Thr Ala Gly Ila Aap Cya Aap (94 3151 TCT Q 0C TCC -fT T∞GCG GCG Q α. O0C O0G OCE C._3 CAT CλS CCT CAS C>rr α tor Ala tor Thr tor Ala Ala Ala Ala Ala Ala Gin Hla Gin Pro Gin Pro Gin Pro Gin Pro Gin Pro tor tor Uu Thr Gin Aan Aap tor 725 3244 CAG CAC CAO ACA CAS OCC CAG CTA CAA OCT CAB CTA CCA CCT CAC CTG CAA OGT CAA CTG CAA CCC CAG CTC CAA CCA CAG CTT CAG ACG CAA Gin Hla Gin Thr Cln Pro Gin Uu Gin Pro G n Uu Pro Pro Gin Lau Gin Gly Gin Uu Cln Pro Cln Uu Cln Pro Gin Uu Gin Thr Gin 75( 3337 CTC CAG OCA CAG ATT CAA CCA CAG CCA CAG CTC CTT CCC GTC TCC OCT CCC GTG CCC OCC TCC GTA AOC GCA CCT OGT "JCC TTG TCC GCG GTC Uu Cln Pro Gin Ila Gin Pro Gin Pro Gin Uu Uu Pro Val tor Ala Pro Val Pro Ala tor Val Thr Ala Pro Gly tor Uu tor Ala Val 7(7 3430 ACT -__G __C ._-C GAA TAC ATC<_GC GGA -_π θ∞ OCr ATAOGAαX ATC A∞ tor Thr tor tor Glu Tyr Hat Gly Gly tor Ala Ala Ila Gly Pro Ila Thr Pro Ala Thr Thr tor tor Ila Thr Ala Ala Val Thr Ala tor 111 3523 TCC MX ra TCA Q ∞ CTA αX ATC Grc AK GGΛ Gπ GGAGTC GCT GTI GOG CTG GGC ∞ Sar Thr Thr tor Ala Val Pro Hat Gly Aan Gly Val Gly Val Gly Val Gly Val Gly Gly Aan Val tor Hat Tyr Ala Aan Ala Gin Thr Ala 149 3(1( ATG GCC TTG ΛTG GCT CTA OCC CTG CAT TCG C-£ CAA GK (_λG m ATC GQS OGA GTG OCG CT Hat Ala Lau Hat Gly Val Ala Lau Hla tor Hla Gin Glu G n Uu Ila Cly Cly Val Ala Val Lya tor Glu Hla tor Thr Thr Ala - 171 3709 θαaCAGAGTCIIOCTα__tX-AAαiTC-_X*-X_C^ 3133 OTAMTACTMU__ira_AATJUCTMTQGACAA^ 3957 CTI-_B-CrπAATTβAAAAAQCrπc_α__AACAATT^ 4011 TGTATGTCOCATCΛGACTCCCATCAATTCTCGAATTTTtm^ 4205 »«»«»»T»»"-T«"W»T-T »""aT»«"""»»»»»» ^a»^^ 4329 MTCTCTTAAA1CJUUCJUUU_iTMTCATAATJUiα_m^ 4453 TTTTni_ATCATMAG»l>l>COC_JKgTCAAAAAAATATTIgAAIUU_:_JαTAACAACATATTπAW 4577 CATCOUUUttTAnA<-0CA0CAAAAACCTTTATTATT0QCATTCTTTnACaiCAT8TTTTC 4701 TC-JUUUBX-UUUM-reATCAAAAOCTAWAAAmAWTAT.^ 125 TACATOCATACA<rAAAAnil_rTTCAATATATATTTTTAAAATnACATTCATAATTCCAAATT^^ 4949 λλAosτ _ι__λnτsτnj_-τrnc__MττπτλτcπλTACAλλλτn 507 AATTTTI__TnAAATTCTTOOCCTtATTTTAACTTAAATCAAATnATTCTAATTW-CT cDM__ DBR3-9 4.2 kb 1 GAATTCATTCAAα_XAAAGAGC_ XCI_ttTTθagATAα^^ 125 TTGCJUCTATT1CACCMTCJUtCX_CC-__α»C^^ ATG TAT ACG CAA CGT MT Tye Thr G n Arq 242 ATG m GAC A?G TGG A_C ._X GTC ___7 .CG AAA CTG GAA 0CA CAC βCΛ AAC AΛT Cr_C QCT C_U HCT Pha Aap MT Tip tar Sar Val Thr Sar Lya Lau Clu Ala Hla Ala Aan Aan Uu Cly Cln Sar Aan Val Cln Sar Pro Ala Gly Gin Aan 3( (gtaaag--y'-teacag) 335 AAC TCC AOC OCT TCC ATT AAA OCT CAA ATT GAS ATA ATT CCA TOC AAA CTC TOC OOC GAC AAC TCA TCC OOC CTG CAT TAC GGA GTG ATC AOC Aan Sar Sar Cly Sar Ila Lya Ala Gn Ila Glu Ila Ila Pro Cv. l.w. V.l Cv. Blv ____ l.va __.. __τ Cl, v.l 11. Tvr Civ V.l Ila Thr (7 421 TOC ( __G OOC TOC -dβ OGA TTC TTT O_A AGλ Tσ: CAA MX: TCC βTβ GIC AAC TK: CAβ TCT C^ Cva Glu Civ Cva Lva Civ Pha Pha Am Am Sar Gla Sar Sar V.l V.l __._. Tvr Bla C . Pan Am A.n T_ψa Cln Cv. V.l V.l Am Am V.l 91 (Otc t- - v --tt«ca_ι. 521 AAT COC AAC OGA TGT CAA TAT TGT ABA CIC CAA AAG TOC CTA AAA CTC OSA ATC ADC CCT CAT CCT CTA AAG TTCβOC AOβ ATG TCC AAG λAS Aan Am In Am Bva Cln Tvr Cv. Am u Cln T.ya Cv. laau a laau Blv MM S r Arq Aap Ala Val Lya Pha Cly Arg MET Sar Lya Lya 129 (14 CAG CGC GAG AAG CIC CλG CAC GAC GTA CGC TTC CAT COG OOC CAG ATG CCS OCA CAA ABC CAC OCS OCA CCC GAT AOC TCC CTA TAC CK ACA G n Ax? Glu Lya Val Glu Aap Glu Val Arg Pha Bla Arg Ala Gin MCT Arg Ala Gin Sar Aap Ala Ala Pro Aap Sar Sar Val Tyr Aap Thr 1(0 (gtgcag- ' W ' -actcag) 707 CλG λC αX: TCG f_X AOC CK (__C CTG CM CK AAC AAT T-C AλC λOC T-C λOC OOC OK Gin Thr Pro Sar Sar Sar Aap Gin Lau Bla Bla Aan Aan Tyr Aan Sar Tyr Sar Gly Gly Tyr Sar Aan Aan Glu Val Gly Tyr Gly Sar Pro 191 100 TAC GGA TAC TCG OCC TCC GTC ACG CCA CAG CAG ACC ATG CAS TAC GAC ATC TCG GCG CMC TAC GTG CAC HOC ACC AOC TAC CAG CCG COC AGT Tyr Gly Tyr Sar Ala Sar Val Thr Pro Gin Gin Thr Htt Gin Tyr Aap Ila Sar Ala Aap Tyr Val Aap Sβr Thr Thr Tyr Glu Pro Arg Sar 222 |gtaaag-- v - ctecag) (Cl 193 ACA ATA ATC CAT OCC GAA TTT ATT AGT CAC COG CAT OOC GAT ATA AAC CAT GTG CTG ATC AAG ACG CTC OCC GAG OCC CAT OCC AAC ACA AAT Thr Ila Ila Aap Pro Glu Pha Ila Sar Hla Ala Aap Gly Aap Ila Aan Aap Val Uu Ila Lya Thr Uu Ala Glu Ala Hla Ala Aan Thr Aan 253 <gtgagf v "«t«αag) <G| 9I( __X AAA CTG CAλOCT GTG (-K CA ATC TTC (Sλ AλG CJIβCOβ CλT β_G TCA C An CtC TK Thr IiVI lau Clu Ali Val H.I im HIT P a Am t.va Bin Pm A_τ. Val t.. In, !l. lam Tvr Tyr Lya t r, la... Bl Bin Bl.. Blu la»u Tm 214 <cι 1079 CTG CAC TOC OCT CAB AAG CTT ACA CAA ATC ATA CAS AAC ATA ATC CAA TTT GCT AAB CTC ATA COG GGA TTC ATG CSC CTG AST CAG GAC GAT Uu AMI Cva Ala Clu Lva Uu Thr Cln HIT Ila Cln Aan Tla Ila Clu Pha. Ala l.ya lam Tl. Pm Blv Ph. HUT Am lau. —r Bin Am Aan 315 (C| 12(5 GAC GTG ATG CTG CXC CK GAG GCG TC TK ACA TCC GAC TCG GAA GAG ATG CGT CTG CTG TCG CGC ATC m Am V.l MT Uu Pm Cln Glu Ala Pha Tvr Thr Sar Am Sar Clu Blu MET Am laau V.l far Am Tla Pha Bla. Thr Al. l.va t.r Tla Al. 377 (gtgαg-- v --octtag| 13SI Gλλ C_C AMCTG _-T GAλ ACC GAA CTG GCC CTG TAT CAG AOC TTλ GTG CTG CIC T∞ OCA (_M Blu Uu l.va Uu Thr Clu Thr Glu Uu Al. Uu Tvr Gin Sar lam V.l Uu la... Tm Pm Gin Arς. Aaa Blv Val Am Blv Aan Thr Glu II. 401 1451 CAG AGG CTT TTC AAT CTG ABC ATC AAT CCG ATC COG CAC CAB CTG CAA ACG AAT CAT OOC CCG CTC AAS OOC CAT CTC ACC CTG CTG GAC ACA filn Arn I_ru Pha Asn Uu Sar HCT Jan A Ila Ara Cln Clu lau Clu hr __■» HI. Aia m ι_... ι. y . cι y ^_p v.i Th v.l la. A Thr 43 (gtaegf v --_tccag) 1544 CTC CTG AAC AAT ATA OOC AAT TTC COC GAT ATT TOC ATC TTG CAC ATG GAA TCC CTG AOC AAC TTC AAG CTG CAG CAC CCG AAT GTC GTT TTT Uu Uu Aan Aan Ila Pro Aan Pha Am Am Ila Sar Ila Uu Hla MET Glu Sar Uu Sar Lv« Pha I.v. Uu Bin HI. P Aan V.l V.l Ph.. 470 1(37 CCG OCC CTC TAC AAG GAG CTC TTC TCG ATA GAT TCG CAG CAG GAC CTC ACA TAλ CAA__r__CAC_-JW-Cα__TCC_OGACaαA_rθ^^ P Al. lam Tyr Lya Clu Uu Pha Sar Ila Aap Sar Gin Gin Aap Uu Thr - 417 1742 GCO(XrK-0CG ∞ re_ TU.-_Mjα--^ 11(( GCλTGCAX_A_aτ-__M__AACTmTCATCλTTTAACCT-^ 1990 A__30GATC_ggAAAO0GAACOSAAAATATTTCAAAAATATTCTTAACTCA_rnAAGACIIIT0CII^ D h 1. h h h h H R v O B E E G M R A D U R R R R R 3 R R P R R 1 2 D1_R3 51 CIWCGDKSSGVHTGVITCBGCKG_TIUlSQSSVV--HYQCPRhnQCVVDRVMI mCQTCr-a^^CI_KU-H KcR 264 CLVCGDFUSGYHYNI_LTC3CaCGFr!UttVTKSA~-VYCCOTG_ttra K75A 245 CRVCGD__ASGFHYOVHSCBGCKGrrRRSIQOTI-QYRPCTlMQQCSII_RIl»^ kni 5 CKVCCBFAΛGr_trC-_rTC3_G<__-SnrGRSYNNIS-^^ hRARα 58 Cr_TTCQDKSSGΪ_reC-VSAClGCKG_TIUWIQK-m--Vr_C_ hTRβ 102 CVVCGDIUaTGTBTRCITαCGC3CGrnwτiQ-«_J-_.S¥SC-irnGK .IDKV^ hVDR 24 CGVCGDRλTCr_niJMTα-GCKC__TIUttMiαUUt--:_^^ CODP-TF <_vvcβDκsscac_iYβojτcBβα_sιτ_αuvRR-π,--τγτc--U_^ hJtRRl 175 CLVCCDVASCY_reGVλS(_KAιC_K__f iαiTIQGSI--KYSCTASNB^ hBRR2 103 CLV GDIJlSGϊHΪGVASC-IA KAI - .TIQ(-MI--KϊSCPA_Tffi<_«IlTCR_UυCSCQA hIR 185 CAVCNDYASCXHYGVHSC3GClUOTiaUIQGM--DirMCPATMQCTXD_Q^^ hGR 421 CLVCSDXlSGCI_YGVLTCC8ClCVriαUVBGQH--NnX-AGM bHR 603 CLVCCDBJ_SGCHYGVVTCGSαCVrriα«VBGQH--HY_X:^^ hPR 567 CLICCD_ASGC_n_GVLTCCSC-_r_TiαiA__BCQH--NY_£.^ E1 DHR3 255 ια_*AV_roHr_WQPDV__ iLϊYiαπΛQULrrωcM! τ^ B EcR 431 QDGΪBQPSIBDI_f _MSQPDB«SQTDVSITU-ITBITILTVQ IV__fAKC__PATTK__.QlDQIT__t_^ B75A 380 QRARDCMϊSMPT__LACPI__TJ-PEiX}SlQW--SQRr__βVra hRARα 170 F__£QLCI_YTΪinUSBQRVB__3__D.--1IDKr--SB_ hT_ 238 PKri_PBOIGQAPZVN__PBGG-irVD___J-rSBr--TXIITPAITRVVDrAXlCt_.MrCB__PCX hVDR 198 DSSSrM_0I_SMDSDDPSVTI__ISQl_9K__?___ADLVSY cOOP-TT CYI3I__XUCFro TSRYGS{ H_F>ni__ClBHICBIUUU^ IRITQ hXRRl 294 LVS___AV-VEPB_LΪAHPDPAGPM__LXAVAT_ D__rD-«l^ - ATABDLVLDEBCARA- AGLGBL- - CAALL hIRR2 211 CTS YI_LV-ABPDi T__H_>PDDVPB6DπU-LTΪ_-CD___A^ -UYABDYXMDBBHSR -VGLLBL YRAXL h__R 315 MVSA__tΛ-A__PPI Y8BTDPTRPrSE_SH_«_ATN__ADRB V_^ hGR 531 T_-VSI___mBFBVLYAOYDSSVVDSTim_-hπTI_-lH_-3CRQVI^ MLTVS hMR 737 SPVHV__«NIEPErVTAGYD3SKPDT_-t-r__t__TI_NR__ACT^ MHQIS hPR 686 P lT.___«SI__PDVIYAG_©NT PDTSSSI_LTSIJIQ_XΛRQI_ SVVKir_fKSI* MHQIP E2 E3 OBR3 380 KL- ---ZBTB__λ YαS V_-L«B-RMGVRCMTBIQRI_PNI_SMH-_IRQ Bi_rnr __pucGDvτvι_DX____ι._niF_ωιs^ WFPA YKB BcR 557 -— DHVBYA__LTAIV-l_rSD-RPGL__IAQLVΪAIQSYYIDTI_RI - YILHR- - -BCCDSMS VTYAiα___ILTBIJlT_»QH-CH-rS_JCL N_tK LPKTLBB B75A 503 NL- ---TDMIG_rC_AIVLXTPD-_U.CUlN__CL_«MXS_U_BC Q -YIVAQ NR_>DQPBri_Aiα_l_ TMPDIJRTl_STI__tTBK_- WFRTBHKB hRAR 292 DDABTG____SAICLICCD-RQD__CQPDRVD__LQ__P__t_UUJV -Y-VRK _UtPSRPtlMπiα_U-KITOI_RSISλXGλ__RVXT__-______?CSM PF XQEM hTR0 361 DDTBV-_t_M^VI_____3SD-RPG_JUnriRI___rrQDSr_-_JUrBH -YIHYR K_-_rVTH_T»Piα_I_MKVTD__ftrøGAC__A_JRir____MIVBCP hVDR 325 H BBB_rV__ CAICIVSPD-RPCVQDλλ ] _IBAIQDR SNTLQT -YIRCRHPPPCS_t__LYAXMXQK__λ OLRSUrDDHSKgYRC SrQ-PBC-SMi TP VLBV cOUP-TF VElUJCAI__rVDSABYSC__rUlIV__rTSD--_ GLSDAAH__S_3KI_SQCA_ t-l YVRSQ-YPNQPSIVC_α_U_RXP_1__RZVSSSV__ Q__rπ_-_LVCKTPIB-T I-ωMU hBRRl 410 VRR QJ_Ut__BR__BYV__f_- U_A λMSD SVHIB-DBPRLWSSCB-KI.TJHBAtJJ YB- AGRACTGGCA__RRR__-nU__XTI_P_XRQTA__KV____arYCViα_CK^ -K-JT BMLBA hBRR2 328 VRRYK-__J_VEK__KITrMI__-___A_J_rISD SMYIKNI_CAVQK_Λ)---D__l__«AL-DYI- ωQRHE-_ΪPRR__3-__XLTI-. LIΛQTJLAKAVQ^ hBR 437 MM-O GBBrVCIXSII LMSG — VYTFLSSTLKSLS _Uα>HXmV_-DKXTDTLIHI_κnKACLTI<QQQHQ_ ^ hCR 653 LHR__Q VSYBBYlC-βW lJXASVPKDGL KSQB__rDBXMITYXn_-5X----_IV_fU_G-IS_O-mQ^ YCFflTf __D-KTM3B_TPBHLABI hMR 859 rVRIQ TRBYTl-HKVU LSTIPKOCL KSQλλπ__--RniYXiα_UlK---MVTKC_PNMSCQSlfQRrYQ-L^^ r<_rXϊnU_StAI_KVBrPAM.VBX hPR 808 FVKLQ- - - VSQ__B»LC__KVIJ____JITIP__eGL RSQTQTBBMRSSYIRBLIK AIC RQKGWSSSQRT YQ- TKI_t_ONL-TDLVKQ LH YC_NTFIQSRA__SVBFPB-M_ KV DHR3 51 CKVCGDKSSGVHYGVITCTGCKGFITtRSQSSW--NYQCPRNKQCVVD^ EcR 264 CLVCGDRASGYHYNJU.TC_EGC1OTF1UISVTKSA^ E75A 245 OAVCCDlU_SGFHYGVHSCEGC3CGrπrø kni 5 C VCCUJUOTIl GirTCXGCKSTrGRSlrø hIRR2 103 CLVCGDIASGιΕYGVlSClλClU_πi(RSIrølI--lY^ hBR 185 OLVClTOY_ttGTOYGWlfSCIGCXl_^^ hGR 421 CLVCSD£ISGCOTGVLTCGSOCVFIiαULVlGrø--« hMl 603 CLVCGDl__SGCHYSVVTCβSCKVITIlUU»^^ hPR 567 C ICGD»a^GCHYGV TCGS<___π>TrKIU_M__GQH--NYLC^^ E1 hRARα 170 P_-___CQI/__KYTTNNSSI<»VSI_DID --iroOT^ hTRβ 238 FKri_FXDXGQ_tøIVNJ PBGG-KVDI __irSHF--TKIIΪPΗ hVDR 198 DSSSFSNI_DI_SEBDSDDPSVTIΛI_SQ SM_-P_πJtoLVS^ cOUP -TF GYISI_I_LRJU P YPTSRYGSQαrøMNlllSISNICRLAJkRLI^ hBRRl 294 LVSiπ_LV-VΪPBiα.Y_U-PDP_bGPDGHI_PAVXTIΛ_DI_FDra hBRR2 211 :πraYl_LV-_UlPDiα-YJ l_FPDDTOICD:__lU LITI£DI^ hER 315 MVS_U_LD-A»PPILYSKYDPTRPrSBJ_S_»βI_LTNI^ hGR 531 TLVSI_I_EVI*PIVLYJ 3YDSSTODSTlfRIMTTI_N*-I-GGRQro hMR 737 SPVMVl_ENI»PIIVY_ι_3YDSSlΦDTAlHI_I^TI_NRIAGKQMIQVViα^^ hPR 686 PLIl.I_I_MS:__EPDVTYAGHDNT_rcDTSSSI_LTSI_NQ GK^^ E2 -IJ>LSQNAVLYGDVMLPQBAFYTS--DSBBMRLVSRIFQTAKSXABL KL TETB ALYQSLVLLHPB-RNGVRGΗTEIQ -YDHSSDSIFFANNRSYTTOSYKM-AGMADNIBDLIIHFCRQMFSMKV DNVBYALLTAXV-IFSD-RPGLEKAQ VE -FDSSINSIICI_N-GQVMRRDJU:Q-MGANARFLVDSTFNFABRMNSM N TDJIBIGIJCJ ΓVLITPD-RPG RNLELIE -YTPBQDTMTFSDGLTI_NRTQI-L_N.-A___FGPLTDLWAFANQI_I_PI_BM DDABTGLLSAICLICGD-RQDLEQPDRVD -YDPBSBTLTIANGBLAVIRGQUQI-GG GVVSDJLIFDLGMSLSSFNL DDTBVAI_I^VI_I_MSSD-RPGI_ACVERIE -FTIDDMSINCGNQDYKYRVSDVTLUUSHSLBLLBPLIKFQVGXJCKLN LH EEEHVI_I_MAICIVSPD-RPGVQDAALIE HPI^VAPI-LAAAGLHASPMSADRV-VAFMDH IRIFQBN VBKUUOaHVDSABYSCIXAIVLFTSD-ACGLSDλAHIB IAPLQDB--I_AFLBDLVLDBBG _RA.-AG GEL GAA LQL VRRLQALRLERBBYVT.T. AT.1T.--NSD SVHIE LP YDDK- - LAYABDYIMDBBHSRL- VGLLEL YRAILQL HB__P-V_C__L-FAPNI_I_I_DIU.QG_KC-VB^ MMNLQ GBBFVCLKSIILLNSG VYTFL YRQSSAffl_I_C_FAPDLIIim-QlU.T-I_PC_1IYDQC_KH MLYVSSB I_HRI_Q---VSYXBYLCMKTLLI_LSSVPKDGL YKHTNSQFLYFAPDLVFNR-SKMH-QSAMYBLCQG MHQISLQ FVRLQ TFBBYTIMKVLLLLSTIPKDGL YKHVSGQMLYFAPDLILNB-QRMK-BSSFYSLCLT M QIPQB FViα_Q---VSQEBFI_CMKVI_I_I_I_NTIPI_EGL 110 D E E k h h h c h h h h h h α 1 2

Claims: WHAT IS CLAIMED IS: 1. An isolated recombinant nucleic acid which, upon expression, is capable of coding for other than a native vertebrate steroid receptor or fragment thereof, said nucleic acid comprising a segment having a sequence substantially homologous to a coding region of domains A, B, D, E or F from an insect steroid receptor superfamily member gene having substantial homology to a steroid binding domain. 2. An isolated recombinant nucleic acid of Claim 1, wherein said insect steroid receptor superfamily member is EcR, DHR3, E75A or E75B. 3. An isolated recombinant nucleic acid of Claim 1, wherein said nucleic acid encodes a polypeptide capable of binding to a ligand for an insect steroid receptor superfamily member. 4. An isolated recombinant nucleic acid of Claim 1, wherein said nucleic acid is capable of hybridizing to an insect steroid receptor superfamily member gene segment under selective hybridization conditions. 5. An isolated recombinant nucleic acid of Claim 4, wherein said selective hybridization conditions are stringent hybridization conditions. 6. A cell transformed with an isolated recombinant nucleic acid of Claim 1. 7. An isolated recombinant nucleic acid having a sequence exhibiting identify over 20 nucleotides of a coding segment of an insect steroid receptor superfamily member having steroid binding domain homology. 8. An isolated recombinant nucleic acid of Claim 7, wherein said nucleic acid encodes a polypeptide which binds to a control element responsive to a ligand of an insect steroid receptor superfamily. 9. A cell transformed with an isolated recombinant nucleic acid of Claim 7. 10. An isolated recombinant nucleic acid comprising a DNA sequence capable of binding to an insect steroid receptor superfamily member other than 20-OH ecdysone receptor. 11. An isolated recombinant nucleic acid of Claim 10, wherein said insect steroid receptor superfamily member is DHR3, E75A or E75B. 12. An isolated recombinant nucleic acid of Claim 10, wherein said DNA sequence promotes transcription of an operably linked sequence in response to binding by said insect steroid receptor superfamily member. 13. An isolated recombinant nucleic acid of Claim 10, wherein said DNA sequence is operably linked to a DNA sequence encoding a polypeptide. 14. An isolated recombinant nucleic acid of Claim 10, wherein said isolated recombinant nucleic acid is an expression vector. 15. A cell transformed with an isolated recombinant nucleic acid of Claim 10. 16. A cell of Claim 15, wherein said cell also comprises said insect steroid receptor superfamily member. 17. A recombinant nucleic acid comprising: a control element responsive to a ligand of an insect steroid receptor superfamily member ligand responsive control element; a non-heat shock promoter sequence; and a sequence comprising a reporter gene. 18. A recombinant nucleic acid of Claim 17, wherein said non-heat shock promoter sequence is an alcohol dehydrogenase promoter. 19. A cell transformed with a recombinant nucleic acid of Claim 17. 20. A cell of Claim 19, wherein said cell is a mammalian cell. 21. A recombinant nucleic acid of Claim 17, comprising additional copies of control elements responsive to a ligand of an insect steroid receptor superfamily member. 22. A method for monitoring expression of a reporter gene comprising the steps of: expressing a recombinant nucleic acid of Claim 17, wherein no radioactive reagent is used in said monitoring of said reporter gene. 23. A polypeptide comprising an insect steroid receptor superfamily member or fragment thereof, wherein said polypeptide is substantially free of naturally- associated insect cell components and exhibits a biological activity characteristic of an insect steroid receptor superfamily member with a steroid binding domain. 24. A polypeptide of Claim 23, wherein said insect steroid receptor superfamily member is selected from the group consisting of EcR, DHR3, E75A and E75B. 25. A polypeptide of Claim 23, wherein said insect steroid receptor superfamily member or fragment thereof also comprises a DNA binding domain. 26. A polypeptide of Claim 23, wherein said insect is Drosophila melanogaster. 27. A polypeptide of Claim 23, which is capable of binding to a hormone analogue selected from the group consisting of an insect hormone and an insect hormone agonist. 28. A polypeptide of Claim 27, wherein said insect hormone is an ecdysteroid. 29. A polypeptide of Claim 27, wherein said insect hormone is 20-OH ecdysone. 30. A polypeptide of Claim 23, which is capable of binding to a DNA control element responsive to an insect hormone. 31. A polypeptide of Claim 30, wherein said polypeptide comprises a zinc-finger domain. 32. A polypeptide of Claim 30, wherein said insect hormone responsive DNA control element is operably linked _ to a transcription unit which is responsive to said binding. 5 33. A polypeptide of Claim 32, wherein said insect hormone responsive DNA control element is upstream from said transcription unit. 34. A polypeptide of Claim 23 fused to a second polypeptide. 10 35. A polypeptide of Claim 34, wherein said second polypeptide is a heterologous polypeptide. 36. A polypeptide of Claim 35, wherein said heterologous polypeptide comprises a second steroid receptor superfamily member. 15 37. A polypeptide of Claim 23, wherein said fragment has a sequence substantially homologous to a consensus El region sequence. 38. A polypeptide of Claim 23, wherein said fragment has a sequence substantially homologous to a 20 consensus E2 region sequence. 39. A polypeptide of Claim 23, wherein said fragment has a sequence substantially homologous to a consensus E3 region sequence. 40. A polypeptide of Claim 23, wherein said 25 fragment has a sequence comprising: a segment at least about 25% homologous to a consensus El region sequence; a segment at least about 30% homologous to a consensus E2 region sequence; and 30 a segment at least about 30% homologous to a consensus E3 region sequence. 41. A composition of matter comprising a polypeptide of Claim 23. 42. A cell comprising a polypeptide of Claim 23. 35 43. A cell of Claim 42, wherein said cell is a human cell. 44. An antibody or binding fragment thereof exhibiting binding specificity to a polypeptide of Claim 23, wherein said binding specificity is directed to an epitope characteristic of an insect steroid receptor superfamily member. 45. A method for selecting DNA sequences capable of being specifically bound by an insect steroid receptor superfamily member, said method comprising the steps of: screening DNA sequences for binding to a polypeptide of Claim 23; and selecting said DNA sequences exhibiting said binding. 46. A method of Claim 45, wherein said DNA sequence is operably linked to a gene selected from the group consisting of EcR, DHR3, E74 and E75 genes. 47. A method for selecting ligands specific for binding to a hormone binding domain of an insect steroid receptor superfamily member, said method comprising the steps of: screening compounds for binding to one or more superfamily members; and selecting compounds exhibiting specific binding to the members. 48. A method of Claim 47, wherein said ligand is an ecdysteroid. 49. A method of Claim 47, wherein said ligand is a 20-OH ecdysone antagonist. 50. A method for modulating insect physiology or development comprising the steps of: screening compounds for binding to an insect steroid receptor superfamily member; selecting said compounds exhibiting said binding; and administering to an insect said ligand. 51. A method of Claim 50, wherein said modulating is lethal to said insect. 52. A fusion polypeptide comprising a hormone binding domain of an insect steroid receptor superfamily member and a second polypeptide. 53. A fusion polypeptide of Claim 52, wherein said 5 second polypeptide comprises a DNA binding domain from a second steroid receptor superfamily receptor member. 54. A nucleic acid encoding a fusion polypeptide of Claim 52. 55. A method for selecting ligands specific for 0 binding to a ligand binding domain of an insect steroid receptor superfamily member, said method comprising the steps of: combining: (i) a fusion polypeptide of Claim 52, wherein 5 said fusion polypeptide comprises said ligand binding domain functionally linked to a DNA binding domain of a second steroid receptor superfamily member; and 0 (ii) a second nucleic acid sequence encoding a second polypeptide, wherein expression of said second nucleic acid sequence is responsive to binding by said DNA binding domain; and screening compounds for an activity of inducing expression of said second polypeptide; and selecting said compounds. 56. A method of Claim 55, wherein said combining occurs within a cell. 57. A method of Claim 56, wherein said combining step results from expression upon transformation of said cell with a nucleic acid encoding said fusion polypeptide. 58. A method for modulating insect physiology comprising the step of: administering to an insect a ligand selected by a method of Claim 55. 59. A method of Claim 55, wherein said binding domain is selected from binding domains of insect steroid receptor superfamily members selected from the group consisting of EcR, DHR3, E75A and E75B. 60. A method of Claim 58, wherein said ligand is lethal to said insect. 61. An isolated receptor control element non- responsive to 20-OH ecdysone comprising a DNA segment capable of binding to an insect steroid receptor superfamily member and capable of controlling expression of an operably linked gene. 62. An isolated receptor control element of Claim 61, wherein said operably linked gene is within about 50 kb of said control element. 63. An isolated receptor control element of Claim 61, wherein said insect steroid receptor superfamily member is DHR3, E75A or E75B. 64. A method for producing a polypeptide comprising the steps of: selecting a cell which is substantially insensitive to exposure to an insect steroid receptor superfamily ligand; introducing into said cell: (i) a receptor for said ligand; and (ii) a nucleic acid sequence encoding said polypeptide, said nucleic acid sequence operably linked to a control element responsive to presence of said selected ligand, wherein a transformed cell is produced; and exposing said transformed cell to said ligand. 65. A method of Claim 64, wherein said cell is a mammalian cell. 66. A method of Claim 64, further comprising the step of introducing said cell into an intact organism. 67. A method of Claim 64, wherein said cell is a plant cell. 68. A method of Claim 64, wherein said ligand is 20-OH ecdysone. b:\5490A-76.PCT

Inventors: HOGNESS DAVID S, KOELLE MICHAEL R, SEGRAVES WILLIAM A, HOGNESS, DAVID, S., KOELLE, MICHAEL, R., SEGRAVES, WILLIAM, A.
Applicants: UNIV LELAND STANFORD JUNIOR, THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIVE
Application year: 1991
Main classification: A61K35
IPC codes: A61K38, C07K14, C07K16, C07K19, C12N15, C12P21